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ABSTRACT 
Regulation and Function of the Cancer Stem Cell Transcription Factors GLI1 and 
Krüppel-like Factor 4 
Daniel B. Vanderbilt 
 Transcription factors are crucial to the normal and pathologic biology of cells. Aberrant 
genetic regulation underlies all facets of cancer, including metastasis, therapeutic resistance, and 
other clinically relevant manifestations. Krüppel-like factor 4 (KLF4) and GLI1, transcription 
factors that interact with DNA through conserved zinc finger domains, are implicated in human 
malignancy. The stability of GLI1 protein is a central determinant of Hedgehog pathway 
signaling output, and is regulated through interaction with the F-box protein β-TrCP. In 
pancreatic ductal adenocarcinoma, GLI1 may be activated by oncogenic mechanisms. While 
KLF4 is not specific to any discrete signal pathway, KLF4 is well-characterized in numerous 
biological processes, including pluripotency and stress response. The functions of KLF4 are 
highly context-dependent, and the role of KLF4 in metastasis and other emergent phenotypes 
remains unclear. This dissertation addresses two distinct topics: Mechanisms underlying GLI1 
stabilization in pancreatic cancer, and the function of KLF4 in the metastasis of breast cancer 
cells.  
 As an effector protein of the Hedgehog (Hh) signal pathway, GLI1 is implicated in 
pancreatic ductal adenocarcinoma (PDA) and other cancer types. Like other GLI proteins, GLI1 
stability is regulated by the ubiquitin-proteasome system through the E3 ligase SKP1/CUL1/F-
box (SCF) protein SCF
β-TrCP
. While Hh signaling is known to induce expression of the high 
mobility group box protein SOX9 in several contexts, the function of this signaling mechanism 
in PDA is poorly understood. In Chapter 2, we report the stabilization of GLI1 protein by SOX9 
in PDA cells, finding that SOX9 inhibited SCF
β-TrCP
-mediated protein degradation.  In the 
presence of SOX9, the association of GLI1 and β-TrCP was reduced. The discovery that SOX9 
interacts with the F-box domain of β-TrCP led us to question whether SOX9 could inhibit SCFβ-
TrCP
 complex assembly, as this region is known to function in binding the SKP1 adaptor protein. 
Indeed, we observed enhanced association between SKP1 and β-TrCP upon suppression of 
SOX9, whereas overexpression of SOX9 led to drastically reduced SKP1-β-TrCP interaction. 
Additionally, SOX9 functioned to promote the nuclear tethering and degradation of β-TrCP. In 
PDA cells, deficiency of SOX9 resulted in loss of malignant properties and cancer stem cell 
(CSC) traits, effects that could be rescued by suppression of β-TrCP. We also provide evidence 
that additional substrates of β-TrCP may be similarly regulated by SOX9. These results identify 
a positive feedback mechanism of GLI1 stability in PDA cells, revealing that SOX9 can inhibit 
SCF
β-TrCP
 activity to suppress degradation of oncoproteins. 
 While KLF4 inhibits cell proliferation and is downregulated in some tumor types, KLF4 
promotes survival and therapeutic resistance in breast cancer cells. Metastasis remains a 
significant clinical problem, yet a comprehensive understanding of the metastatic process 
remains elusive. In Chapter 3, we address the function of KLF4 in a mouse model of breast 
cancer metastasis. In triple-negative breast cancer cell lines, stable suppression of KLF4 resulted 
in enhanced spontaneous metastasis to the lungs and liver. Similarly, we observed fewer 
metastases in association with KLF4 overexpression. KLF4 had minimal impact on primary 
tumor initiation and growth. Although increased circulating tumor cells (CTCs) arose from 
KLF4-knockdown tumors, this effect was not predicted by function of KLF4 in 2D assessments 
of motility and invasion. Discoidin domain receptor 1 (DDR1) is a collagen-binding receptor 
tyrosine kinase associated with metastasis. We found that KLF4 suppresses expression of DDR1. 
Accordingly, suppression of KLF4 resulted in greater expression of DDR1 mRNA and protein, 
and increased adhesion to collagen. We propose that KLF4 inhibits metastasis of breast cancer 
cells through downregulation of DDR1. 
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CHAPTER 1 
Introduction and Literature Review 
 Chapter 1 is divided into two parts, with a broad focus on zinc finger proteins that 
function as major regulators of cell fate in development and cancer. The first section contains a 
brief overview of GLI proteins and the Hedgehog signaling pathway, a focused introduction to 
GLI and Hedgehog signaling in cancer including therapeutic applications, and a review of the 
mechanisms determining the regulation of GLI protein by SCF
β-TrCP
.  The second component 
describes the normal functions of another major regulator of cell fate, Krüppel-like factor 4 
(KLF4), the context-dependent roles of KLF4 in cancer, and current concepts in metastasis 
research as they may relate to KLF4. 
Part I: GLI 
Part I overview: Hedgehog signaling, GLI proteins, and the ubiquitin-proteasome system 
  The hedgehog (Hh) signal pathway is critical in embryonic development and has 
numerous additional functions, including the maintenance of adult stem cells. GLI proteins are 
zinc finger transcription factors and are effectors of vertebrate Hh signaling. While the Hedgehog 
pathway was first characterized in Drosophila melanogaster, GLI1 was originally discovered as 
a candidate oncogene in human tumors by purification of amplified genomic sequences. 
Aberrant activation of GLI proteins, including GLI1, a potent transcriptional activator of Hh-
responsive genes, contributes to numerous human malignancies. GLI protein stability and 
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processing is regulated by the ubiquitin proteasome system (UPS), and the interaction of GLI 
with the E3 ubitquitin ligase SCF
β-TrCP 
is a crucial determinant of Hh signaling output. For this 
reason, mechanisms governing GLI1 stability have significant translational relevance. This 
introductory section reviews some elements of Hh-GLI signaling, emphasizing the role of this 
pathway in certain malignancies, and describes the biochemical basis of GLI protein stability. In 
the Results section (Chapter 2), a novel mechanism governing GLI1 stability is presented, along 
with biological effects of this mechanism in the context of pancreatic cancer cells. 
Hedgehog signal pathway 
 In 1980, the hedgehog gene (hh) was identified through a screening process to identify 
genes that regulate the development of Drosophila larvae (1). In hh mutant larvae, the cuticle 
was short and spiked, possibly in imaginative resemblance to a hedgehog. In vertebrates, the Hh 
family of genes crucially regulates development (Fig. 1) as well as diverse cellular processes 
such as differentiation, cell fate, and survival (2). The components and mechanisms functionally 
associated with Hh proteins make up the Hedgehog signaling pathway (Hh pathway). Much of 
the pathway found in Drosophila is well-conserved in vertebrates, including Hh pathway 
homologues found in mouse and human cells, although some structural and functional 
differences have been characterized (3,4). 
 In vertebrate species, multiple Hh homologues are found, including three in mammals. 
These are Desert hedgehog (Dhh), Indian hedgehog (Ihh), and Sonic hedgehog (Shh). Additional 
Hh genes are sometimes found elsewhere in the animal kingdom, such as the curiously titled 
tiggy-winkle hedgehog (twhh) of the zebrafish (5). The proteins encoded by Hh genes share 
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important features aside from droll allusions to video games and juvenile literature. 
Phylogenetically, Dhh is more closely related to Drosophila Hh, whereas Shh and Ihh are more 
similar to each other. Shh is most widely expressed, and Shh deletion results in severe defects 
including cyclopia (6). Hh proteins undergo substantial posttranslational processing, involving an 
autocatalytic cleavage event and subsequent addition of cholesterol and palmitic acid moieties. 
Additional mechanisms release Hh peptides from the cell surface, where they may subsequently 
move towards distant targets, establishing a gradient. The mechanisms through which Hh 
proteins move between cells are less understood in comparison to intracellular Hh events (2). 
 The Patched (Ptch) gene encodes a transmembrane protein (7,8) that functions as the 
receptor for Hh ligands (9). The Drosophila homologue was previously identified through 
genetic screening as belonging to the Hh signaling pathway, functioning downstream of Hh (10). 
In mammals there is an additional Ptch gene, Ptch2 (11,12). Additionally, a number of proteins 
have been identified that act as co-receptors of Hh ligands (13). The GLI family of transcription 
factors, effector proteins of Hh signaling, regulates Ptch1 and Ptch2 expression such that Ptch 
expression is induced by Hh signaling. As Ptch protein, in the absence of Hh ligand, serves to 
suppress Hh signaling, GLI-mediated upregulation of Ptch serves as a negative feedback 
mechanism. 
 An additional transmembrane component of the Hh signal pathway is the protein 
Smoothened (Smo), a seven-transmembrane G protein-coupled receptor (GPCR) (14,15). Smo 
was originally hypothesized to act as a receptor for Hh ligands, the role now attributed to Ptch. 
As the physiologic ligand or ligands for Smo remain unresolved, Smo is an orphan receptor (13).  
In the absence of Hh ligands, Ptch prevents the membrane localization of Smo, which in 
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vertebrates occurs at the primary cilia (16). The binding of Ptch by Hh ligands permits the 
translocation of Smo from cytoplasmic vesicles to the plasma membrane at the primary cilia 
(17,18). The mechanisms whereby Ptch regulates Smo are incompletely understood, but are 
thought to involve signaling by small molecules (19). Evidence suggests Ptch can regulate 
transport of oxysterols, which in turn activate Smo (20-22). While homozygous null Shh, Ihh, or 
Dhh mice develop to term, genetic ablation of Smo is lethal in embryogenesis (23).  
 In Drosophila, Hh signaling regulates development through the transcription factor 
Cubitus interruptus (Ci), of which the GLI protein family found in vertebrates is homologous 
(24,25). This regulation occurs through a multiprotein complex involving Hh pathway mediators 
such as Fused (Fu), Costal2 (Cos2), and Suppressor of Fused (SuFu). The signal transduction in 
vertebrates is thought to occur in a similar process, including the involvement of microtubules, 
although the localization of the signal transduction machinery to the primary cilia distinguishes 
Hh signaling in vertebrates (13). Some aspects of vertebrate Hh signal transduction may be 
independent of the cilia (26). 
 The stability and processing of Ci, and of the GLI family in vertebrates, is determined 
through interaction with the UPS, and this interaction is heavily regulated by phosphorylation 
events involving numerous kinases (27). Kif7, homologous to the Drosophila protein Cos2, acts 
as a scaffold for kinases including Protein kinase A (PKA), Glycogen synthase kinase 3, 
(GSK3), and Casein kinase 1 (CK1)(13). Kif7, a member of the kinesin motor protein 
superfamily, also serves to regulate primary cilia architecture, which appears essential to proper 
control of Hh signaling (28). Vertebrate GLI proteins are negatively regulated by SuFu, and Hh 
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signaling both recruits the SuFu-GLI complex to the cilia and promotes dissociation of SuFu and 
GLI proteins (29). 
  Hh signaling, as transduced through Smo and other mediators, modulates the interaction 
of Ci and GLI proteins with a Skp, Cullin, F-box (SCF) multiprotein complex. The SCF complex 
is an E3 ubiquitin ligase, acting to ubiquitylate the Ci/GLI substrate and thereby target Ci/GLI to 
the proteasome for degradation or processing. The F-box component is responsible for 
recognition of the Ci/GLI substrate. In Drosophila, the responsible F-box protein is 
Supernumerary limbs (Slimb/Slmb) (30). The homologous protein in vertebrates is F-box/WD 
repeat protein 1A (β-TrCP) (31). Ci/GLI proteins are known substrates of other E3 ubiquitin 
ligases in addition to SCF
Slimb/β-TrCP
, as is noted in the section “Processing of Ci/GLI proteins”. 
 This dissertation is primarily focused on the stability of GLI1 protein in a context where 
GLI may be regulated by mechanisms other than classical Hh signaling (32-34). Classical Hh 
signaling is reviewed for historical context and clinical relevance. The interaction between β-
TrCP and GLI1 is of great importance in both classical Hh signaling and in alternative 
mechanisms of GLI activation. As β-TrCP targets GLI1 for proteasomal degradation, reduced β-
TrCP/GLI1 interaction is hypothesized to result in GLI1 accumulation, with consequences 
including oncogenic effects of GLI1 in malignancy (35).  
GLI family proteins as effectors of Hh signaling 
 Whereas some chordates express only a single, Ci-like GLI protein (36), in vertebrates 
the processing-dependent transcriptional regulatory functions of Ci are divided amongst multiple 
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GLI proteins (Fig. 2). In mammals, GLI1 and GLI2 may both function as transcriptional 
activators of Hh target genes, whereas transcriptional repression is accomplished by GLI2 and 
GLI3 (37). The greater functional overlap between GLI1 and GLI2 , as compared to GLI1 and 
GLI3, is exemplified in mice, in which mutation of GLI2, but not GLI3, results in a severe 
developmental phenotype in combination with homozygous GLI1 mutations (38). The 
proteolytic cleavage of GLI2 and GLI3 into the repressor forms resembles the Ci processing 
found in Drosophila (6). This processing into cleaved forms occurs via the UPS, and is mediated 
by the E3 ligase SCF
Slimb/β-TrCP
 as described.  
 Hedgehog signaling positively and negatively regulates the transcription of Hh target 
genes by modulating the balance between GLI activator (GLI
A
) and GLI repressor (GLI
R
) forms, 
or the Ci homologue in Drosophila. GLI3 is most similar to Ci protein (2). In principle, the GLI
A
 
and GLI
R
 forms could represent any of the GLI family, with the caveat that GLI1 does not have 
the N-terminal repressor domain and thus cannot function as GLI
R
. The effect of Hh ligand 
binding is to tip this balance towards GLI
A
  (37). In a simplified model, Hh signaling can be seen 
to effect an increase in GLI
A
 proteins, and a decrease in GLI
R
 forms (Fig. 3). In this manner, Hh 
signaling functions to transcriptionally promote Hh target gene expression. 
 A complicating factor in vertebrate Hh signaling is that GLI proteins directly influence 
GLI expression, an example of positive feedback. The GLI family of proteins can bind to 
promoter response elements and regulate transcription of GLI genes. Indeed, one of the most 
recognized transcriptional consequences of Hh signaling is upregulation of GLI1, and so Hh 
signal transduction can directly increase expression of the potent Hh effector protein, GLI1 (39). 
In the classical Hh signaling pathway, GLI1 seems to function mainly to reinforce pathway 
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activation, and temporally extends the cellular response to Hh ligands (2,40). This effect may be 
attributed to the positive feedback effect in which GLI1 directly promotes transcription of GLI1. 
GLI proteins regulate each other through coordinated mechanisms that determine pathway output 
through the balance of GLI activator (GLI
A
) and GLI repressor (GLI
R
) functions. This process 
has been described as a “GLI code” (40). Deletion of GLI3 can lead to ligand independent GLI 
activity, supporting a model of regulation by the three mammalian GLI proteins. In the absence 
of Hh ligand, GLI3 directly represses transcription of Gli1 and Gli2. GLI2 protein also binds the 
promoters of Gli1 and Gli2 as shown by chromatin immunoprecipitation (ChIP) (41). In the 
canonical Hh pathway, GLI
R
 activity is suppressed by Hh ligand, and this effect may be 
reproduced through GLI3 deletion. GLI2 is then able to promote expression of Gli1 and Gli2, 
leading to increased promotion of Gli1 transcription by GLI1 protein. Additionally, GLI1 does 
seem to promote expression of Gli2, although likely through indirect mechanisms (42). Genetic 
lesions in cancer cells may also make GLI1 independent of Hh signaling, as discussed later.   
GLI discovery and structure 
 In 1987, a gene found to be highly amplified in a malignant glioma was named GLI, and 
traced to chromosome 12q13 (43). The GLI gene was then cloned from a glioma cell line with 
75-fold amplification of GLI (44). Within the cDNA clone, a 3.3 kb open reading frame 
predicted a peptide of 1,106 residues with a calculated mass of 118 kDa, and containing five 
repeats of a zinc finger motif. GLI2 and GLI3 were later discovered through low stringency 
hybridization with GLI cDNA (45,46); GLI1 is a retronym for GLI. The Drosophila gene 
Cubitus interruptus (ci) was cloned later, and immediately recognized to have sequence 
homology to human GLI (25). 
8 
 
 Three GLI genes and corresponding proteins are found in mammals, likely derived from 
duplications of an ancestral gene. Among the most obvious and conserved features of GLI 
proteins are the five zinc fingers, which are of the C2H2 type. The C2H2 zinc finger is a common 
structural motif and is composed of a β-hairpin and an α-helix. Two cysteine residues within the 
“zinc knuckle” of the β-hairpin, as well as two histidine residues from the C-terminal end of the 
α-helix, are responsible for the coordination of a zinc ion (47). In GLI proteins, the zinc finger 
domains interact with DNA. The sequence 5’-GACCACCCA-3’ functions as a binding site for 
the GLI family of transcription factors, and has been shown to be a Shh-responsive element (48).  
 GLI proteins are also characterized by a C-terminal transactivation domain. This 
sequence is essential to the transcriptional function of Hh target genes through interaction with 
GLI co-activators (49). Notably, GLI1 lacks the N-terminal repressor domain that is found in 
GLI2 and GLI3 proteins. This absence is reflected in the role of GLI1 as the most potent 
transcriptional activator in the Hh signal pathway (40), and also the lesser mass of GLI; although 
GLI1 protein has a calculated mass of 118 kDa, it comigrates in denaturing gels with proteins of 
150kDa (46). GLI1 also lacks the processing determinant domain found in GLI2 and GLI3. Lack 
of this domain partially explains why GLI1 is completely degraded by the proteasome (50). 
Other characterized features of GLI proteins include sites of phosphorylation and other 
posttranslational modifications, degron motifs that mediate protein stability, and SUFU binding 
sites (37). 
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Genomic GLI1 and splice variants  
 GLI spans around 12 kb of genomic DNA and is located at 12q13.2-q13.3. The 5’ exons 
1 and 1A are non-coding, and splice variants affecting the non-coding exons have been reported 
(51). There are 11 coding exons distributed as exons 2-12 (52). Several variant forms of GLI1 are 
described. Skipping of exons 2 and 3 results in N-terminal truncated (GLI1ΔN) variant proteins 
(53). Interestingly, GLIΔN expression is downregulated in tumor tissue as compared to full-
length GLI1 (GLI1FL). GLIΔN lacks the N-terminal SuFu binding motif, and is therefore 
resistant to the negative regulatory effects of Sufu, and also is resistant to the activity of dual-
specificity tyrosine phosphorylation-regulated kinase 1 (Dyrk1). In mouse C3H10T1/2 cells, 
Dyrk1 acts to retain GLI1 in the nucleus, and may also enhance GLI1 transcriptional activity by 
other mechanisms (54). 
 An additional variant of GLI1, truncated GLI1 (tGLI1) lacks 123 base pairs 
corresponding to exon 3 and part of exon 4 (55). In contrast to the GLI1ΔN variants, tGLI1 was 
not detected in normal tissue, but highly upregulated in the tumor context of glioblastoma 
multiforme. Although tGLI1 nuclear localization and the transactivation of GLI binding sites 
was similar to GLI1, overexpression of tGLI1 led to distinguishing phenotypes. In comparison to 
GLI1FL, tGLI1 promoted increased migratory and invasive properties in vitro, and seemed to 
differentially promote CD24 expression in vitro and in vivo. tGLI1 was later detected in breast 
cancer cells, and found to promote additional factors such as vascular endothelial growth factor 
A (VEGF-A) (56). The differing expression and transcriptional regulation of target genes by 
tGLI1 may contribute to a number of cancer cell characteristics, accounting for some of the 
tumorigenic activity of Hh signaling (57). 
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GLI interactions and co-activators 
 The C-terminal transactivation domain of GLI proteins was determined through deletion 
analysis, and characterized to interact with the human transcription factor IID (TFIID)  TATA 
box-binding protein-associated factor (TAF9) (49). TAF9 is a subunit of the general transcription 
factor TFIID, which contributes to the preinitiation complex for RNA polymerase II (58). The 
interaction with TAF9 therefore provides a mechanistic basis for GLI-mediated transcriptional 
activation. This interaction may also be amenable to pharmacologic inhibition using the small 
molecule FN1-8 (59). 
 The functions of GLI proteins are also regulated by histone modifying and chromatin 
remodeling proteins. GLI1 acetylation at the K518 residue inhibits the GLI transactivation 
function (60). GLI2 is similarly acetylated. Deacetylation through enzymes such as histone 
deacetylase 1 (HDAC1) enhances GLI1 transcriptional activity. Degradation of HDAC1 via an 
E3 ligase complex containing Cullin3 and potassium channel tetramerization domain containing 
11 (REN/KCTD11) could thereby promote GLI1 activity. Hh signaling suppressed this process, 
resulting in upregulation of HDAC1 levels and increasing the transactivation function of GLI1. 
Previously, loss of REN/KCTD11 activity had been implicated as a mechanism of Hh pathway 
activation in developing granule cell progenitors (61) and in medulloblastoma (62). 
 GLI3, but not GLI1, associates with the co-activator cAMP response element (CRE) 
binding protein (CBP). This interaction promotes the transcriptional activator function of GLI3 
(39). This mechanism helps account for GLI3-mediated induction of GLI1 expression that is 
observed following stimulation with Hh ligands. In contrast, SKI protein acts with GLI3 as a co-
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repressor by recruiting HDAC enzymes. SKI cooperates with GLI3 to suppress the transcription 
of GLI1 (63). HDACs might act directly on GLI3, as seems to be the case with GLI1. 
Alternatively, the recruited HDACs could alter histone proteins and chromatin structure. An 
HDAC complex containing SAP18 and Sin3 can also negatively regulate GLI transcriptional 
activity, interestingly mediated by a nuclear function of Sufu (64). 
  GLI proteins are also implicated in chromatin remodeling through the ATP-dependent 
switch/ sucrose nonfermentable (SWI/SNF) complex. The interaction of GLI and the chromatin 
remodeling protein Snf5, an SWI/SNF complex member, along with other SWI/SNF proteins 
such as Smarcc2 and Smarce1 was detected through mass spectrometry (65). Snf5 did not 
interact with GLI2. Inactivation of SWI/SNF complex subunits Snf5 and Brg1 resulted in 
enhanced GLI1 expression and activation of GLI target genes. The SWI/SNF complex in this 
way functions as a negative regulator of Hh signaling. 
 In addition to HDAC-related interactions, GLI proteins are also regulated by small 
ubiquitin-related modifier (SUMO) conjugation. GLI1 is likely subject to SUMOylation on the 
K180 and K815 residues, but GLI2 and GLI3 were also found to be SUMOylated (66). The 
SUMOylation of GLI2 and GLI3 were negatively regulated by protein kinase A (PKA) 
signaling, whereas GLI1 SUMOylation was less affected. GLI protein SUMOylation was 
mediated by the SUMO E3 ligase Pias1. Expression of wild-type Pias1, but not a Pias1 mutant 
lacking E3 ligase activity, enhanced GLI transcriptional activity.  
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Processing of Ci/GLI proteins 
 In the absence of Hh ligand stimulation, Drosophila Ci protein is proteolytically cleaved, 
resulting in the N-terminal repressor form Ci
R
 (67). The cleaving of Ci is regulated by 
phosphorylation, involving kinases such as PKA, GSK3, and CK1. Ci then interacts with the E3 
ubiquitin ligase SCF
Slimb
 (30,68). Ci was later found to contain a processing determinant domain 
(PDD) that was critical for Ci to undergo processing instead of complete degradation in the 
proteasome. The transcription factor NF-κB is regulated similarly (69). Deletion of the PDD 
from Ci in Drosophila prevents the formation of Ci
R
 (70), and Ci is instead completely degraded 
(71). 
 GLI3 in vertebrates seems to act similarly to Drosophila Ci. GLI3 is subject to 
phosphorylation by PKA, GSK3, and CK1 (72,73). GLI3 then interacts with SCF
β-TrCP
, in which 
the F-box protein β-TrCP is homologous to Slimb in Drosophila(74). GLI2 is likely regulated in 
similar fashion by phosphorylation (75,76). GLI2 is predominantly degraded by the proteasome, 
and not processed to truncated forms. This observation was explored by experiments with GLI2 
and GLI3 chimeric proteins, which suggested that the GLI2 PDD was less efficient in preventing 
protein degradation (77).  
 Unlike GLI family members GLI2 and GLI3, and unlike the Drosophila Ci protein, GLI1 
lacks a PDD as well as an N-terminal repressor domain. Therefore in the proteasome GLI1 does 
not undergo processing to create a cleaved repressor form. GLI1 exists as a potent transcriptional 
activator that is degraded by the proteasome. By linking ubiquitin to GLI1, β-TrCP directly 
destabilizes GLI1 by targeting GLI1 to the proteasome. The association of GLI1 and β-TrCP is 
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therefore a determinant of GLI1 protein levels, and in this manner can regulate GLI1-dependent 
phenotypes including oncogenic effects. For this reason, the interaction between GLI1 and β-
TrCP is a central focus of this dissertation. 
 Ci/GLI proteins can also be substrates of E3 ubiquitin ligases other than SCF
Slimb/β-TrCP
. In 
Drosophila, Ci protein can interact with a Cul3-based E3 ligase complex through Roadkill 
(Rdx), also known as Hh-induced MATH and BTB domain-containing protein (Hib) (78,79). In 
addition to UPS-mediated degradation, Rdx can also regulate nuclear entry of Ci (80). This dual 
function of Rdx is dependent upon Su(fu) levels (81). The vertebrate homologs of Rdx are 
Speckle-type POZ proteins (SPOPs), and the interaction of Ci/GLI with Rdx/SPOP is determined 
by conserved Ser/Thr (S/T)-rich motifs (82). Most cells in Drosophila lack primary cilia, and in 
vertebrates, Sufu-mediated GLI regulation through SPOP is cilium-independent (26). GLI1 
protein, in comparison to GLI2 and GLI3, is a less efficient substrate for SPOP. Instead, GLI1 
protein is regulated by the E3 ligase Itch, through interaction with Numb, in addition to the 
addition to the SCF
β-TrCP
 interaction (83,84). 
Genes regulated by GLI 
 In addition to well known GLI targets such as GLI1 (39) and PTCH1 (85), several studies 
have used chromatin immunoprecipitation (ChIP) and gene expression analyses to determine 
putative GLI transcriptional targets. In both granule neuron precursor cells and medulloblastoma, 
a malignancy characterized by oncogenic Hh pathway activation resulting from mutation of the 
PTCH1 tumor suppressor, hundreds of loci were bound by GLI1 (86). Similar methods and 
additional validation have revealed many GLI targets, including genes encoding the homeobox 
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factors Nkx2.1 and Nkx2.2 (87). ChIP and transcriptional profiling of GLI3-bound sites in the 
limb buds of mouse embryos reveals suggested thousands of GLI-binding regions (GBRs) (88). 
The authors ultimately derived a core set of 205 Shh-responsive limb GLI target genes. 
Components of Wnt and TGF-β signaling pathways were significantly enriched, in addition to 
Hh pathway components. Of these genes, 48 encoded known transcription factors. These targets 
included numerous homeobox factors of the HoxD family, and related cofactors such as Pbx, 
Meis1, and Meis2. Tbx transcription factors were also enriched.  
 Although the GLI-mediated regulation of some genes, such as Hh pathway components 
GLI1 and PTCH1, may be preserved in many cell types or “universal” (37), other GLI targets 
exhibit tissue specificity. These include transcription factor targets of Hh signaling. For example, 
GLI-mediated expression of Foxa2 is comparatively limited to processes of neural development 
(48). The prevalence of transcriptional regulators amongst the targets of GLI and Hh signaling 
reflect the crucial role of Hh signaling in the development of metazoans. As is described later, 
some Hh-responsive transcriptional targets of GLI are also involved in cancer, accounting for the 
oncogenic functions of GLI1 and GLI2. 
Hedgehog signal pathway in cancer 
 The literature implicating Hh signaling in malignancy is extensive. Conceptually, 
oncogenic Hh signaling could occur through multiple mechanisms. There may be increased 
signaling through overproduction of Hh ligands, or mutation of pathway mediators such as 
PTCH, as is observed in basal cell carcinoma and medulloblastoma. Independently of Hh and 
Smo, other pathways such as RAS signaling can promote GLI protein activity. There are 
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additional mechanisms of Hh pathway activation in some tumor types. For example, GLI1 is 
transcriptionally upregulated in Ewing sarcoma by a well-characterized fusion oncoprotein (89-
91). Like gliomas, some other forms of sarcoma can also exhibit gene amplification of GLI 
(43,92). This review will focus primarily on the role of the Hh pathway in pancreatic ductal 
adenocarcinoma (PDA). While Hh signaling seems to contribute to PDA, there is controversy as 
to whether the signaling is dependent upon hedgehog ligands. The role of Hh signaling in tumor 
cells versus stroma also remains unclear. As some of our data in the Results section concerns the 
cancer stem cell (CSC) population in PDA cells, the well-established role of Hh signaling in 
CSCs is also reviewed.    
Basal cell carcinoma and medulloblastoma: Archetypal Hh-driven malignancies 
 Basal cell carcinoma is the most common type of cancer in humans, although advanced 
disease and metastasis are rare (93). The casual role of Hh signaling in this disease was identified 
through study of nevoid basal cell carcinoma syndrome (NBCCS), also known as basal cell 
nevus syndrome or Gorlin syndrome (94). NBCSS is an inherited condition affecting multiple 
organ systems, and patients are particularly prone to developing basal cell carcinomas (95). In 
comparison to sporadically occurring basal cell carcinoma, tumors associated with NBCCS may 
develop at a very early age, and in areas unrelated to sun exposure, such as the soles of the feet.  
Notably, patients are also predisposed to other tumors, including medulloblastoma. Identification 
of the tumor suppressor responsible for NBCCS led to the discovery of the human PTCH gene 
(96). Sporadic basal cell carcinoma is also highly associated with mutations that inactivate PTCH 
protein (97), and occasionally with activating mutations of Smo (98). Hh signaling is also 
frequently implicated in medulloblastoma through inactivation of the PTCH, resulting in 
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unrestricted Smo activation (99-103). The role of Smo-mediated Hh signaling in 
medulloblastoma and in basal cell carcinoma suggests the rational therapeutic use of Smo 
inhibitors, which is discussed separately. 
Hedgehog signaling in pancreatic ductal adenocarcinoma  
 Reports from human specimens, as well as several model systems, including mouse 
models and cell lines, suggest Hh-GLI signaling has oncogenic functions in pancreatic ductal 
adenocarcinoma (PDA). The widespread Hh expression amongst pancreatic tumors and other 
gastrointestinal malignancies, and the lack of characteristic mutations of Ptch or Smo, suggested 
that Hh signaling in GI cancers may occur through the canonical Hh signaling pathway (104). In 
this respect, GI tumors are distinct from basal cell carcinoma and medulloblastoma, in which Hh 
signaling is constitutively activated through mutation of the Ptch or Smo receptors. 
 In pancreatic cancer, specific genetic lesions are highly prevalent, making PDA one of 
the best-defined cancer types (105). Activation of the small GTPase KRAS is highly prevalent, 
occurring in at least 95% of cases (106,107). Additionally, mutations of the tumor suppressors 
p53 (108,109), INK4A (110), and SMAD4 (111) are common. Sequencing efforts have 
expanded the list of mutations associated with PDA (112). Still, the oncogenic activity of 
activated KRAS is central to the development of PDA, and as KRAS remains an elusive target 
for intervention, signaling pathways downstream of activated KRAS may offer better 
opportunities for pharmacologic inhibition (113).  
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 Many GEM models of pancreatic cancer are based on expression of activated KRAS. 
Mice with a Cre-inducible conditional allele (LSL-Kras
G12D
) (114) at the endogenous Kras locus 
develop lesions resembling pancreatic intraepithelial neoplasia (PanIN) that progress to PDA-
like tumors, albeit at low frequency (115). In these models, Cre recombinase is expressed under 
control of a pancreatic progenitor gene promoter, typically that of pancreatic and duodenal 
homeobox 1 (Pdx1) or pancreas transcription factor 1α (Ptf1a), also known as p48. This system 
results in expression of activated KRAS largely restricted to the pancreas. The combination of a 
loss-of-function allele, usually of either Trp53 or Ink4A, with the Kras
G12D
- based model greatly 
enhances PDA formation (116,117). In addition to promoting PDA tumorigenesis, it has also 
been shown that expression of activated KRAS is necessary for tumor maintenance in this 
system (118). 
 Overexpression of Hh ligand is found in human PanIN and PDA (119), as well as in 
models based on the Kras
G12D
 allele (117). Additionally, a Pdx-Shh mouse model results in 
proliferative lesions of the pancreatic ducts, and these structures were found to harbor Kras 
mutations and other PDA-relevant changes (119). Pancreatic epithelial expression of activated 
GLI2 (Pdx-CLEG2) likewise results in pancreatic tumors, although of undifferentiated histology 
(120). In support of the role of Hh signaling in PDA, therapeutic blockade of Hh signaling by 
cyclopamine or similar agents has efficacy in PDA cell lines and orthotopic PDA tumors 
(121,122), and cyclopamine prolonged survival in a Kras
G12D
- driven model (123). Hh signaling 
also cooperates with oncogenic Kras to promote PDA formation in mouse models (120,124). 
 While these results implicated the overall Hh pathway in PDA, further investigation has 
suggested that upstream Hh pathway agents such as Smo inhibitors exert antitumor effects by 
18 
 
acting on the tumor stroma. The responsiveness of cell lines representing PDA and other cancers 
to Smo inhibitors has been challenged (125), with evidence for a model of paracrine Hh 
signaling in cancer, in which tumor cells produce Hh ligands that act on stromal cells. In support 
of this hypothesis, genetic ablation of Smo in fibroblasts or treatment with Hh blocking antibody 
suppresses orthotopic tumor growth (125). Overexpression of Shh also enhances growth in vivo 
of pancreatic epithelial cells when co-injected with fibroblasts (126). There was evidence of Hh 
ligand-mediated signal transduction in the fibroblasts, as shown by accumulation of Smo in the 
primary cilia. 
 Similarly, treatment of Kras
G12D
- induced tumors with Hh inhibitor enhanced the 
response to the chemotherapeutic agent gemcitabine (127). In this case, the Hh inhibitor acted to 
reduce tumor stromal tissue, which had the effect of increasing the tumor vascular density and 
enhancing the concentration of gemcitabine within the tumor. In agreement with the paracrine 
model of Hh pathway activation in the stroma, expression of an activated Smo mutant in 
pancreatic epithelial cells did not seem to activate Hh-GLI signaling, and did not enhance 
Kras
G12D
-driven PDA formation (128). Interestingly, a recent report showed that small-molecule 
inhibition of stromal Hh signaling could actually accelerate PDA formation in mouse models, 
and suggested that the stromal tissue acted to restrain the progression of PDA (129). 
Collectively, these results suggest that targeting the classical Hh signal pathway in PDA mainly 
acts to restrict stromal cells, with consequences that may or may not be beneficial towards 
inhibiting tumor growth. 
 While it has been proposed that Hh signaling in PDA may be entirely limited to the tumor 
stromal compartment (128), more recent reports have argued for a direct role of Hh pathway 
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components in PDA cells, albeit through Hh ligand-independent processes. As is discussed 
below, RAS and TGFβ signaling are suspected to promote GLI activity in PDA and possibly 
other tumors. Of these two mechanisms, the function of RAS signaling to activate GLI is best 
characterized. Conditional deletion of Smo does not impair Kras-driven PDA, and expression of 
Hh target genes is maintained in Smo
-/-
 , Kras-driven tumors (Fig. 4), suggesting a non-canonical 
means of GLI protein activation (34). One means of disrupting GLI signaling is through 
expression of a GLI3 mutant that exerts a dominant repressive function on GLI-mediated 
transcriptional activation (130). Expression of this dominant negative GLI3 protein does not 
impair normal development of the pancreas, suggesting that GLI transcriptional activation is 
dispensable in this context. In contrast, GLI antagonism by this method significantly delays 
pancreatic tumorigenesis in the Kras
G12D
 model. Additionally, ectopic expression of GLI1 in the 
pancreas accelerates formation of Kras
G12D
-driven tumors (Fig. 5). In mice homozygous for 
GLI1 loss-of-function alleles, tumor formation resultant from pancreatic expression of oncogenic 
Kras is significantly delayed (131).  
 In summary, current evidence suggests a multipart role for Hh signaling in PDA (34,132). 
In this model, the GLI protein activity may contribute to PDA in both tumor and stromal cells, 
albeit through different mechanisms (Fig. 6). Ligand-dependent Hh signaling seems to occur in 
stromal cells, especially in fibroblasts. This mechanism helps reconcile evidence that PDA cells 
may overexpress Hh ligand to promote malignant progression, and yet be comparatively 
insensitive to ligand-dependent, Smo-mediated classical Hh signaling. In contrast, Hh ligand-
independent activation of GLI proteins occurs in within PDA cells, and contributes towards 
KRAS-mediated tumorigenesis. As reviewed below, there are several reports that have shed light 
on RAS-GLI crosstalk mechanisms that may be active in PDA cells. These are relevant towards 
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our Results (Chapter 2), which describe a mechanism of GLI1 stabilization involving the HMG-
box factor SOX9. 
RAS and MAPK signaling: an alternate mechanism of GLI activation in cancer 
 In some contexts, GLI protein activity can be activated through mechanisms independent 
from the classical Hh signaling pathway. In both PDA cells and in melanoma cells, GLI activity 
seems to be promoted by oncogenic RAS-MAPK signaling. These examples of Hh-RAS 
crosstalk may help explain the upregulation of GLI activity in cancers that lack upstream Hh 
mutations such as PTCH inactivation. Such interactions are intriguing from a therapeutic 
perspective, offering additional possibilities for targeting oncogenic GLI activity. 
 In PDA cells, GLI activity is partially dependent on activated KRAS and MAPK 
signaling (32). Transformation of nonmalignant human pancreatic ductal epithelial (HPDE) cells 
by KRAS
G12D
 results in upregulation of GLI transcriptional activity and GLI1 mRNA. In PDA 
cell lines, silencing of activated KRAS or treatment with MEK inhibitor decreased GLI 
transcriptional activity and GLI1 mRNA. In contrast, the phosphoinositide 3-kinase (PI3K) 
inhibitor wortmannin did not result in decreased GLI activity. In addition, expression of 
constitutively active BRAF, but not AKT, restored GLI signaling in PDA cells with knockdown 
of activated KRAS. 
 Hh ligand-independent GLI activity has also been demonstrated in the often-used 
Kras
G12D
 mouse model of pancreatic cancer (Fig. 4). In this result, the genetic ablation of Smo 
did not seem to affect normal development of pancreatic ductal or acinar structures, and did not 
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affect development of PanIN-like lesions or PDA tumors (34). Intriguingly, expression of the Hh 
target genes Gli1 and Ptch was not decreased in the Smo-knockout tumors. In vitro, knockdown 
of Kras suppressed expression of Gli1 and Ptch mRNA in PDA cells. 
 Comparable results are found in melanoma cells. Melanoma is similar to PDA in that it is 
an aggressive malignancy frequently characterized by oncogenic activation of RAS-MAPK 
signaling (133). Hh pathway components are expressed in melanoma specimens and in tumors 
from an NRAS
Q61K
/Ink4a
-/-
 mouse melanoma model (33). While melanoma cells were sensitive to 
cyclopamine, this effect was synergistic with MEK inhibition. In melanoma cells, AKT signaling 
was also implicated in mediating RAS-GLI signaling, in contrast to reports using PDA cells (32).  
Notably, the effect of GLI1 transfection on GLI transcriptional reporter activity was highly 
synergistic with NRAS
Q61K
 co-transfection in several cell lines.  
Hedgehog signaling and GLI proteins in cancer stem cells 
 Cancer stem cells (CSCs), a subpopulation of tumor cells originally described in 
hematologic malignancies, are increasingly identified and characterized in solid tumors. Hh 
signaling is implicated in CSCs of many tumor types, including pancreatic adenocarcinoma. 
Unlike some other signaling mechanisms of CSCs, there are effective inhibitors of the Hh 
pathway, and some are approved for clinical use. Therapies that inhibit Hh signaling may 
therefore be a useful strategy to target CSCs in a variety of tumor types. This section reviews 
literature characterizing the role of Hh signaling in CSCs. Methods of targeting the Hh pathway 
are reviewed separately. 
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Cancer stem cells 
 Cancer stem cells (CSC) are considered to represent a distinct population of cells within a 
tumor that have some characteristics of normal stem cells. The comparison of CSCs to normal 
stem cells includes the capacity of CSCs to undergo asymmetric division, facilitating self-renew 
and to differentiation into other types of tumor cell such as the transit-amplifying cells thought to 
make up most of a tumor population (134). Human CSCs can be functionally defined through 
xenograft assays, in which injected CSCs are able to recapitulate a tumor in an 
immunocompromised mouse model. Tumor cells can be serially transplanted, demonstrating 
self-renewal (135). Efforts to integrate the hierarchical model of CSCs in tumors with the clonal 
evolution model of tumor progression are ongoing, and it seems likely that both models will 
ultimately contribute to a common framework of cancer biology (136).  
 Cancer stem cells could possibly arise from the oncogenic transformation of normal stem 
cells, or from dedifferentiation of somatic cells (137). Evidence also exists for stochastic 
transitions within a cell population, in which cells may interconvert between CSC and non-CSC 
states (138). The biological significance of cells that function experimentally as CSCs is not 
without controversy (139,140). Some skepticism arises from the considerable dependence of the 
CSC-like phenotype on the specific strain of host mouse, as has been shown for melanoma cells 
(141). Disagreement over what constitutes appropriate molecular markers of CSCs, poor 
understanding of the physiologic functions of these markers, inability to visualize CSCs in 
primary tumors, and the failure of many markers to generalize across multiple cell lines and 
tumors are all complicating factors in CSC research.  
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 Despite these caveats, further understanding of CSCs offers the potential to improve 
cancer outcomes. Many studies have shown CSCs to have increased resistance to therapeutic 
interventions as compared to control cells (142). For example, breast cancer CSCs may be 
resistant to chemotherapy (143), and glioma stem cells may exhibit radioresistance (144). This 
resistance of CSCs to therapy, along with the ability of CSCs to recapitulate a tumor, supports 
the hypothesis that CSCs may contribute to therapeutic failure and cancer relapse (145). 
Mechanisms currently understood to account for this resistance may involve pro- and anti-
apoptotic signaling pathways, DNA repair mechanisms, and expression of ATP-binding cassette 
(ABC) transporters (146). Other processes in CSCs such as aldehyde dehydrogenase (ALDH) 
expression, interaction with the microenvironment, and the epithelial-to-mesenchymal transition 
may also contribute to therapeutic resistance (147). 
 CSCs may also serve additional roles in malignancy. In particular, there is some evidence 
that CSCs may be implicated in dormancy (148), tumor cell dissemination (149), and overt 
metastasis (150). One intriguing possibility is that while CSCs may be resistant to conventional 
therapies, if specific CSC-related pathways can be determined, then some type of CSC targeted 
therapy might be devised (151-153). By targeting the cells that may contribute to therapeutic 
resistance and malignant progression, CSC-directed therapies offer the potential of increased 
survival.  
Role of Hedgehog pathway in cancer stem cells 
 The Hh signaling pathway is highly implicated in CSCs, and consequently there is 
significant interest in Hh pathway inhibitors as a way of targeting CSCs (154,155). The 
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widespread involvement of Hh signaling in CSCs parallels the importance of the Hh pathway in 
normal stem cells (40). In model systems, there is evidence that inhibitors of Hh signaling 
disrupt activities associated with CSC function, including the serial passage of spheroids and 
grafted cells. 
 One context in which Hh signaling in CSCs is especially well studied is glial cell tumors, 
and glioma CSCs appear to have active Hh signaling. As shown by spheroid formation, an in 
vitro correlate of CSC activity, glioma CSCs are sensitive in a dose-response manner to the Smo 
inhibitor cyclopamine (156). Targeting of Smo through RNAi methods also decreased glioma 
CSC function in xenograft assays. Hh inhibition may exhibit synergistic effects with 
chemotherapy on glioma cell proliferation (156,157). Other in vivo results using Hh-targeted 
therapy supports the contribution of Hh signaling to glioma tumor initiation (158,159). Paracrine 
Shh signaling from endothelial cells may be responsible for Hh pathway activation in glioma 
CSCs (160).  
 In addition to glioma, Hh signaling has been studied in many additional tumor types. 
Reports indicate Hh-GLI activity contributes to CSC maintenance in cancers of the colon (161), 
stomach (162), and pancreas (121), as well as melanoma (163), chronic myeloid leukemia 
(CML) (164), and multiple myeloma (165), and also has tumorigenic effects suggestive of a CSC 
role in small cell lung cancer (166).  
 In breast cancer and lung squamous cell carcinoma, novel mechanisms have been 
identified in the function of Hh-GLI signaling in CSCs. Both GLI1 and GLI2 are upregulated in 
breast cancer cell spheroids, and Hh signaling maintains mammospheres in culture, as spheroids 
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are increased by Hh pathway activation and decreased by cyclopamine treatment (167). In triple 
negative breast cancer (TNBC) cells, GLI1 promotes tumor initiation in a signaling pathway 
mediated by autocrine signaling through the VEGF receptor neuropilin 2 (168). This mechanism 
also involved RAS/MEK signaling, in agreement with the hypothesis that RAS may promote Hh-
GLI activity. An autocrine signaling mechanism involving the Hh pathway also serves to 
maintain the CSC-like phenotype in lung squamous cell carcinoma (169). The transcription 
factor SOX2, when activated by PKCΙ, promotes transcription of hedgehog acetyl transferase 
(HHAT), an enzyme crucial to the production of Hh ligands. This mechanism enhances Hh-
dependent GLI activity in lung squamous cell carcinoma tumorspheres. 
 Consistent with the role of the Hh pathway in CSCs of diverse tumor types, the 
therapeutic inhibition of Hh signaling frequently has synergistic effects in combination with 
other chemotherapies (170-173). One mechanism by which Hh signaling may promote 
chemoresistance in tumor cells is through upregulation of ABC transporter proteins that mediate 
drug efflux (174).  
Therapeutic targeting of the Hedgehog pathway in cancer 
 Hh pathway inhibitors show promise for treatment of human malignancy and are subject 
to ongoing research (155,175-177). Small molecule inhibitors of Smo currently represent the 
most developed class of anti-Hh pathway agents (178), and have shown success in clinical trials. 
Still, only basal cell carcinoma and medulloblastoma have been shown to be responsive to Smo 
inhibitors in human trials, and even amongst these malignancies there is efficacy only in some 
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patients. Drug toxicities and the development of resistance are also significant limitations of 
current anti-Hh therapies in clinical use. 
Methods of Hedgehog targeting 
 The Hh pathway can be targeted at multiple levels. Most reported compounds that 
suppress Hh signaling either function as inhibitors of Smo, or are thought to act directly on GLI 
proteins. Strategies to disrupt Hh signaling at other steps of the pathway are also reported. The 
development of therapies that target Hh signaling involve testing compounds in cells to 
determine the effect on GLI transcriptional activity, followed by studies in animal models of Hh-
related malignancy, possibly leading to clinical trials. To date, clinical trials of therapies 
targeting the Hh pathway have focused on Smo inhibitors, and of these, only the agent 
vismodegib is currently approved by the FDA in an antineoplastic role. 
Smo inhibitors 
 As a GPCR, Smo is a viable target for pharmacologic inhibition, such as by the naturally 
occurring compound cyclopamine (179). A number of Smo inhibitors have been developed with 
promising anticancer activity in preclinical studies. As of 2015, clinical trials are underway to 
determine the benefit of Smo inhibitors in a variety of cancers, including hematologic 
malignancies and solid tumors (155). Smo inhibitors have shown efficacy in treatment of basal 
cell carcinoma and of medulloblastoma. This review highlights some of the more promising 
results in the development of Smo inhibitors, especially with regards to the drug vismodegib. 
Additionally, there are other small molecule inhibitors of Smo that have been examined in 
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clinical trials, or are currently under investigation (154,155,178). It is therefore possible that 
additional Smo inhibitors will be added to the clinical repertoire of Hh-targeting agents in the 
near future. 
Smo inhibitors for treatment of basal cell carcinoma 
 The Smo inhibitor vismodegib, or GDC-0449, has activity against basal cell carcinoma in 
both animal models and in clinical trials. Mice with the PTCH
+/-
 heterozygous genotype are 
prone to develop basal cell carcinoma-like cutaneous tumors, especially with exposure to UVB 
(180). Mice with overexpression of Shh (181), GLI1(182), or GLI2 (182) also develop similar 
tumors. Cyclopamine administration effectively prevents formation of basal cell carcinoma in the 
PTCH
+/-
 UVB model (183).  
 Cyclopamine, because of unfavorable pharmacokinetics, toxicities, and other factors, is 
not a good candidate for systemic use in humans (184), although the development of 
cyclopamine analogs is a promising strategy (185). In contrast, topical formulations of Smo 
inhibitors have showed mixed success for basal cell carcinoma in clinical trials. Cyclopamine 
may be effective in this application (186). While the compound LDE225 was beneficial in some 
cases, CUR61414, a drug effective in a murine PTCH
+/-
 model, did not seem to affect human 
disease in a phase I trial (187).  
 Clinical trials have established the efficacy of oral vismodegib for basal cell carcinoma. 
In a phase I trial of vismodegib for locally advanced or metastatic basal cell carcinoma, a 
therapeutic response as determined by imaging or physical examination was established in 18 of 
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33 patients (188). In another vismodegib phase I trial, a tumor response was observed in 20 of 33 
patients with basal cell carcinoma (189). Aside from one unconfirmed response in a case of 
medulloblastoma, a tumor response was not seen in other solid tumors, including pancreatic 
cancer. A further phase I trial involving 33 patients with metastatic basal cell carcinoma 
established a response rate of 43% and median response duration of 7.6 months (190). 
 Given the apparent efficacy of vismodegib against sporadic basal cell carcinomas, a 
phase II trial sought to determine whether vismodegib would benefit patients with nevoid basal 
cell carcinoma syndrome (191). Under randomized, double-blind conditions, patients received 
vismodegib or placebo therapy. In this study, vismodegib was associated with a reduction in new 
basal cell carcinomas, as well as a decrease in size of existing lesions (Fig. 7). Additionally, the 
expression of Hh pathway target genes was suppressed by 90% in tumors. While vismodegib 
was effective in reducing basal cell carcinoma tumor burden and incidence in patients with basal 
cell nevus syndrome, the frequency of adverse events was also notable. Over half of patients 
discontinued therapy because of adverse events. Grade 1 and 2 adverse events were common and 
included muscle cramps, hair loss, weight loss, and loss of taste. 
 Vismodegib is approved by the FDA for use in recurrent, locally advanced, or metastatic 
basal cell carcinoma (192). Development of resistance to vismodegib therapy remains a 
significant problem (193). One mechanism of resistance is through mutation of Smo so as to 
prevent drug binding, as has been demonstrated in medulloblastoma (194).  
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Smo inhibitors for treatment of medulloblastoma 
 Hh pathway inhibitors targeting Smo have shown potent antitumor activity in preclinical 
models of medulloblastoma. Mice homozygous for a conditional Ptch knockout, in which Ptch is 
deleted in cerebellar granular neuron precursor cells, develop medulloblastoma with 100% 
penetrance by at most 3 months of age (195). Hh pathway inhibitors can dramatically reduce 
disease progression in this model.  In one study, all mice treated with the small molecule Smo 
inhibitor saridegib were alive at 80 weeks, whereas each mouse receiving vehicle control 
succumbed to progressive disease by 40 weeks (196). Notably, saridegib also showed activity 
against Smo protein that acquired resistance to vismodegib through a D473H point mutation. 
Another small molecule Smo inhibitor, PF-5274857, similarly suppresses tumor progression in 
mice with primary medulloblastoma, and was shown to readily penetrate the blood brain barrier 
even in healthy animals (197). In comparison to other types of brain tumor, Hh pathway 
inhibition seems particularly effective against medulloblastoma cells, consistent with the 
mutational status of PTCH and the oncogenic role of Hh signaling in medulloblastoma (198). 
 Vismodegib has also shown efficacy in human patients with medulloblastoma. In one 
case, a 26 year old medulloblastoma patient with tumor-specific inactivating mutations of PTCH 
showed dramatic, although transient, reduction in tumor burden as shown by radiography (199). 
The cause of the disease relapse was and traced to a new mutation of Smo, which abolished drug 
binding (194). NCT00939484, a phase II trial of vismodegib in the treatment of 
medulloblastoma, is ongoing with an estimated primary completion date of June 2015.  
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Inhibitors of GLI activity 
 The compounds GANT61 and GANT58 were identified as small molecules capable of 
regulating a GLI transcriptional reporter (200). While belonging to distinct chemical classes, 
each compound exhibits dose-dependent interference with GLI1 and GLI2-mediated 
transcriptional activity. Similar screening methods using a library of naturally occurring 
compounds identified several inhibitors of GLI transcriptional activity, including physalin, an 
extract of the plant Physalis minima (201). Another small molecule inhibitor of GLI is FN1-8, 
which is thought to suppress GLI-mediated transcription by interfering with the interaction of 
GLI with the transcriptional co-activator TBP-associated factor 9 (TAF9) (59). Treatment with 
FN1-8 suppresses GLI transcriptional activity and also interferes with the colocalization of GLI 
and TAF9.  
 In contrast, the compound glabrescione B interferes with Hh signaling by binding to the 
zinc fingers of GLI1, thereby interfering with the interaction of GLI with DNA (202). As is 
generally true with Hh pathway inhibitors, glabrescione B has significant effects on CSC 
properties. Compound NMDA298-1, developed as a derivative of FN1-8, similarly inhibits GLI-
mediated transcription, with an effect threefold greater for GLI1 as compared to GLI2 (203). 
Other Hedgehog pathway inhibitors 
 In addition to inhibitors with Smo and agents that act on GLI proteins, there are a number 
of compounds that target Hh signaling in other ways. A monoclonal antibody against Shh may 
effectively suppress Hh signal transduction (204). The small molecule robotnikinin, in reference 
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to the adversary of the fictional Shh namesake, may function in a similar mechanism (205). 
Robotnikinin binds extracellular Shh with a KD of 3.1 μM as determined by surface plasmon 
resonance (SPR). Itraconazole, an antifungal agent, prevents the ciliary accumulation of Smo 
that is part of normal Hh signal transduction (206). Itraconazole showed strong dose-dependent 
inhibition of GLI reporter activity and was effective in a mouse model of medulloblastoma. A 
phase II trial has also showed some activity of itraconazole against basal cell carcinoma (207). In 
addition, various other compounds such as arsenic trioxide (ATO) (208,209) and vitamin D3 
(210,211) have been shown to inhibit Hh signaling through distinct mechanisms. ATO was 
effective in mouse tumors with drug-resistant Smo (208) a result in agreement with reported 
mechanisms involving ATO binding to GLI1 (209).  
Limitations of existing Hedgehog therapies 
 The clinical utility of targeting Hh signaling is evidenced by the effectiveness of small 
molecule Smo inhibitors in basal cell carcinoma and medulloblastoma. Unfortunately, Smo 
inhibitors have not yet shown efficacy in other types of malignancy, including colorectal (212) 
and ovarian (213) carcinoma. A number of trials for other malignancies are ongoing (155). The 
failure of Smo antagonists in tumors thought to involve oncogenic Hh signaling may be due to 
the underlying mechanisms of Hh pathway activation. Mutations of the PTCH1 tumor suppressor 
are often characteristic of basal cell carcinoma (96,97) and medulloblastoma (214). In contrast, 
GLI proteins may be activated by mechanisms independent of Hh and Smo in other 
malignancies, including pancreatic cancer, possibly explaining the failure of Smo inhibitors in 
this context. In this case, Hh pathway inhibitors that act downstream of Smo may prove useful, 
although there is as yet no clinical data. Increased understanding of the mechanisms governing 
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GLI1 protein stability may help devise new strategies to target oncogenic Hh signaling. 
Destabilization of GLI1 protein could prove therapeutically useful in tumors resistant to Smo 
inhibitors, resultant either from intrinsic independence of Smo, or from acquired Smo mutations 
associated with resistance (194).   
The ubiquitin pathway and regulation of GLI1 protein stability 
 The processing and degradation of GLI family proteins is regulated by the ubiquitin-
proteasome system. By interacting with the SCF
β-TrCP
 complex, GLI proteins are ubiquitylated, 
targeting them to the 26S proteasome. The association of GLI1 with the F-box protein β-TrCP is 
a critical subject of the Results section (Chapter 2), wherein we describe novel mechanisms 
governing GLI1 stability. The interaction of β-TrCP with the SCF component SKP1 also has an 
important role. 
The ubiquitin-proteasome system 
 Protein degradation is highly selective and regulated, serving to control many cellular 
processes. The major pathway of protein degradation in eukaryotic cells is the ubiquitin-
proteasome system (UPS) (215). The discovery of the UPS is a significant achievement in 
biological chemistry, upending earlier paradigms of protein homeostasis (216).  In this pathway, 
the small protein ubiquitin functions as a tag to achieve selectivity in the targeting of substrates 
to the proteasome. The UPS therefore involves two successive mechanisms (217). First, in a 
specialized type of posttranslational modification, proteins are marked with ubiquitin through a 
multistep mechanism. Secondly, ubiquitin-conjugated proteins are degraded by the 26S 
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proteasome, or in some cases processed without complete degradation. There are four ubiquitin 
genes in humans. In addition, several other small proteins are added as posttranslational 
modifications in a manner analogous to ubiquitin, although often with distinct functions. 
 A sequence of enzyme activities (Fig. 8) leads to the ubiquitylation of proteins (218). 
Ubiquitin is first activated by an E1 ubiquitin activating enzyme, leading to a thioester linkage 
connecting the C-terminal carboxyl group of ubiquitin to a cysteine residue of the E1 enzyme. 
The ubiquitin is then transferred to a cysteine residue of an E2 ubiquitin conjugating enzyme. 
Finally, an E3 ubiquitin ligase catalyzes the ubiquitylation of the target protein. Typically this 
ubiquitylation occurs via an isopeptide bond of ubiquitin to a lysine residue of the substrate.  
 A substrate that is monoubiquitylated can dissociate from the E3 ligase, in which case the 
monoubiquitylation likely serves to alter protein function rather than promoting degradation. 
Alternatively, the E3-bound substrate can receive additional ubiquitylation, as the ubiquitin 
peptide is also a suitable substrate. This mechanism leads to proteins modified by chains of 
ubiquitin. The function of polyubiquitin chains depends on the particular residue of ubiquitin 
involved in linkage. Some types of chains, such as ubiquitin K63 chains, may act to regulate 
protein function rather than targeting to the proteasome. In contrast, chains formed through 
residues such as K48 and K29 direct the polyubiquitylated substrate to the proteasome. The 
particular lysine residues involved determine the structure of the polyubiquitin chain, which 
affects the interaction with ubiquitin-binding domains present on other proteins (219,220). For 
some substrates, ubiquitin receptor proteins are important in delivering the ubiquitylated 
substrate to the proteasome or otherwise determining the biological effects of ubiquitylation 
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(221).The 19S regulatory subunit of the mammalian 26S proteasome recognizes ubiquitin tags 
and controls access to the core particle, which results in proteolysis (215).  
 The UPS regulates many pathways that are relevant towards human disease, and UPS 
dysregulation is implicated in pathologies such cancer, neurodegeneration, and other conditions 
(217,222). Moreover, pharmacologic inhibition of the proteasome may be clinically useful in 
some malignancies (223,224). In phase III trials, the proteasome inhibitor bortezomib was 
associated with increased response and survival in multiple myeloma (225) and mantle cell 
lymphoma (226), and bortezomib is approved by the FDA for treatment of these cancers. A 
second-generation proteasome inhibitor, carfilzomib, has also gained regulatory approval. 
Further pre-clinical and clinical studies for these and other proteasome inhibitors are in progress 
(227).     
  While current UPS therapies act to target the proteasome, abnormal functioning of the 
ubiquitin cascade is also highly linked to disease processes, including neoplasia. There is some 
evidence for the contribution of E2 ubiquitin-conjugating enzymes towards tumorigenesis (228), 
although most malignant alterations of the UPS in cancer seem to involve dysregulation of E3 
ubiquitin ligases (229). Conceptually, an E3 ligase could promote tumor formation by 
ubiquitylating tumor suppressor proteins, or oppose tumorigenesis by targeting oncoproteins. In 
fact, many of the well-characterized E3 ligases target both oncoproteins and tumor suppressors, 
and therefore the overall role of the specific E3 ligase complex remains context-dependent, as is 
the case for the F-box protein and E3 ligase component β-TrCP (229,230). 
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The E3 ubiquitin ligase  
 In the ubiquitylation cascade, the E3 ligase functions as a substrate-specifying factor. 
This is reflected in the diversity of E3 ubiquitin ligases in comparison to E1 and E2 enzymes. 
Currently are at least 600 recognized E3 ubiquitin ligases, but only 30-some E2 enzymes and a 
smaller number of E1 enzymes (231-233). E3 enzymes can be broadly classified based on 
several structural motifs, which often relate to the mechanism of interaction with the E2 
ubiquitin conjugating enzyme. The largest group of E3 ligases is of the RING-finger type, of 
which SCF complexes, including SCF
β-TrCP
, belong (222). Other types of E3 ligase include the 
HECT, U-box, and PHD finger domains. 
 SCF complexes 
 The earliest described SCF complex was characterized in yeast, identifying the pathway 
responsible for degradation of the cyclin-dependent kinase (Cdk) inhibitor Sic1. In 
Saccharomyces cerevisiase, the degradation of Sic1 via the ubiquitin-conjugating (E2) enzyme 
Cdc34 allows the G1-S transition to occur (234). Extensive efforts have led to a model in which 
the Cdc34-mediated ubiquitylation of Sic1 occurs via an E3 ubiquitin ligase complex containing 
the proteins Skp1, Cdc53, Rbx1, and Cdc4 (235-242). This type of E3 ubiquitin ligase is known 
as an SCF complex, representing the proteins Skp1, Cdc53, and one of numerous F-box proteins.  
 The yeast protein Cdc53 is a cullin protein, and in metazoans the homologue of Cdc53 is 
CUL1. Therefore, in humans the SCF moniker denotes the three factors: SKIP1, CUL1, and an 
F-box protein. The SCF complex also includes the subunit RING box protein 1 (Rbx1). SCF 
36 
 
complexes belong to a larger group of E3 ligases, known as the Cullin-RING family, which 
represent the largest family of E3 ubiquitin ligases (243). RING-based E3 ligase complexes are 
structurally and functionally distinct from the homologous to E6AP (HECT) domain-involving 
E3 ligases, in that RING-based E3 ligases such as SCF complexes do not form a ubiquitin 
thioester intermediate (244,245). While SCF complexes are historically recognized for functions 
in the regulation of the cell cycle, the SCF family of E3 ubiquitin ligases also participates in 
other processes, including development, differentiation, apoptosis, an lipid metabolism (229).  
 A specific SCF complex is denoted by specifying the particular F-box protein. The SCF 
class of E3 ubiquitin ligases includes SCF
β-TrCP
, which mediates the ubiquitylation of GLI 
proteins and other substrates. In brief, β-TrCP functions to recognize the SCF substrate, while 
SKP1 functions as an adaptor linking β-TrCP to CUL1, which in turn acts as a scaffold to link 
the β-TrCP/SKP1 complex with Rbx1. Through the RING domain, Rbx1 mediates the 
interaction of an E2 ubiquitin-conjugating enzyme with the SCF complex. In this manner, the 
SCF promotes ubiquitylation of F-box substrates. As SCF
β-TrCP
 is a key determinant of GLI 
protein stability, the structure and function of the SCF complex is reviewed in further detail. 
SKP1 
 Human S-phase kinase-associated protein (SKP1) was first identified in a complex with 
cyclin A/Cdk2 and the F-box containing protein SKP2 (246). The homologue in yeast was then 
described (247). A small protein found in eukaryotes, SKP1 contains around 160 amino acid 
residues and functions as an adaptor protein to mediate the interaction of F-boxs protein with 
CUL1. SKP1 may also promote SCF complex assembly and function through other mechanisms. 
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The expression of SKP1 serves to promote F-box protein expression by aiding in the correct 
folding and preventing formation of aggregates. Additionally, SKP1 expression promotes the 
substrate binding function of F-box proteins (248).The interaction of SKP1 and the F-box protein 
SKP2 has been determined by crystal structure (249). SKP1 and SKP2 directly associate through 
a complex interface that is highly hydrophobic, involving interactions of helical structures of 
both SKP1 and SKP2 in an interdigitated manner.  
CUL1 
 Cullins are a family of proteins found in eukaryotes (250) that perform a scaffolding 
function in the structure of multiple E3 ubiquitin ligases (251). Cullin proteins are characterized 
by a C-terminal globular structure, known as the cullin homology domain, which mediates 
protein-protein interactions. Human CUL1 was identified as an interacting partner with the 
SKP1/SKP2 complex (252), and is now recognized as the cullin component of SCF complexes 
(243). Another example is the anaphase promoting complex (APC), a type of E3 ubiquitin ligase, 
which contains the subunit APC2 with cullin homology (253). 
  Cullin proteins are notable as substrates for neddylation, in which the ubiquitin-like 
protein NEDD8 (254) is covalently conjugated through mechanisms similar to the ubiquitin 
system (255). This posttranslational modification is important for the function of CUL1 in the 
SCF complex (256), and promotes the ubiquitination of the SCF
β-TrCP
 substrate IκBα (257). 
Although only a small fraction of the cellular CUL1 is neddylated, the NEDD8-modified CUL1 
may preferentially associate with β-TrCP (257). Unneddylated CUL1 is also bound by CAND1 
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(258), which prevents CUL1-SKP1 association, thereby implicating CAND1 as a factor that 
regulates SCF complex assembly (259,260). 
 The structure of CUL1 is critical towards the SCF complex function, and the crystal 
structure of SCF
SKP2
 in association with Rbx1 reveals the essential scaffolding role of CUL1 
(261). In this structure, CUL1 interacts with each other element: SKP1, SKP2, and Rbx1. The 
SKP1/SKP2 site of interaction is located at the opposite end of CUL1 from the site of Rbx1 
association. The N-terminal domain of CUL1 is a stalk-like structure composed of three repeats 
of a five-helix motif, of which the N-terminal repeat interacts with the SKP1/SKP2 complex. The 
C-terminal region of CUL1 is globular, and interacts with Rbx1. The rigidity of the CUL1 
scaffold seems essential to the SCF complex function. Mutations that disrupted the rigidity of 
CUL1, in which the N-terminal and C-terminal CUL1 domains were connected by a flexible 
linker, disrupted the E3 ubiquitin ligase activity of SCF
SKP2
 (261). 
Rbx1 
 Rbx1, also known as ROC1 or HRT1, contains a RING domain that is found in numerous 
human proteins. The RING domain was first identified in really interesting new gene 1 (RING1) 
and is a type of zinc finger structure (262,263). While RING domain-containing proteins are 
widespread throughout eukaryotic organisms, performing a variety of roles, many RING proteins 
are crucial participants in the interplay of E2 ubiquitin-conjugating and E3 ubiquitin ligase 
complexes (243,264,265). Indeed, almost all RING domain proteins are thought to have some 
function in the transfer of ubiquitin (244). In a yeast two-hybrid screen, the human ubiquitin-
conjugating enzyme E2 L3 (UBCE2L3) was found to associate with the RING protein human 
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homolog of Ariadne (HHARI) (266). This structure was later determined by crystallography 
(267). In yeast, Rbx1 stimulates SCF ubiquitin ligase activity by promoting the association of 
Cdc53 with Cdc34 (242), which is homologous to the ubiquitin-conjugating enzyme E2R1 in 
humans(268).   
 A model of the interaction of the SCF
SKP2
-Rbx1 complex with UBCE2L3 has also been 
studied (261). UBCE2L3 interacts with the RING domain of Rbx1. With respect to CUL1, 
UBCE2L3 is situated in the same plane as the leucine-rich repeats of SKP2. Analogous in 
function to the WD-repeats of β-TrCP, the leucine-rich repeats of SKP2 determine substrate 
specificity. At a distance of about 50 Å, the active cysteine of the E2 enzyme is directly aligned 
with the tip of the leucine-rich region. The F-box protein, in this case SKP2, can interact with a 
number of different substrate proteins, each of which may contain multiple lysines or alternate 
residues to be conjugated with ubiquitin. From this standpoint, the structure of the SCF-Rbx1 
complex, and in particular the length of the CUL1 N-terminal region, serves to accommodate the 
diversity in F-box substrates (261). 
F-box proteins 
 In 1995, the homology of protein Scon2 was compared with the proteins β-TrCP, Cdc4, 
Met30, and FBXW2 (269). Each peptide sequence contained C-terminal WD repeats. 
Additionally, the analyzed sequences contained an N-terminal region of homology. This motif 
was later recognized to be a domain of interaction with Skp1 (235).  
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 The F-box motif, as the defining characteristic of F-box proteins, has around 50 residues. 
Only a few specific residues are conserved strongly (270). As SCF components, F-box proteins 
interact with SKP1 through the F-box motif, and F-box proteins found in SCF complexes also 
mediate SCF substrate recognition. This occurs through a region of the F-box protein that is 
distinct from the F-box domain. Typically, F-box proteins recognize substrates with site-specific 
phosphorylation of a small conserved sequence known as a destruction motif, or degron (264). 
The binding of F-box proteins to phosphodegrons of the substrate protein represents the 
canonical mechanism of substrate recruitment, although there alternative means of interaction 
(271). In addition to the role of F-box proteins in SCF complexes, some F-box proteins also 
participate in non-SCF protein interactions, in a variety of biochemical contexts (270).  
 In humans, there are several dozen F-box proteins (272,273). F-box proteins often 
contain either a WD repeat region or a leucine rich repeat, but many F-box proteins contain 
neither motif. Moreover, the wide diversity of secondary structures found within various F-box 
proteins, which includes zinc fingers, leucine zippers, ring fingers, cyclin domains, proline-rich 
regions, and tetratricopeptide (TPR) repeats, is interpreted to suggest an evolutionary history in 
which the F-box motif has been transferred into various existing proteins (270). Bioinformatics 
analysis demonstrates that amongst human F-box proteins, examples containing either WD-
repeat or leucine-rich repeats are most conserved in S. cerevisiae and C. elegans, whereas F-box 
proteins lacking either motif are frequently not conserved. Interestingly, C. elegans possesses 
around 10-fold more F-box proteins than do humans, many of which comprise F-box subclasses 
not found in either humans or the yeast S. cerevisiae (270).   
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 Formally, human F-box proteins may be named in reference to the substrate recognition 
domain: FBXL in the case of F-box proteins that contain leucine-rich repeats, FBXW for WD 
repeat-containing F-box proteins, and FBXO for F-box proteins not containing either leucine-
rich or WD-repeat motifs. Under this scheme, β-TrCP is represented as FBXW1. Most F-box 
proteins that participate in SCF complexes are either of the FBXW or the FBXL type, although 
some FBXO proteins might also associate as SCF complex members (272).  
 One way in which the ubiquitylation of SCF substrates is regulated is through assembly 
of the SCF complex. Intriguingly, some evidence suggests that substrate binding promotes SCF 
complex assembly (274). Conversely, SKP1 binding to the F-box domain of an F-box protein is 
thought to promote the interaction of the F-box protein with SCF substrates (248). These 
hypotheses are relevant to our studies of the interaction of SCF
β-TrCP
 with the substrate GLI1. In 
the Results section (Chapter 2), we show that β-TrCP-SKP1 binding is altered in correlation with 
the interaction of β-TrCP with the substrate GLI1. 
β-TrCP  
 β-TrCP is the F-box protein component of the E3 ubiquitin ligase compex SCFβ-TrCP, and 
is homologous to the Drosophila protein supernumerary limbs (Slmb). In addition to the F-box 
motif, β-TrCP and Slmb contain a C-terminal region of WD40 repeats. The WD repeat is a 
sequence of approximately 40 residues, typically ending in tryptophan-aspartate (W-D). This 
motif was first identified in the peptide sequence of the β subunit of retinal transducin, a 
heterotrimeric G protein. This sequence was immediately observed to have homology to yeast 
CDC4, which is now recognized as a WD repeat-containing F-box protein (275). β-TrCP is an 
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abbreviation for β-transducin repeat containing protein, in recognition of the WD repeat 
homology. As the function of β-TrCP is that of an F-box protein, the systematic name FBXW1 
may be preferable, in that it enumerates both F-box and WD structural features. In this 
dissertation, β-TrCP is used for consistency with existing literature. 
 Mammalian β-TrCP is subfamily of F-box proteins composed of β-TrCP1 and β-TrCP2, 
although the existence of the latter protein seems frequently overlooked. In F-box nomenclature, 
β-TrCP1 is FBXW1 and β-TrCP2 is FBXW11. Differences in the N-terminal sequences near the 
F-box motif are proposed to relate to the homo- and hetero-dimerization of β-TrCP proteins 
(276). Homodimerization of β-TrCP, mediated through the N-terminal domains, has been 
associated with IκBα ubiquitylation (277). β-TrCP1 and β-TrCP2 appear to partially overlap in 
function. Some evidence suggests β-TrCP1 and β-TrCP2 exhibit functional redundancy. In a 
mouse model with β-TrCP1 loss-of-function, β-TrCP1-/- male mice had defects in 
spermatogenesis associated with cell-cycle dysregulation, but there was no observed stabilization 
of the β-TrCP substrates IκBα or β-catenin (278). A contrasting report has demonstrated loss of 
IκBα degradation in β-TrCP1 knockout cells (279). Recently, proteomics methods using mass 
spectrometry were used to identify prospective β-TrCP1 substrates (280), as well as to compare 
β-TrCP1 and β-TrCP2 substrates (281). While most β-TrCP1 associated proteins, including those 
previously characterized as β-TrCP1 substrates, were also putative targets of β-TrCP2, there 
were many proteins associated with β-TrCP2 that did not immunoprecipitate with β-TrCP1. The 
functional consequences of these differences remain largely unknown. 
 As with other F-box proteins, substrates of β-TrCP are classically characterized by 
destruction motifs known as degrons. Degrons found in β-TrCP substrates are often of the form 
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DSGXXS. Serine phosphorylation by specific kinases facilitates β-TrCP recognition, and 
ubiquitylation by SCF
β-TrCP
 at lysines positioned 9-13 residues on the N-terminal side of the 
degron (230,276). Alternative degrons for β-TrCP have also been described (276). GLI1 does not 
possess classical degrons for β-TrCP, but does have DSGVEM sequences that appear to function 
similarly to the traditional DSGXXS degrons. This DSGVEM sequence is also found in GLI2 
(35). 
 The structure of SCF
β-TrCP
 interaction with the substrate β-catenin is partially solved. In 
this case, the crystal structure of β-TrCP-SKP1 bound to a 26-residue β-catenin substrate peptide 
was determined (282). As with SKP2 (261), the F-box domain comprises multiple helices with 
linkers, forming a bipartite interface with SKP1. The propeller or torus-like structure composed 
of WD domains contains a central pore, partially entered by the critical degron residues of the β-
catenin fragment. The Asp32 residue, of the β-catenin destruction motif DSGIHS, most 
extensively interacts with key residues of the β-TrCP WD structure (261). It is possible to 
recreate a full model of SCF
β-TrCP
 bound to the β-catenin substrate peptide by combining the 
relevant structures of the β-TrCP-SKP1-β-catenin complex (282) with the previously reported 
SCF
SKP2
 structure (261). Notably, this structure places the substrate-binding WD propeller motif 
of β-TrCP facing the E2 interacting site of Rbx1 (Fig. 9). In this manner, the WD domains of β-
TrCP, and the overall structure of SCF
β-TrCP
, facilitate the transfer of ubiquitin from the E2 
conjugating enzyme to the E3 ligase substrate.   
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Substrates of β-TrCP and function of β-TrCP as oncoprotein or tumor suppressor   
 There are numerous reported substrates of β-TrCP, implicating SCFβ-TrCP in the 
regulation of many biological processes.  Cell cycle regulation and apoptosis are two functions 
incorporating multiple protein substrates of β-TrCP. Similarly, pathways such as NF-κB and 
growth hormone signaling involve multiple β-TrCP-targeted proteins (230). Krüppel-like factor 
4(KLF4), the second topic of this dissertation, is also a reported substrate of β-TrCP (283). 
Compilations of verified β-TrCP substrates are available (230,284), but new research quickly 
renders such listings outdated. In addition to true substrates, in which the β-TrCP-substrate 
interaction mediates substrate ubiquitylation by the E3 ligase SCF
β-TrCP
, there is also at least one 
factor, heterogeneous nuclear ribonucleoprotein U (hnRNP-U), that functions as a 
pseudosubstrate (285). The WD region of β-TrCP interacts readily with hnRNP-U, but this 
interaction does not affect hnRNP-U stability.  
 Rather than to list all reported β-TrCP substrates, the proposed functions of β-TrCP in 
cancer are discussed, with several examples of β-TrCP substrates that are implicated in 
malignancy. By targeting cancer-relevant proteins for degradation, or in some cases processing, 
β-TrCP can exert both pro- and anti- tumorigenic effects depending on context, although tumor-
promoting roles seem to be emphasized in the literature (229,230,276). The interaction of β-
TrCP and GLI proteins is discussed separately, in greater detail. Proteomics and bioinformatics 
methods are increasingly utilized in the study of β-TrCP substrates (280,281), and are likely to 
expand knowledge of the function of SCF
β-TrCP
 and other E3 ubiquitin ligases. 
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 The proteolysis of cell cycle regulators through the ubiquitin-proteasome system, 
involving multiple E3 ligases, is a central mechanism controlling the activity of cyclin-dependent 
kinases (CDKs) and cell cycle progression. SCF
β-TrCP
 can function to both positively and 
negatively regulate the cell cycle through multiple substrates (230). For example, β-TrCP 
promotes degradation of CDC25A to inhibit CDK1 activity in S phase (286,287), but can 
enhance CDK1 activity in G2-M phases by promoting degradation of WEE1 (288) and claspin 
(289,290). β-TrCP also promotes degradation of EMI (also known as FBX5/FBXO5) in mitosis 
(278). These substrates are also relevant to the function of β-TrCP in S-G2 cell cycle arrest in 
response to DNA damage (230). Increased degradation of WEE1 and claspin are proposed to 
explain the delay of the G2-M transition and mitosis in β-TrCP1 knockout MEFs (230). 
 A classic example of the role of β-TrCP in cancer-relevant signaling processes is through 
NF-κB. The NF-κB pathway mediates inflammatory signaling and is regulated by β-TrCP 
through IκB. β-TrCP recognizes phosphorylated IκBα, IκBβ, and IκBε proteins, facilitating their 
ubiquitylation via SCF
β-TrCP
 (291) (292-298). This ubiquitylation and subsequent degradation of 
IκB peptides permits NF-κB nuclear localization and transcriptional regulation. NF-κB pathway 
activation may contribute to malignancy (299), and overexpression of β-TrCP is associated with 
constitutive NF-κB signaling in pancreatic cancer cells through enhanced degradation of IκB 
(300).  
 Other tumor types associated with upregulation of β-TrCP include breast cancer (301), 
colon cancer (302), melanoma (303,304), and hepatoblastoma (305). In mice overexpressing β-
TrCP by use of the mouse mammary tumor virus (MMTV) promoter, there was abnormal 
development of the mammary gland related to increased epithelial proliferation, whereas the 
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mammary glands of female β-TrCP-/- mice were hypoplastic (306). There was also increased 
nuclear and DNA-bound NF-κB in MMTV-β-TrCP mice, of which 38% developed tumors such 
as mammary, ovarian, and uterine carcinomas. In addition to IκB, β-TrCP-mediated 
ubiquitylation exerts tumor-promoting effects by enhancing degradation of tumor suppressor 
substrates such as programmed cell death 4 (PDCD4) (307). By binding the eukaryotic 
translation initiation factor 4A1, PDCD4 suppresses translation, and has the phenotypic effects of 
suppressing proliferation and promoting apoptosis (308). 
 Although there is evidence that β-TrCP promotes tumorigenesis in some contexts, other 
well-known substrates of β-TrCP are oncogenic in function, suggesting β-TrCP could have 
tumor-suppressive effects. One of the best characterized substrates of β-TrCP is β-catenin. As a 
protein with dual functions in cell adhesion and transcriptional signaling, β-catenin has essential 
roles in development and other biological processes, and dysregulation of β-catenin signaling 
contributes to cancer development and progression (309,310). The Wnt signaling pathway 
regulates phosphorylation of β-catenin by kinases including GSK3β (311,312), which is 
“primed” through phosphorylation by CK1 (313-315). β-catenin contains a degron motif similar 
to that found in IκB proteins, of the form DSGXXS, that is essential for recognition by β-TrCP 
(276). The β-catenin degron sequence is DSGIHS, of residues 32-37. Mutations of β-catenin that 
affect interaction with the degradation pathway components are found in some human tumors, 
although β-catenin stabilization through mutation of factors such as APC or overexpression of 
Wnt ligands is more common (316). Experimental suppression of β-TrCP does result in β-
catenin stabilization, but whether β-catenin stabilization in human tumors may occur through 
decreased β-TrCP activity is uncertain (276).   
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 Another example of a β-TrCP oncogenic substrate is the transcription factor SNAI1, 
often known as Snail, which is a potent suppressor of E-cadherin and inducer of EMT (317). In a 
pathway similar to that observed for β-catenin, phosphorylation by kinases including GSK3β 
promote association with β-TrCP, ubiquitylation, and degradation by the UPS (318,319). The 
oncoprotein mouse double minute homolog 2 (Mdm2), itself a type of E3 ubiquitin ligase, is also 
a β-TrCP substrate. Mdm2 functions as an E3 ligase for the tumor suppressor p53, promoting 
degradation of p53 (320). Increased β-TrCP-mediated turnover of Mdm2 in response to DNA 
damage leads to stabilization of p53, suggesting a tumor-suppressive function of β-TrCP (321).  
Regulation of GLI proteins and β-TrCP interactions 
 The GLI family of proteins, and the Drosophila homolog Ci are regulated by 
phosphorylation, which governs interaction with SCF
β-TrCP/Slimb
. Ci undergoes multisite 
phosphorylation by PKA (322), which seems to prime Ci for additional phosphorylation by 
GSK3β (323) and CK1  (324). In mammals, the related mechanisms are best understood for 
GLI2 and GLI3.  
 For GLI2 protein, a cluster of serine residues located within the carboxyl terminus is 
phosphorylated by PKA, leading to subsequent phosphorylation by GSK3β and CK1 (76). 
Phosphorylation of GLI2 enhances GLI2- SCF
β-TrCP
 interaction, which inhibits the transcriptional 
activity of GLI2 (75). Notably, expression of GLI2 with phosphorylation site mutations can 
rescue some of the developmental consequences of Shh mutation (75). This result is consistent 
with the understanding of classical Hh signaling, in which Hh ligand binding regulates the 
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stability and processing of the GLI/Ci effector proteins through site-specific phosphorylation and 
interaction with the SCF
β-TrCP/Slimb
 component of the UPS. 
 Highly similar processes also regulate GLI3 function, and the putative phosphorylation 
sites involved in GLI3 processing have been described using sequence analysis and mutagenesis 
(72). Serine phosphorylation in PKA consensus RRXS sites initiates the phosphorylation 
cascade. GSK3β targets serine residues for phosphorylation four residues N-terminal of a 
phosphorylated serine, and CK1 phosphorylates serines three residues on the C-terminal side of a 
phosphoserine. Thus, once initial priming phosphorylations by PKA have occurred, 
phosphorylation by GSK3β and CK1 can create additional GSK3β and CK1 consensus 
sequences, resulting in multisite phosphorylation. 
 The interaction of β-TrCP with the substrate GLI1 is less understood in comparison to 
GLI2 and GLI3. Although structural elements are thought to determine why proteasome does not 
process GLI1 into a truncated form, in contrast to GLI2/GLI3 and Ci (50), the regulation of 
GLI1- β-TrCP binding remains relatively enigmatic. Still, the association of β-TrCP and GLI1 is 
readily observed, and can be shown to destabilize GLI1 protein (35). A C-terminal DSGVEM 
motif seems to function as a degron in GLI1; this is notably distinct from the canonical 
DSGXXS degrons found in β-TrCP substrates such as IκB proteins and β-catenin. Additionally, 
a conserved N-terminal sequence acts to destabilize GLI1 through interaction with β-TrCP. 
Deletion of both motifs strongly stabilizes GLI1 protein, and mice expressing stabilized GLI1 in 
the skin develop lesions resembling basal cell carcinoma. 
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Part II: Krüppel-like factor 4 
Part II overview: KLF4 and breast cancer metastasis 
 Krüppel-like factor 4 (KLF4) is a zinc finger transcription factor and regulator of 
proliferation, differentiation, and cell fate. KLF4 has important developmental roles, functions in 
the homeostasis of adult tissues, and is especially significant in pluripotency. The effects of 
KLF4 in cancer biology are varied, and while KLF4 may function as a tumor suppressor in some 
contexts, KLF4 expression promotes malignant properties in breast cancer cells. The role of 
KLF4 in the metastasis of breast cancer cells is poorly characterized. Although metastasis 
contributes heavily to morbidity and mortality in breast cancer, the biological mechanisms of 
metastasis are perhaps less understood in comparison to other hallmarks of malignancy. This 
introductory section reviews normal functions of KLF4, and describes the contrasting roles of 
KLF4 in breast cancer and other tumor types. Additionally, some of the translational aspects of 
metastasis research are discussed, and existing research into the role of KLF4 in metastasis is 
described in greater detail. In the Results section (Chapter 3), the function of KLF4 in the 
spontaneous metastasis of breast cancer cells is presented, in association with a signaling 
mechanism involving the collagen-binding discoidin domain receptor 1 (DDR1). 
Krüppel-like factor family 
 Krüppel-like factors (KLFs) are transcription factors with diverse roles in biology, and 
are named for homology to the Krüppel gene found in Drosophila melanogaster (325). Common 
to Krüppel and KLFs are three conserved zinc fingers. There are 17 KLFs in the human genome, 
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and KLFs are highly conserved in other mammalian species, including Mus musculus, Rattus 
norvegicus, Canis lupus, and Bos Taurus. Homologous KLF genes are described in the non-
mammalian vertebrates such as Gallus gallus, Danio rerio, and Xenopus laevis, while the 
invertebrate Caenorhabditis elegans contains at least 3 KLFs (326). The three carboxy-terminal 
C2H2 zinc fingers found in Krüppel and in KLFs are also found in the transcription factor Sp1 
(327). KLFs may then be classified as part of the Sp1/KLF family of zinc finger-containing 
transcription factors.  
 Krüppel was shown to regulate segmentation of the Drosophila embryo, and numerous 
functions are described for human KLFs. In addition to developmental roles, human KLFs are 
important regulators of cell proliferation, differentiation, and apoptosis (325). The KLFs are 
characterized by distinct expression and function in different cell types. KLFs 6, 10, and 11 are 
expressed widely. In contrast, KLF1 levels are high in erythrocytes, while KLF4 and KLF5 are 
abundantly expressed in gut tissue (328). Through the homologous carboxy-terminal zinc finger 
domains, KLFs interact with GC-rich elements of promoter and enhancer sequences to regulate 
gene expression. Amino-terminal sequences mediate interaction of KLFs with different protein 
binding partners, which helps determine whether the KLF serves to promote or to suppress 
expression of the target gene. For example, KLFs 3, 8, and 12 interact with the transcriptional 
corepressor CtBP (329-331).    
KLF4 discovery, expression, and structure 
 The study of KLFs originates with the identification of loci that affect segmentation of 
the Drosophila melanogaster embryo (1). Mutations of these “gap” genes could result in loss of 
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particular segments, and one such gap gene was named Krüppel, as loss could result in the 
“cripple” phenotype. All KLFs contain three C2H2 zinc fingers (Fig. 10). This motif is the most 
prevalent type of zinc finger, characterized by a ββα secondary structure containing two cysteine 
and two histidine residues that provide tetrahedral coordination of a zinc atom (332). In Krüppel 
and in KLFs, the spacing sequence between the zinc fingers is highly conserved, consisting of 
seven amino acids residues: TGEKP(Y/F)X, where X represents any residue. Aside from the 
three zinc fingers, and the intervening linker sequences, the homology between different KLFs is 
poor (328,333). The KLF proteins recognize GC-rich DNA binding sites, and the sequence 5’-
CACCC-3’ is a binding motif for KLF4 and other KLFs (330,334,335).  
 The gene presently known as KLF4 was first reported in 1996, by two different groups. 
In one study, an NIH3T3 library-derived cDNA clone was found to interact in reduced-
stringency conditions with a probe composed of a zinc-finger DNA sequence from the 
transcription factor EGR-1 (336). The corresponding mRNA was most highly expressed in the 
colon, and so the gene was named gut-enriched Krüppel-like factor (GKLF). The same gene was 
concurrently identified in primary mouse fibroblasts from E13.5 embryos, and named epithelial 
zinc finger (EZF) as high expression was observed in epithelial cells of the skin and other tissues 
(337). The homologous gene in humans was found in 1998, by screening a human umbilical vein 
endothelial cell (HUVEC) cDNA library with a probe derived from the zinc finger-coding region 
of KLF1, previously known as erythroid KLF (EKLF) (338). The tissue-specific naming of KLFs 
was eventually discarded in favor of sequential numbers, and GKLF/EZF became KLF4. 
52 
 
Expression of KLF4 in human tissue 
 KLF4 is expressed to varying degrees in many tissues. In addition to the gut, skin, and 
vascular endothelial cells, KLF4 is expressed in the cornea (339), cardiac myocytes (340), 
lymphocytes (341), and thymus (342). Expression is also found in the lung and testis (336). In 
these reports, the comparatively high expression of KLF4 in postmitotic cells of the skin and gut 
suggested that KLF4 may serve to promote epithelial differentiation.  
Structure of KLF4 
 In humans, the KLF4 gene is found on chromosome 9q31, spanning 6.3 kb and 
containing five exons (Fig. 11). The KLF4 transcript encodes a protein of 470 amino acid 
residues with a predicted 55 kDa mass (338). Together, the three carboxy-terminal C2H2 zinc 
finger domains and spacers comprise 81 residues with strong homology to other KLFs and to the 
Drosophila protein Krüppel, and mediate DNA interaction. Adjacent to the zinc finger domains 
is a nuclear localization signal (NLS). Other functional domains of KLF4 protein are known. The 
N-terminal region contains an acidic transactivation domain, while a repression domain is found 
in the middle region (338). Between the transcriptional activation and repression domains are 
two PEST sequences, which are rich in proline (P), glutamate (E), serine (S), and threonine (T). 
These elements are thought to promote degradation, possibly through the ubiquitin-proteasome 
pathway (343). 
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Transcriptional mechanisms of KLF4 
 KLF4 protein contains functional domains that mediate transcriptional activation and 
repression. Similarly to other sequence-specific transcription factors, KLF4 may promote or 
suppresses transcription by recruiting other factors to the regulatory regions of target genes. 
These elements may include chromatin modifiers, which are enzymes regulating acetylation, 
phosphorylation, methylation, and ubiquitylation. KLF4 may also interact with chromatin 
remodeling complexes, which are ATP-dependent protein complexes that move or restructure 
nucleasomes.  
KLF4 as a transcriptional activator 
 The transactivational role of the N-terminal sequence was demonstrated through analysis 
of KLF4 mutant constructs. These experiments demonstrated that a fusion fragment containing 
109 N-terminal residues with the GAL4 DNA-binding domain could activate a luciferase 
reporter, and compete with wild-type KLF4 (344). KLF4 was further shown through 
immunoprecipitation to interact with CREB binding protein (CBP), a histone acetyl transferase 
(HAT). CBP, and the closely related protein p300, can act as transcriptional co-activators by 
catalyzing transfer of acetyl groups to positively charged residues of histone proteins. This is 
thought to promote transcription by loosening the chromatin structure and altering interaction 
with other regulatory proteins (345). Mutations designed to disrupt the KLF4-CBP interaction 
also suppressed KLF4 transactivation (344). KAT5, a HAT enzyme that also has histone 
deacetylase (HDAC) activity, may also interact with KLF4 (346). Other factors that function as 
co-activators with KLF4 include EGR2 and the p65/RelA subunit of NF-κB (347). 
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Transactivation targets of KLF4 are diverse and include KLF4 (348), E-Cadherin (349), keratin 4 
(350), keratin 19 (351), intestinal alkaline phosphatase (352,353), type 1 cGMP-dependent 
protein kinase (PKG I) (354), inducible nitric oxide synthase (347), Laminin-α 3A (355), 
Laminin-γ 1 (356), SPRR1A and SPRR2A (350), Involucrin (357), Lefty-1 (358), the stem cell 
factors Nanog, Oct4, Tbx3, and Sox2 (359), p21
Waf1/Cip1
 (360), p27
Kip1
 (361), p57
Kip2
 (362), Rb 
(361), miR-206 (363), platelet isoform of phosphofructokinase (PFKP) (364), and the urokinase 
receptor (uPAR) (365). 
KLF4 as a transcriptional suppressor 
 KLF4 can repress transcription of target genes through competition with other factors. 
This mechanism of passive repression is illustrated through the competition between KLF4 and 
SP1, which share strong homology in the DNA binding domain. The binding of KLF4 to 
promoter regions inhibits SP1-mediated transactivation of genes such as SP1 (366), CYP1A1 
(367), and HDC (346). KLF4 also possesses a central repression domain, which serves to 
negatively regulate transcription through recruitment of factors such as HDACs. The removal of 
acetyl groups from the histone proteins promotes closer interaction between positively charged 
histone residues and the negatively charged phosphates groups found in DNA, with the effect of 
suppressing transcription. For example, KLF4 mediates suppression of CD11d through 
recruitment of HDAC1 and HDAC2 (368), interacts with HDAC3 to suppress Cyclin B1 (369), 
and suppresses TP53 through HDAC1 and HDAC3 (370). In a complex with HDAC7 and 
KAT5, KLF4 binds the HDC gene promoter to suppress expression of HDC (346). KLF4 is also 
a negative transcriptional regulator of the Wnt signaling pathway. In this mechanism, KLF4 
interacts with β-catenin/TCF-4 (371). Additional genes that are suppressed KLF4 at the 
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transcriptional level include Bax (372), Cyclin D1 (373) and Cyclin D2 (374), Cyclin E (375), 
Fibroblast growth factor 5 (359), KLF2 (358,359), Lactate dehydrogenase (376), Laminin α1 
(353), Nes (359), Ornithine decarboxylase (377), SM22α (378), SM α-actin (379), MAPK8/Jnk1 
(380), N-Cadherin and Vimentin (380), and IFITM3 (381).  
Normal functions of KLF4 
 KLF4 is implicated in several normal biological functions. These include cellular 
processes of proliferation, differentiation, and apoptosis. KLF4 can be induced by DNA damage 
and other types of stress. This is exemplified by KLF4 expression in the processes of growth 
arrest and differentiation as part of normal maintenance of the intestinal epithelium, or by the 
growth arrest and apoptotic resistance conferred by KLF4 upregulation in response to ionizing 
radiation. In concert with the role of KLF4 in maintaining normal epithelia, homozygous KLF4 
knockout mice are born live but quickly perish from dehydration as the skin lacks an effective 
permeability barrier to moisture. Additionally, KLF4 has more recently been implicated in the 
biology of stem cells.   
Proliferation and differentiation 
 KLF4 frequently has antiproliferative effects. This consideration is based on several lines 
of evidence, and mechanistically related to transcriptional effects of KLF4 on target genes that 
regulate cell cycle progression (325). Moreover, the antiproliferative role of KLF4 in epithelial 
cells is linked to cell differentiation. Observationally, KLF4 expression in epithelia is highest in 
differentiated, growth-arrested cells. Early reports of KLF4 expression in human tissue found 
56 
 
that KLF4 mRNA expression in the colon was localized to cells undergoing growth arrest as part 
of differentiation into mature colonocytes (336). In contrast, proliferating cells at the base of the 
crypts had low expression of KLF4. These results demonstrate a gradient pattern of KLF4 
expression in the colonic crypts, in which KLF4 upregulation is associated with decreased cell 
proliferation and increasing epithelial differentiation. In vitro, KLF4 expression corresponds to 
growth arrest resultant from serum starvation in NIH3T3 fibroblasts (336). In rat kidney 
epithelial cells (RK3E), KLF4 is upregulated in association with growth arrest when cultured 
cells become confluent (363). A similar effect is seen in the NIH3T3 line, where cells in 
complete media are subject to contact inhibition of growth in association with KLF4 
upregulation if not passaged (336). In addition to the spatiotemporal association of KLF4 
expression and growth-arrest, gain-of-function experiments implicate KLF4 as antiproliferative. 
Upon transfection of a KLF4 expression vector, cells expressing KLF4 failed to incorporate the 
nucleoside analog BrdU, whereas BrdU+ cells did not express KLF4 (336). As is documented in 
B lymphocytes, KLF4 is not invariably antiproliferative in function. 
 Multiple gene products mediate the antiproliferative activity of KLF4. The failure of 
DNA synthesis in KLF4-overexpressing cells (336) is further explained by analysis of cells 
containing an inducible KLF4 vector (382). In this system, ectopic expression of KLF4 was 
dependent upon a promoter responsive to the insect hormone ecdysone, and treatment with an 
ecdysone analogue blocked the G1/S phase transition. In subsequent work, expression profiling 
by microarray revealed a number of cell-cycle regulatory genes that were activated or suppressed 
by KLF4 (362). Upregulated products included the cyclin-dependent kinase inhibitors 
p21
Waf1/Cip1
  (383)and p57
Kip2
 (384), the insulin-like growth factor (IGF) signaling pathway 
antagonist IGFBP6 (385), and stratifin, a 14-3-3 protein that promotes G2 arrest (386). Increased 
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expression of these antiproliferative genes in KLF4-overexpressing cells was verified by 
northern blot. In the same study, a number of proliferation-related genes were downregulated, 
including transcripts coding for Ki-67, CDK1, Cyclin D1, and Forkhead box protein M1 
(FOXM1). In addition, KLF4 transcriptional profiling by microarray revealed a role for KLF4 as 
a negative regulator of certain macromolecule anabolic pathways, most notably protein 
biosynthesis (387). This function might conceivably also serve to inhibit proliferation. 
Collectively, these studies indicate that in many contexts KLF4 mediates an antiproliferative 
transcriptional program.      
Skin and gut development 
 There are crucial functions of KLF4 in the differentiation of skin and gut tissues. The 
phenotypes of knockout mice are illustrative, as Klf4
-/-
 mice exhibit deficiency of the skin 
moisture barrier that is fatal soon after birth (388). In normal development, the skin barrier forms 
at day 16 of gestation (389). The defect in barrier function is demonstrated by rapid passage of 
body fluids and permeability to external dyes (Fig. 12). The basal and spinous layers of the skin 
of newborn Klf4
-/-
 mice appear normal, whereas electron microscopy of osmium tetroxide-fixed 
specimens shows abnormal distribution of lipids on the cornified envelope (CE) protein scaffold. 
KLF4 is also transcriptionally implicated in the protein kinase C δ (PKCδ)-related upregulation 
of involucrin in the differentiation of keratinocytes (357). In this mechanism, KLF4 expression is 
induced by PKCδ (357,390). 
 Consistent with the role of KLF4 in the maintenance of the colonic epithelium, the 
number of goblet cells in the colon of Klf4
-/-
 mice is vastly decreased,  (391). Remaining goblet 
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cells appeared to have altered morphology (Fig. 13).The residual goblet cells were also abnormal 
by ultrastructural analysis and appeared to have defective secretory function with aberrant 
expression of Muc2. Intestine-specific knockout of murine Klf4, from crossing Klf4-floxed mice 
with mice expressing Cre recombinase as controlled by the Villin promoter (392), revealed 
additional features. In addition to defects in goblet cell differentiation, abnormalities included 
increased proliferation and migration of intestinal cells, decreased brush-border expression of 
alkaline phosphatase, and decreased expression of carbonic anhydrase-1, a differentiation marker 
of colonic enterocytes (392). In the normal human colon, expression of KLF4 is lowest in 
proliferating cells at the base of the crypts (371). KLF4 protein becomes highly expressed at the 
apex, where the epithelial cells are differentiated and growth-arrested (Fig. 14). 
 KLF4 may also mediate some effects of the Notch signaling pathway on the 
differentiation of cells in the gastrointestinal tract. Treatment with a Notch pathway inhibitor 
increased the number of KLF4-positive cells in the crypts of the mouse small intestine and colon, 
and the amplifying crypt cells in control mice were replaced by differentiated goblet cells in the 
small intestine (393). Mechanistically, Notch signaling can suppress a response element in the 
human KLF4 promoter (393). The transcription factor Hairy and enhancer of split 1 (Hes1), a 
downstream target of Notch signaling, can also suppress KLF4 promoter activity (394), and 
Notch-mediated suppression of KLF4 may account for the proliferative and tumorigenic 
properties of Notch signaling in colon cancer cells (395). 
 Differentiation, metabolism, and apoptosis in colonic cells can be regulated by short-
chain fatty acids such as butyrate, which may be obtained by bacterial fermentation of dietary 
fiber (396).  These effects may be partially mediated through KLF4, as levels of KLF4 increased 
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during butyrate-induced differentiation (397,398), and butyrate can transactivate the KLF4 
promoter (397). The actions of KLF4 to promote differentiation and suppress proliferation in 
cells of the intestine seem linked to the role of KLF4 as a tumor suppressor in gastrointestinal 
malignancy. 
 KLF4 also functions in other gastrointestinal tissues, including esophagus and stomach. 
In esophageal squamous epithelial cells, KLF4 is highly expressed and promotes a differentiated 
phenotype through transactivation of Keratin 4 (399) and Keratin 19 (351) promoters. 
Esophageal deletion of Klf4 in mice results in increased proliferation and defects in 
differentiation of esophageal cells (400). In the stomach, tissue-specific deletion of Klf4 results 
in mice with gastric epithelial hypertrophy, mucus cell hyperplasia, and partial loss of parietal 
cells (401). Although mice did not develop tumors up to one year of age, the altered epithelial 
differentiation, increased proliferation, and abnormal expression of acidic mucins were 
considered indicative of a premalignant state. It is possible that the changes in gastrointestinal 
epithelial tissue associated with Klf4 deletion may result from loss of the epithelial permeability 
barrier. In this respect, the tumor-suppressive effects of KLF4 in the mouse gut might not reflect 
the clonal origin of human tumors. 
Blood cells 
 The role of KLF4 in regulating proliferation and differentiation is not limited to epithelial 
cells, and KLF4 expression seems to be important in various types of hematocytes. Although 
KLF1 is the KLF most associated with erythropoiesis (325), KLF4 is significantly upregulated in 
the HEL and K562 leukemic lines when these cells are induced towards erythroid differentiation 
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(402). KLF4 also has significant functions in the development of B lymphocytes (325). KLF4 
expression is upregulated in populations of pre-B cells (403). Mice with the tissue-specific 
knockout of Klf4, from the crossing of Klf4-loxP mice with CD19-Cre mice, have decreased 
numbers of pre-B cells and of mature B lymphocytes (374). In this study, the activation-induced 
proliferation of Klf4
-/-
 B cells was impaired, with decreased proliferation into S phase. Klf4 was 
demonstrated to act directly on the cyclin D2 promoter. In contrast, downregulation of KLF4 in 
memory B cells is essential to the secondary antibody response, in which the memory B cells 
undergo rapid proliferation and differentiate into immunoglobulin-secreting plasma cells (404). 
KLF4 may additionally promote survival of natural killer (NK) cells (405). 
 KLF4 also regulates the development and function of monocytes. Although Klf4
-/-
 
hematopoietic cells from fetal mouse livers could engraft equivalently to Klf4
+/+
 cells in lethally 
irradiated mice, there were interesting differences in the resulting monocytes populations in the 
chimeric system (406). While the resident Klf4
-/-
 monocyte population was unchanged or 
modestly reduced in compartments such as bone marrow, spleen, and peripheral blood, the 
inflammatory monocytic population was almost completely depleted. The leukemia cell line HL-
60 is another notable model for the role of KLF4 in monocyte differentiation. Treatment with 12-
O-tetradecanoylphorbol-13-actetate (TPA) promotes macrophage-like differentiation in HL-60 
cells, whereas all-trans-retinoic acid promotes differentiation to mature granulocytes. KLF4 
overexpression in HL-60 cells induced expression of the monocytic markers CD11b and CD14 
(407), and inducible expression of KLF4 potentiated differentiation into macrophages as induced 
by TPA (406). Suppression of KLF4 also enhanced HL-60 granulocyte differentiation (406).  
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Smooth muscle  
 KLF4 suppresses transcription of the smooth muscle cell (SMC) markers, including 
smooth muscle 22-alpha (SM22α) and alpha smooth muscle actin (α-SMA), antagonizing the 
activity of transforming growth factor-beta (TGFβ) signaling (378). This effect may be partly 
attributed to direct transcriptional suppression by KLF4. An additional mechanism, shown in 
fibroblasts, is based on interaction between KLF4 and Sma and MAD-related protein 3 (Smad3) 
(408). KLF4-Smad3 binding prevents Smad3, a key intracellular mediator of TGFβ signaling, 
from interacting with control elements of the SM22α and α-SMA genes. This interaction occurs 
through the Mad Homology 2 (MH2) domain of Smad3. KLF4 therefore acts as a negative 
regulator of TGFβ-dependent lung myofibroblast differentiation.    
Adipogenesis 
 Experiments using the 3T3-L1 cell model of adipogenesis have implicated KLF4 in 
adipocyte differentiation (409). When stimulated with insulin, glucocorticoids, and the 
phosphodiesterases inhibitor 3-isobutyl-1-methylxanthine (IBMX), fibroblast-like 3T3-L1 pre-
adipocytes adopt the morphology of mature adipocytes with accumulation of lipids (410). This 
involves early upregulation of the CCAAT-enhancer-binding proteins (C/EBP) including 
C/EBPβ, a leucine zipper transcription factor that promotes peroxisome proliferator-activated 
receptor gamma (PPARγ) expression (411). PPARγ transcriptionally regulates key metabolic 
pathways and is considered necessary and sufficient for adipocyte generation in fibroblasts 
(411). KLF4 expression is induced by exposure to the adipogenic cocktail, directly binds the 
C/EBPβ promoter, and can transactivate a C/EBPβ promoter in cooperation with early growth 
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response protein 2 (EGR2) (409). These data characterize KLF4 as an early mediator of 
adipocyte differentiation.  
Neural development and regeneration 
 Immature neurons in the central nervous system (CNS) are able to regenerate axons after 
injury, an ability that is lost in adult organisms. Of 111 candidate genes identified through 
expression profiling of developing retinal ganglion cells (RGCs), KLF4 transfection was most 
able to suppress axon growth (412). In mice with Klf4 knockout in RGC cells, there was 
increased axon growth and regeneration after experimental injury to the optic nerve. As with 
other processes, various additional KLFs provide complimentary or opposing functions to KLF4 
in axon regeneration (412,413). More recently, the negative effects of KLF4 on axon 
regeneration were linked to direct association of KLF4 with signal transducer and activator of 
transcription 3 (STAT3), suppressing STAT3 transcriptional activity (414). The implications of 
this STAT3 interaction towards KLF4 function in contexts such as tumor biology will be of 
interest. KLF4 also regulates the migration of neural progenitor cells in the developing cerebral 
cortex, and constitutive expression of KLF4 directed cells towards glial differentiation instead of 
developing into mature neurons (415). 
Stress response and inflammation 
 KLF4 plays a critical role in the response of cells to various forms of stress. KLF4 
expression is induced by treatment with methyl methanesulfonate (MMS) (360), an agent that 
causes DNA damage by interfering with the replication fork (416). Similarly, KLF4 is 
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upregulated in response to DNA-damaging gamma radiation (417). KLF4 then directly bound 
the promoter of p21
Waf1/Cip1
 (360) in a p53-dependent manner, thus inhibiting cell-cycle 
progression. Therefore, the mechanisms by which KLF4 proliferation may apply not only to the 
context of normal epithelial differentiation, but also to the response of cells to DNA damage. The 
induction of KLF4 by genomic damage may also be modulated by the extent of damage, such 
that severe and irreversible damage results in KLF4 suppression and p53-mediated apoptosis 
(418). The roles of KLF4 in apoptosis are discussed later in the context of malignancy.   
 The function of KLF4 as a stress-response factor also extends to other forms of stress. 
KLF4 in vascular endothelial cells is induced by shear stress (419,420). Furthermore, mice 
lacking endothelial expression of KLF4 are more sensitive to stress resultant from aortic banding 
(421). Interestingly, smooth muscle cells involved in human aortic aneurysms exhibit 
upregulation of KLF4, and experimentally induced aneurysms in perfused mouse aortas likewise 
showed significant elevation of KLF4 expression (422). By interfering with NF-κB functioning, 
KLF4 blocks TNFα-mediated induction of vascular cell adhesion molecule 1 (Vcam1), 
suppressing the inflammatory response to vascular injury (423). 
 KLF4 serves to transcriptionally mediate the response of smooth muscle cells to injury or 
inflammation (378,422,424,425). In normal blood vessels, KLF4 is minimally expressed, but is 
upregulated in the smooth muscle cells (SMC) of the tunica media after injury (425). The 
function of KLF4 in this context is to suppress the expression of genes that contribute towards 
SMC differentiation, and to promote expression of the anti-proliferative gene p21
Waf1/Cip1
. There 
is also evidence that oxidized phospholipids found in atherosclerotic lesions can induce KLF4 
expression to suppress SMC markers, further implicating KLF4 in the pathogenesis of 
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cardiovascular disease. In airway SMCs, KLF4 is upregulated by treatment with inflammatory 
cytokines including TNFα, IFNγ, and interleukin 1-beta (IL-1β) (426). This occurs through 
decreased expression of KLF4-targeting miR-25. KLF4 is also induced by inflammatory 
cytokines in HUVECs (420). KLF4 modulates these stimuli by differentially interacting with 
pro- and anti-inflammatory genes to exert anti-inflammatory and anticoagulation effects. KLF4 
similarly suppresses VEGF transcriptional induction by the inflammatory transcription factor 
SAF-1 (427). In contrast, overexpression of KLF4 in the mouse esophageal epithelium promoted 
expression of several pro-inflammatory cytokines (428).  
 Macrophages can be activated by inflammatory factors including interferon-gamma 
(IFNγ), lipopolysaccharide (LPS), or tumor necrosis factor-alpha (TNFα), and this activation is 
marked by induction of the enzyme inducible nitric oxide synthase (iNOS/NOS2) (429). KLF4 
plays a critical role in this process (347). Treatment with IFNγ, LPS, or TNFα results in 
upregulation of KLF4, which cooperates with p65/RelA to directly promote expression of iNOS. 
In this context, KLF4 therefore acts in opposition to KLF2, which inhibits phagocytic activity 
and expression of inflammatory genes in monocytes and macrophages (430). Here, as in other 
contexts, different KLFs seem to exert opposing functions, and an imbalance between the 
opposing KLFs can be associated with disease. For example, monocyte expression of KLF2 was 
reduced in patients with atherosclerosis (430). 
Stem cells and pluripotency 
 Pluripotent stem cells are able to differentiate into any of the three germ layers. Induced 
pluripotent stem (iPS) cells, in which adult cells are genetically reprogrammed to achieve 
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pluripotency, are a major achievement in stem cell biology (431). A specific combination of 
factors including Oct3/4, c-Myc, Sox2, and KLF4 was able to create pluripotent cells from 
mouse embryonic or adult fibroblasts (432), and subsequently from human fibroblasts (433). The 
iPS cells have been shown to be indistinguishable in many ways from ES cells (434). Using a 
combination of small-molecule compounds, the minimum requirement can be reduced to only 
Oct4 and KLF4 (435). KLF4 may also be functionally replaced by the small molecule kinase 
inhibitor kenpaullone (436) in iPS cells (437).  
 Oct3/4, Sox2, and Nanog were previously considered core factors in pluripotency 
(438,439). KLF4 could possibly act upstream to activate Nanog, as KLF4 may suppress p53 
(440), which is a transcriptional suppressor of Nanog (441). KLF4 expression may also act as a 
counterbalance to c-Myc, in that KLF4 promotes p21
Waf1/Cip1
 to suppress proliferation (360), 
whereas c-Myc suppresses expression of p21
Waf1/Cip1
 (442). Additionally, suppression of p53 
seems to be vital in rescuing cells from apoptosis induced by c-Myc overexpression (443), 
suggesting another possible role of KLF4. Later experiments provided evidence that KLF4 acts 
upstream of Oct4 and Sox2 in a transcriptional hierarchy (444).   
 KLF4 also regulates self-renewal and differentiation of embryonic stem (ES) cells. Prior 
to implantation, the blastocyst contains an inner cell mass (ICM) or embryoblast which later 
develops into the embryo. ES cells are harvested from the embryoblast, which involves 
destruction of the blastocyst. Leukemia inhibitory factor (LIF) is a cytokine expressed in 
embryos and used experimentally in stem cell research to inhibit differentiation.  LIF treatment 
of murine ES cells induces expression of KLF4 and of suppressor of cytokine signaling-3 
(SOCS-3) (445). While SOCS-3 seemed to negatively regulate LIF signaling, the role of KLF4 
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upregulation was to block ES cell differentiation, and KLF4-overexpressing ES cells had greater 
capacity for self-renewal. Overexpression of KLF4 also reduces or eliminates LIF dependence 
(446,447). LIF induces KLF4 through STAT3 signaling (448). Ectopic expression of KLF4 can 
also revert cells derived from the mouse post-implantation epiblast (EpiSC) into ES-like cells 
(449). Mouse EpiSC cells differ in a number of ways from mouse ES cells, and may actually be 
more similar to human ES cells (450).  
KLF4 in the biology of cancer 
 The role of KLF4 in cancer is complex and context-dependent. KLF4 acts as a tumor 
suppressor in some tissues. In particular, the functions of KLF4 to suppress proliferation and 
promote cellular differentiation help to oppose tumorigenesis in some gastrointestinal cancers. In 
contrast, the role of KLF4 in other cancers, including breast cancer, is less clear. Literature 
specific to the function of KLF4 in cancer metastasis is discussed separately in detail.  
Colorectal cancer and tumor suppressive functions of KLF4 
 KLF4 was originally characterized as a gene associated with growth arrest in the colonic 
epithelium, and ectopic expression of KLF4 was seen to suppress synthesis of DNA (336). This 
effect was further correlated in colon cancer cells with upregulation of p21
Waf1/Cip1
 and G1/S cell 
cycle arrest (382). The antiproliferative activity of KLF4 can be induced through DNA damage 
in colon cancer cells (417). KLF4 additionally suppresses proliferation in response to DNA 
damage by repressing cyclin B1 expression (451). The anticancer activity of investigatory 
compounds such as bis(3’-indolyl)methane (DIM) derivatives is also linked to KLF4-mediated 
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growth arrest (452). In vitro, serum stimulation of HCT116 colon cancer cells promotes 
ubiquitin-mediated proteolytic degradation of KLF4 (453), providing another example of the 
common, albeit not universal, inverse relationship between KLF4 expression and cell 
proliferation. Introduction of KLF4 into the RKO colon cancer line, which is characterized by 
low levels of endogenous KLF4, results in growth arrest with an apoptosis-independent 
suppression of in vivo tumorigenicity (454). KLF4 also suppresses radiation-induced apoptosis 
in colon cancer cells (372), and in concert with this mechanism, has a radioprotective effect in 
the mouse colon (455).  
KLF4 expression in colon cancer 
 Multiple independent studies have shown the expression of KLF4 to be decreased in 
colorectal carcinoma as compared with epithelial tissue of the normal colon (373,456-459). In 
one study of 30 colon cancer specimens, KLF4 mRNA was downregulated nearly 50%, with of 
loss of heterozygosity (LOH) in some samples (456). In a panel of six colon cancer cell lines, 
five exhibited LOH of the KLF4 gene, and expression of KLF4 protein and mRNA was 
decreased. Some of the cell lines also had KLF4 point mutations that suppressed the 
transactivation function of KLF4 on the p21
Waf1/Cip1
 promoter (456). These data suggest both the 
expression and activity of KLF4 are suppressed in colon cancer. A larger analysis of 125 
specimens by RT-qPCR showed decreased expression of KLF4 mRNA in colon tumor samples, 
and also that KLF4 expression in normal tissues was correlated with patient survival (459). 
Expression of KLF4 in colon cancer tissue may also have prognostic value, as there is greater 
disease-free survival time in patients (Fig. 15) associated with tumor expression of KLF4 (458). 
KLF4 expression can also be related to the histologic grade of colon tumors. Whereas KLF4 
68 
 
expression is low or undetectable in poorly-differentiated tumors, specimens of well-
differentiated tumors are more likely to demonstrate expression of KLF4 protein (460).  
KLF4-β-catenin pathway interaction 
 In the human cancer syndrome familial adenomatous polyposis (FAP), and in multiple 
intestinal neoplasia (Min) mice, mutations of the adenomatous polyposis coli (APC) tumor 
suppressor lead to intestinal neoplasms. Compared to normal intestinal tissue, KLF4 expression 
is progressively downregulated in adenoma development in both FAP patients and Min mice 
(461). APC acts as a scaffold protein, associating with β-catenin and helping to promote β-
catenin phosphorylation through enzymes such as glycogen synthase kinase 3 (GSK3). This 
phosphorylation marks β-catenin for degradation by the ubiquitin-proteasome system (462). The 
Wnt/β-catenin pathway is central in the pathogenesis of colon cancer, in which mutations 
involving APC or other genes including β-catenin itself result in stabilization of β-catenin and 
oncogenic signaling by the Wnt/β-catenin path (463).  
 Studies indicate that the tumor suppressive properties of KLF4 in colorectal cancer may 
occur in part through interaction and crosstalk with β-catenin signaling. Expression of wild-type 
APC results in upregulation of KLF4 in colon cancer cells, whereas expression of KLF4 blocks 
activity of a β-catenin-TCF reporter (464). One mechanism underlying the antagonistic effect of 
KLF4 on β-catenin signaling is the binding of KLF4 to the transactivation domain of β-catenin, 
which inhibits β-catenin-mediated transcription (371). Mice with intestinal-specific deletion of 
Klf4 have increased intestinal activation of Wnt target gene (392), consistent with a tumor-
suppressive role of KLF4 in repressing β-catenin signaling. The inverse relationship of KLF4 
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and β-catenin protein expression in gastric cancer suggest that KLF4-β-catenin crosstalk 
mechanisms may apply in this context as well (415). 
Other gastrointestinal malignancies  
 The roles of KLF4 in other gastrointestinal carcinomas are often similar to those 
observed for colorectal cancer. Esophageal knockout of Klf4 in mice using the ED-L2 viral 
promoter led to increased basal cell proliferation, defective epithelial differentiation, and 
hypertrophy and dysplasia of the esophageal epithelium (400). Interestingly, esophageal 
overexpression of KLF4 led to increased inflammatory signaling, and suggests that KLF4 may 
exert disparate non-cell autonomous functions in tumorigenesis (428). As with colorectal cancer, 
KLF4 protein is decreased in human specimens of esophageal carcinoma, with a positive 
correlation of KLF4 expression and patient survival (465). Mice with gastric knockout of Klf4 
have abnormal proliferation and differentiation of the gastric epithelium (Fig. 16), including 
premalignant changes that may lead to cancer (401), and as with colon cancer, human specimens 
of gastric adenocarcinoma lack expression of KLF4 (401,466). These data suggest a tumor 
suppressive role for KLF4 in the context of gastric malignancy. Mechanisms of downregulation 
could include methylation and hemizygous deletion (466). Analysis of 49 human gastric 
carcinoma specimens by immunohistochemistry also showed decreased expression of KLF4 
(467). KLF4 is similarly downregulated in hepatocellular carcinoma (468) and cytoplasmic 
KLF4 expression is associated with patient survival (469). Keratin promoter-linked deletion of 
Klf4 also supports a role of KLF4 in suppressing tumorigenesis of the oral epithelium (470). In 
pancreatic cancer cells, KLF4 directly promotes p27
Kip1
 expression, leading to suppression of 
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tumor growth and metastasis (471). Pancreatic ductal carcinoma specimens frequently exhibit 
genomic loss of KLF4, with concomitant loss of KLF4 expression (472).  
Additional tumor-suppressive functions of KLF4 
 In addition to effects KLF4 to suppress proliferation and promote differentiation, KLF4 
may have other functions that inhibit tumorigenesis. Mouse embryonic fibroblasts (MEFs) with 
deletion of Klf4 exhibit genomic instability that is rescued by exogenous Klf4 expression (473). 
In contrast to wild-type MEFs, Klf4
-/-
 MEFs are capable of anchorage-independent growth (474). 
In murine hepatocellular carcinoma cells, KLF4 suppresses expression of Slug, leading to 
reversion of the epithelial-mesenchymal transition (EMT) (468); KLF4 may have a similar role 
in breast cancer (380) and ovarian cancer (475).  
Breast cancer 
 While KLF4 seems to have tumor suppressive functions in colorectal cancer and several 
other types of gastrointestinal malignancies, the functions of KLF4 in the context of breast 
cancer is less clear. This uncertainty includes a lack of agreement on whether KLF4 mRNA 
expression is altered in breast cancer, and in which direction. Breast cancer is a diverse entity at 
the molecular level and, and KLF4 may have differing functions within the distinct subtypes of 
breast cancer, and also contribute variously towards the myriad of phenotypic alterations 
observed in mammary tumorigenesis. KLF4 seems to have antiproliferative activity in breast 
cancer cells, yet also helps to promote survival and resistance to anticancer agents. Additionally, 
KLF4 may help support the CSC population in breast cancer cells, and contributes towards 
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tumor formation in some mouse models. As the central topic of this dissertation, literature on the 
function of KLF4 in the metastasis of breast cancer cells is reviewed separately in detail. 
 One hypothesis that may partially reconcile these differences is that p21
Waf1/Cip1
 mediates 
the balance of KLF4 function between tumor promoting and tumor suppressing effects (440). 
This work demonstrated that KLF4-mediated proliferation arrest in untransformed cells could be 
blocked by inactivation of cyclin D1 and p21. Additionally, p21 knockout in KLF4-expressing 
MEFs allowed cells to grow to a higher density, and form colonies lacking contact inhibition 
(Fig. 17). These data suggest that p21 may mediate tumor suppressive functions of KLF4, and in 
the absence of p21, KLF4 can exert tumor promoting effects. 
Expression of KLF4 in breast cancer 
 Studies of KLF4 expression in human breast cancers are conflicting. Higher levels of 
KLF4 mRNA and protein are sometimes found in breast cancer in comparison to adjacent tissue 
(476). Amongst 146 human specimens, high nuclear expression of KLF4 by 
immunohistochemistry in breast cancer cells was associated with more aggressive clinical 
progression (477). In contrast, a large-scale RNA sequencing analysis of human breast tumors 
did not find increased KLF4 in comparison to normal tissue, and did not demonstrate prognostic 
significance of KLF4 (478,479). 
 Expression of KLF4 in breast cancer model systems is also variable. Mammary tumor 
Klf4 expression in nine different genetically engineered mouse (GEM) models of breast cancer 
was decreased as compared to whole mouse mRNA (479,480). Notably, GEM models of the 
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luminal subtype of breast cancer exhibited the greatest decrease in Klf4 mRNA. In contrast, 
GEM models of breast cancer such as the C3(1)/TAg model had comparatively higher levels of 
Klf4. Analysis of KLF4 protein across multiple breast cancer cell lines also shows variable 
expression patterns (479,481). In comparison to several breast cancer cell lines, KLF4 protein 
levels are higher in the nontransformed MCF-10A and MCF-12A cell lines (481).  
Functions of KLF4 in breast cancer cells 
 Reports on the function of KLF4 in breast cancer cells have generally indicated that 
KLF4 inhibits proliferation and promotes survival in this context, although there is sometimes 
discordance between gain- and loss-of-function experiments. Evidence also indicates KLF4 can 
promote resistance of breast cancer cells to some targeted therapies. The anti-apoptotic effect of 
KLF4 also correlates with evidence that KLF4 expression promotes tumor formation of breast 
cancer cell lines in immunocompromised mouse models. KLF4 is also implicated in breast 
cancer stem cells. 
KLF4-dependent phenotypes in breast cancer cells 
 Exogenous KLF4 may inhibit proliferation of 4T1 murine breast cancer cells, as shown 
by reduced BrdU incorporation (481). Similarly, KLF4 loss-of-function can enhance cell 
proliferation in MCF-7 cells (482). Mechanisms might include upregulation of antiproliferative 
genes, including p21
Waf1/Cip1
 as previously described (362). Additionally, KLF4 can also suppress 
estrogen dependent growth, by interacting with the estrogen receptor ERα and blocking 
induction of ERα target genes (482). In a variant of MDA-MB-231 cells selected for brain 
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metastasis capability (231BrM), re-expression of KLF4 actually restored tumor growth from the 
inhibitory effects of miR-7 suppression (483). Overexpression of KLF4 alone did not affect 
tumor growth in this context. 
KLF4 promotes survival and drug resistance in breast cancer cells  
 KLF4 has antiapoptotic functions in breast cancer cells. For example, suppression of 
endogenous KLF4 resulted in increased cell death in murine M6 cells, derived from the C3/TAg 
GEM model, and in nonmalignant human mammary epithelial (HMLE) cells (479). KLF4 
overexpression by an adenoviral vector was shown in one study to increase apoptosis of 4T1 
cells (481). In some cases, endogenous KLF4 helps breast cancer cells to form solid tumors in 
athymic mice, but does not substantially affect the growth of tumors that do form (484).  
 One process through which KLF4 may promote survival is through activation of 
mitogen-activated protein kinase (MAPK) signaling pathways. KLF4 promotes extracellular 
signal-regulated kinase (ERK) activity in breast cancer cell lines including MDA-MB-231 cells 
(485). The underlying mechanism was found to be that KLF4 promotes expression of miR-206 
and miR-21, which enhance RAS-ERK signaling by targeting the RAS-ERK pathway 
suppressors SPRED1 and RASA1 (485).  
 Consistent with an apoptotic function of KLF4, protein and mRNA expression of the 
antiapoptotic factors BCL2, BCL-XL, and MCL1 were decreased following KLF4 knockdown 
(479). These effects appear related to a role of KLF4 in the resistance of breast cancer cells to 
therapies. Treatment of Her2-overexpressing BT474 with trastuzumab, a monoclonal antibody 
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targeting Her2, or with lapatinib, a tyrosine kinase inhibitor affecting both Her2 and EGFR, 
resulted in KLF4 upregulation (479). Moreover, there was increased apoptosis in response to 
lapatinib when endogenous KLF4 was stably suppressed. This effect was additive with 
suppression of KLF5. The increased sensitivity of KLF4 knockdown cells to Her2-targeted 
therapy could also be rescued by re-expression of MCL1. 
 KLF4 may also play a role in the response of breast cancer cells to pharmacotherapies 
through the phenomenon of kinome reprogramming. In this process, cells are able to “escape” 
from the antiproliferative effects of MEK inhibitors through broad changes in kinase signaling, 
including upregulation of platelet-derived growth factor receptor β (PDGFRβ) (486). Subsequent 
research has revealed a function of KLF4 in kinome reprogramming and the response of breast 
cancer cells to MEK inhibition (in submission). KLF4 binds an element of the PDGFRβ 
promoter, and activates PDGFRβ transcription in the presence of MEK inhibitors. Furthermore, 
suppression of KLF4 prevents PDGFRβ upregulation and blocks the proliferative escape from 
MEK inhibition. 
KLF4 in breast cancer stem cells 
 Several lines of evidence indicate a role of KLF4 in the breast cancer stem cell 
population. Mammospheres, which arise from mammary cells when grown in non-adherent 
conditions (487), have increased levels of KLF4 mRNA (488). Both Hoechst dye-excluding 
MCF-7 breast cancer cells and the population of CD44
+
/CD34
-
 cells also express increased 
amounts of KLF4 (488). RNAi- mediated knockdown of KLF4 decreased the percentage of cells 
with CSC markers and also inhibited mammosphere formation (488). Additionally, KLF4 
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mRNA expression is enhanced in ALDH-high cells from both breast cancer patient-derived 
xenografts (PDX) and from the C3/TAg model. KLF4 mRNA is similarly increased in C3/TAg-
derived cells grown as spheroids (484). Collectively, these data suggest a function of KLF4 in 
the breast cancer stem cell population. We have also observed increased KLF4 mRNA in the 
pancreatic cancer cell side population, or in pancreatic cancer cells grown as spheroids (Chapter 
2). 
 The function of cancer stem cells is formally determined by the tumorigenic efficiency, in 
which decreasing numbers of cells are successively injected in immunocompromised mice to 
determine the minimum number of cells necessary for tumor formation (135,489). It is not yet 
reported whether that KLF4 has a CSC function in breast cancer cells as defined by an in vivo 
limiting dilution tumor initiation assay. In contrast, miR-206 does appear to have in vivo CSC 
activity (484). As miR-206 expression in breast cancer cells is supported by endogenous KLF4 
(363,485), it seems possible that KLF4 could contribute to tumor initiation through miR-206.  
 One possible mechanism of KLF4 regulation in cancer stem cells is through Zeb1-miR-
200 signaling. An inhibitory, reciprocal feedback mechanism links Zeb1 and the miR-200 family 
(490,491). Zeb1 and Zeb2 suppress transcription of E-cadherin, and several studies indicate that 
targeting of Zeb by miR-200 can result in upregulation of E-cadherin (492-496). miR-200c, miR-
203, and miR-183 inhibit expression of stem cell factors in cancer cells as well as mouse ES cells 
(497). The stem cell factors KLF4 and SOX2 are predicted targets of both miR-200c and miR-
203, and expression of either miRNA suppresses KLF4 levels. Downregulation of miR-200c, 
along with other miR-200 family transcripts, plays a critical role in the breast cancer stem cell 
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phenotype(497), and could possibly account for the increased KLF4 that is observed in breast 
cancer stem cell populations. 
Metastasis 
 In 2000, a seminal review (498) cited metastasis as “the last great frontier for exploratory 
cancer research.” The same authors, in a 2011 revision (499), commented with respect to 
metastasis research that “significant progress has been made.” Despite some advances, many 
fundamental aspects of metastasis remain poorly understood, with increasing attention towards 
metastatic colonization as a particularly enigmatic process. Clinical metastases contribute greatly 
to the morbidity and mortality associated with cancer, ensuring the continuing importance of 
metastasis research.   
Metastatic breast cancer 
 The incidence of breast cancer in the United States is estimated at 230,000 cases per year, 
with about 40,000 deaths (500). Breast cancer is the most common cause of cancer death for 
women in the United States between ages 20-59, and the second only to lung cancer in overall 
contribution to cancer mortality in women (500). Breast cancer prognosis is strongly related to 
staging (see below). In one analysis, five-year survival in stage IV disease, characterized by 
distant metastasis, was only 18% (501). In contrast, survival in breast cancer without distant 
metastasis was as high as 95% in the case of stage I disease.  
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 As is true for many other tumor types, breast cancer favors specific organs as sites of 
distant metastasis. Although breast cancer may potentially metastasize to nearly any location, 
common sites for breast cancer distant metastasis are bone, liver, and lung. Bone metastases are 
most common, and may be indolent and responsive to systemic therapies (502-504). Post-
mortem examination has revealed skeletal metastasis in 70-90% of breast cancer patients (505). 
Bone metastases can also result in morbidity and mortality by causing pain and fractures. Some 
patients with isolated liver metastases may achieve long-term survival through metastasectomy, 
or surgical resection of metastasis (506). Similarly, resection of isolated pulmonary metastases 
may offer improved long-term survival (507-510). In this type of study, it is not always clear 
whether increased survival was a benefit of metastasectomy or from preoperative selection of 
patients (511). 
 Around 5% of patients develop brain metastasis (512,513). The relatively low occurrence 
of brain metastasis overall reflects the tendency of breast cancer to be diagnosed at an early 
stage. In patients with metastatic breast cancer, 10-16% will develop brain metastasis (512,514). 
Other studies have identified even higher rates of CNS involvement in patients with metastatic 
cancer (515). Also striking is the variation amongst subtypes of breast cancer, in which brain 
metastasis occurred in 0.7% of patients with luminal A tumors, 12% of patients with luminal B 
tumors, and 12% of patients with HER2+ breast cancer. In patients with triple-negative breast 
cancer, 7% developed brain metastasis (516).  
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 Survival in metastatic breast cancer 
 In comparing patient cohorts across different time periods, survival in metastatic breast 
cancer is improving (517). Other cohort studies have associated survival improvements in 
metastatic disease with the introduction of taxane therapy (518). Hormonal therapies and 
trastuzumab may also have contributed to longer survival in metastatic breast cancer (519). 
Despite these advances, long-term remission is only achieved by a small percentage of patients 
with metastatic disease (520). In a review of 36 randomized trials with 13,083 total patients 
between years 1999-2009, overall survival for women starting chemotherapy for metastatic 
breast cancer was less than two years (521). Most patients who develop breast cancer metastases 
were originally diagnosed with early-stage disease. In one study, only 23% of patients with 
metastatic breast cancer had initially presented with metastatic disease. Overall survival, 
measured from the start of first-line chemotherapy for metastatic breast cancer (Fig. 18), closely 
adhered to an exponential curve with median survival of 20.4 months (522).  
Model systems for triple-negative and claudin-low breast cancer 
 Overall, about 13% of breast tumors are triple-negative, lacking expression of estrogen 
receptor (ER) and progesterone receptor (PR), and without overexpression of HER2 (523). 
Triple-negative disease, which accounts for much of the basal-like intrinsic subtype of breast 
cancer (524), is overrepresented among African-Americans (525). The basal-like intrinsic 
subtype of breast cancer, which exhibit an expression profile similar to that of basal breast 
epithelial cells(526), is associated with more aggressive disease and a poorer prognosis (527-
529). While basal-like breast cancer does not clinically appear to have an inherent resistance to 
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chemotherapy as compared to other subtypes, the decreased survival associated basal-like 
disease may be related to relapse among patients without complete response to therapy (530). 
 In addition to luminal A, luminal B, HER2-enriched, and basal-like intrinsic subtypes 
(526), a “claudin-low” subtype was later identified (480). Claudin-low tumors are named owing 
to low expression of claudins 3, 4, and 7. Claudins are small transmembrane proteins of 20-27 
kDa that are critical components of tight junctions, thereby controlling paracellular transport 
(531). The claudin-low subtype is also characterized by low expression of occludin, another 
component of tight junctions, as well as E-cadherin. Expression of luminal genes is low, and 
while claudin-low tumors may represent a subset of basal-like disease, expression of the basal 
cluster is irregular (480). In contrast, claudin-low breast cancer cells seem to be enriched for 
CSC and EMT characteristics (532-535). Gene expression in claudin-low cell lines also clusters 
with human mesenchymal stem cells (hMSCs) (536). 
 While claudin-low tumors represent a small subset of human breast cancer, comprising 
12% of tumors in one data set (534), cell lines that cluster with the claudin-low subtype seem to 
be disproportionately represented in breast cancer research (536). In contrast, the luminal A 
subtype, mostly comprising low grade ER+ tumors, accounts for around 70% of human breast 
cancer and is yet apparently unrepresented by any cell line (536) or transgenic mouse model 
(480). One hypothesis to explain the discrepancy between the epidemiology of human breast 
cancer subtypes and the gene expression patterns of established cell lines is that of a selection 
bias conferred by the conditions of cell culture. For example, the passage of cells in culture 
would disfavor outgrowth of luminal A-type cells with low proliferation and stronger attachment 
(536). 
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  The breast cancer cell lines MDA-MB-231 and MDA-MB-435, which are notable for the 
ability to form spontaneous metastases in immunocompromised mice (537,538), cluster with 
human claudin-low tumors (534). The C3/TAg GEM model of breast cancer was developed 
using a transgene containing the early region of simian virus 40 large tumor antigen (TAg) and a 
regulatory region of the rat prostatic steroid binding protein [C3(1)] gene (539,540). Female 
C3/TAg mice develop mammary carcinoma with 100% penetrance by 6 months of age, whereas 
males develop carcinoma of the prostate. Pulmonary metastases reportedly occur in 15% of 
C3/TAg female mice with mammary tumors (540). In unsupervised hierarchical clustering 
analysis, C3/TAg mammary tumors exhibit significant overlap with basal-like breast cancer in 
humans (480). The M6 cell line was derived from C3/TAg mouse mammary tumors (541). 
The metastatic cascade 
 The development of metastasis may be described sequentially, consisting of discrete 
stages of progression (542-545). At each stage, specific functions help cells overcome the 
numerous obstacles to metastasis (Fig. 19). Once a tumor is established, cellular proliferation 
must continue, with sufficient angiogenesis to support ongoing tumor growth. Using invasive 
processes or other mechanisms, cancer cells must gain access to the vasculature, possibly 
through the lymphatic system or by direct access to blood vessels. Malignant cells may then 
enter into circulation. Cells that survive transit through the vasculature may lodge in capillaries 
of distant organs, perhaps adhering to endothelial c ells or subendothelial structures. Cancer cells 
may exit the vasculature through extravasation or other alternative mechanisms, or possibly 
rupture the capillary vessel in which the cancer cells are arrested through continued proliferation. 
In principle, metastasis can be inhibited by targeting any step of the process (542,546).  
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 From the sequence of steps necessary for successful metastasis, it could be questioned 
whether some steps have rate-limiting functions. Increasingly, the ability of tumor cells to 
survive and proliferate are viewed as bottlenecks in the metastatic cascade, explaining why large 
numbers of circulating tumor cells may only result in a small number of macrometastases 
(542,545,547,548). Current cancer staging standards define macrometastases as greater than 
2.0mm in diameter (549). Micrometastases have a diameter greater than 0.2mm and/or more than 
200 cells in cross section, but are less than 2.0mm. One estimation is that less than 1% of 
micrometastases will further develop into macrometastases (550). Single cells or cell clusters 
less than 0.2mm, or a cluster of fewer than 200 cells in cross section, are defined as isolated 
tumor cells (ITCs). Lymph nodes containing only ITCs are not considered positive lymph nodes 
(549).  
Circulating tumor cells 
 Circulating tumor cells (CTCs) represent an intermediate stage of metastasis, dividing 
between early events in the metastatic cascade found at the site of the primary tumor, and later 
events at the site of distant organs (Fig. 19 and 20). Although CTCs are often difficult to isolate 
or quantify, as they are rare in comparison to normal blood cells, these cells are of particular 
interest for several reasons. CTCs may have clinical prognostic and predictive significance, and 
are increasingly used to aid investigation into the underlying mechanisms of cancer metastasis. 
CTCs could possibly also arise as cells shed from metastases, although the literature addressing 
this hypothesis is sparse (551). In contrast, the re-seeding of primary tumors in animal models is 
documented (552,553). 
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 Importantly, the identification and quantification of CTCs has been shown to have 
prognostic significance in clinical studies.  CTC presence is associated with poorer prognosis in 
both early, non-metastatic breast cancer (554-556), and in the context of metastatic breast cancer 
(557-561). This result was also reproducible in a study specific to triple-negative breast cancer, 
as CTCs as determined by two different methods were correlated with reduced time to 
progression (TTP) and overall survival (OS) (562). The prognostic value of CTCs in breast 
cancer is also supported by a meta-analysis of 49 studies with over 6,000 total patients (563). 
Some data suggest CTC measurement may actually be a superior to radiographic methods in 
assessing disease progression (564). CTCs may have prognostic significance in other 
malignancies, including prostate cancer (565), melanoma (566), and colorectal carcinoma (567).  
 CTCs can potentially provide more information than simple quantification. CTCs can 
also be isolated for analysis, and single-cell analysis of CTCs is an increasingly viable approach 
(568) that may provide useful insight into metastatic phenomena, and may possibly lead to 
improved guidance of therapy (569). CTC characterization is proposed to serve as a “liquid 
biopsy” to diagnose malignancy and monitor disease course (570). Single-cell analysis has 
shown that the CTCs in human breast cancer are heterogeneous, and sometimes fail to cluster 
based on case ID (571). 
Metastasis suppressors 
 In 1988, a novel gene was identified based on differential mRNA expression amongst cell 
lines corresponding to metastatic potential (572). This gene, originally named NM23 and now 
known as NME1, codes for the enzyme nucleoside diphosphate kinase A and was the first 
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identified of the class of genes known as metastasis suppressors. Expression of NME1 in cancer 
cells does not impair tumorigenesis in immunocompromised mice but suppresses formation of 
metastasis (573). These observations have led to the concept of the metastasis suppressor: 
“Metastasis-suppressor genes suppress the formation of spontaneous, macroscopic metastasis 
without affecting the growth rate of the primary tumor” (574). A growing list of metastasis 
suppressors are now recognized, including many in breast cancer (575). Metastasis suppressors 
are functionally defined based on animal models, and so whether a protein functions as a 
metastasis suppressor may depend on the chosen model system. 
Animal models of metastasis 
 Models of tumor metastasis can take several forms (544,576). Spontaneous metastases 
occur secondarily to primary malignancy. This primary tumor could be arise from orthotopically 
injected cancer cells, or develop from normal tissue as autochthonous disease. In the latter case, 
tumor development could be prompted by means such as genetic engineering or chemical 
carcinogens. Another type of assay, experimental metastasis, involves direct inoculation of 
cancer cells into circulation. In reference to the metastatic cascade, the spontaneous metastasis 
assay replicates more steps of human cancer progression than does an experimental metastasis 
assay (576).   
  In the Results section (Chapter 3), we describe the function of KLF4 in a spontaneous 
model of breast cancer metastasis using NOD/SCID/γ (NSG) mice. Mutation of the DNA-
dependent protein kinase catalytic subunit results in severe combined immunodeficiency (SCID), 
with defects in both adaptive and innate immunity including lack of mature B and T lymphocytes 
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(577). The NOD.CB17-Prkdc
scid
 (NOD/SCID) model was created through backcrossing CB17-
Prkdc
scid
 (SCID) mice into the NOD/Lt strain (578). While SCID mice retain natural killer (NK) 
cell activity and complement, NOD/Lt mice are have functional deficits in NK cells and antigen-
presenting cells (APC), and lack circulating complement (579,580). NOD/SCID mice exhibit 
immune defects of both models, and are characterized by absence of mature B and T 
lymphocytes, lack of complement, and functional defects in NK cells and in macrophage 
populations (578). In addition, NOD/SCID mice do not develop immune mediated, insulin-
dependent diabetes mellitus, which is a characteristic of non-obese diabetic (NOD) mice.  
 The immune system of the NOD/SCID/γ (NSG) mouse is further altered through loss of 
the interleukin-2 receptor gamma chain (IL-2Rγ) (581). This peptide, also called the common 
gamma chain (γc) or CD132, is additionally a component of receptors for other interleukins 
(582), including IL-4 (583), IL-7 (584), IL-9 (585), IL-15 (586), and IL-21 (587). In humans, 
inactivating mutations of IL-2Rγ lead to an X-linked form of SCID (588). Targeted deletion of 
IL-2Rγ in mice results in drastically reduced B and T lymphocytes, and complete loss of NK 
cells (589). NK cell development is therefore dependent on cytokine signaling through the 
common gamma receptor. The NSG model has greater immunodeficiency compared to 
NOD/SCID mice, as originally demonstrated by superior engraftment of human hematopoietic 
stem cells (581); an additional benefit is that NSG mice do not develop spontaneous thymic 
lymphomas. As would be expected, NSG mice are deficient in NK cells. In the normal immune 
system, NK cells have cytotoxic activity against tumor cells, and NK cell function represents an 
important barrier to tumor cell proliferation and metastasis (590,591). The metastatic capability 
of cancer cells depends greatly on the model in which they are tested (576), and NSG mice 
represent a useful model system to study spontaneous metastasis of cancer cells. In NSG mice, 
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MDA-MB-231 cells readily form macro-metastases in the axillary lymph nodes, lungs, and liver 
(Fig. 21). Metastasis to other organs is sporadic (537).  
Functions of KLF4 in metastasis  
 Literature on the role of KLF4 in cancer metastasis is varied. In some observational 
reports, expression of KLF4 is correlated with metastasis. For example, nuclear expression of 
KLF4 protein as determined by immunohistochemistry was associated with metastasis of 
squamous cell carcinoma (SCC) in human patients (592). Interestingly, nuclear KLF4 was also 
associated with moderate and poor tumor differentiation. This finding is similar to a relationship 
observed in breast cancer, in which increased KLF4 nuclear staining was associated with higher 
histologic grade and poorer prognosis in patients with early-stage disease (477). 
 KLF4 is also implicated in breast cancer metastasis to the brain (483). miR-7 was found 
to directly target KLF4, and overexpression of miR-7 suppressed KLF4 levels and reduced brain 
metastasis in an animal model. In contrast, bone metastasis was not reduced in association with 
miR-7 expression. In a set of human brain metastasis specimens, miR-7 was decreased and KLF4 
was increased as compared to the primary breast tumors (Fig. 22). In this report, KLF4 
expression was not functionally assessed in relation to metastasis. Additionally, suppression of 
KLF4 by miR-29a may be associated with metastasis and poor prognosis in colorectal cancer 
(593). NumbI-mediated suppression of KLF4-dependent transcription is similarly implicated in 
the metastasis of lung cancer cells (594). 
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 Functional studies of KLF4 in metastasis have employed spontaneous metastasis assays. 
The function of KLF4 in the metastasis of autochthonous tumors is unclear, although KLF4 
expression in the stromal compartment may contribute to the spontaneous metastasis of breast 
cancer cells (595). Ectopic expression of KLF4 results in reduced metastasis in models of 
gastrointestinal malignancy, including pancreatic (471), colorectal (596), and hepatocellular 
(597) cancers. This finding is also reported in breast cancer (481). Overexpression of KLF4 can 
strongly suppress proliferation in vitro, and may similarly slow the growth of primary tumors. It 
is important to consider these effects when interpreting the results of experiments involving 
exogenous KLF4 and metastasis. Depending on the mechanism under study, re-expression of lost 
KLF4 to physiologic levels may enable normal course of tumor development, thereby clarifying 
the effect of KLF4 on metastasis (596). In a breast cancer model using murine 4T1 cells, the 
activity of KLF4, as affected by tamoxifen treatment of cells expressing a KLF4-ER fusion 
protein, seemed to have a negative effect on metastasis (380). The actual determination of 
metastasis was reported as the “metastatic index”, in which bioluminescence-determined lung 
and liver metastasis is normalized to primary tumor weight. 
 There is at least one report of the function of endogenous KLF4 in breast cancer 
metastasis (598). In this study, silencing of KLF4 in murine 4T1 cells led to decreased 
spontaneous formation of pulmonary nodules. Knockdown of KLF4 in this context was 
associated with decreased primary tumor growth, showing a difference of 50% or more in tumor 
volumes across time points. The effect of KLF4 on spontaneous metastasis could thus be a 
consequence of the difference in primary tumor volume.  
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 The functions of KLF4 in metastasis are likely not limited to tumor cells alone. While 
Klf4
-/-
 mice are born alive but quickly perish (388), this can be overcome through the use of 
tissue-specific knockout, or through an inducible system such a Cre-ER Klf4
flox/flox
 mouse model 
(595). Using inducible and spontaneous Klf4 knockout systems, mice had decreased KLF4 
expression in the bone marrow. After intravenous injection of murine melanoma or breast cancer 
cells, the mice with KLF4 knockout developed fewer lung metastases, with fewer accompanying 
myeloid-derived suppressor cells (MDSCs). Further experiments showed that the decrease in 
metastasis was attributable to KLF4 knockout in the MDSCs, which led to fewer MDSC-derived 
fibrocytes and myofibroblasts. These data demonstrate a pro-metastatic effect of KLF4 
expression in the microenvironment of cancer metastases. 
Questions addressed in this dissertation 
 Aberrant signaling events are intrinsic to the pathogenesis of cancer, and transcription 
factors influence all aspects of malignancy. Cancer cells exhibit widespread phenotypic 
abnormalities, and the molecular pathways involved in malignancy present opportunities for 
therapeutic intervention. The dual topics of this dissertation are GLI1 and KLF4, zinc finger 
transcription factors that exemplify the subversion of normal biological mechanisms in cancer.  
 The Hedgehog signal pathway is a fundamental determinant of animal development, and 
is implicated in cancer. GLI1 is a potent transcriptional activator and effector protein of the 
Hedgehog signaling pathway. In normal and malignant cells, GLI family proteins are critically 
regulated by the E3 ubiquitin ligase SCF
β-TrCP
. Hedgehog-GLI signaling is implicated in cancer 
of the exocrine pancreas, yet the cause of Hedgehog pathway activation in this setting is unclear. 
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This dissertation presents a novel mechanism of GLI1 protein stabilization involving the HMG-
box transcription factor SOX9. In addition, this research addresses the functional significance of 
SOX9 towards GLI1 activity in pancreatic cancer cells. 
 Similarly, the transcription factor KLF4 is important in numerous pathogenic and non-
pathogenic contexts. Although the functions of KLF4 in some malignancies are well-
characterized, the contribution of KLF4 to breast cancer is less certain. In particular, the function 
of KLF4 in breast cancer metastasis is poorly defined. Research presented in this dissertation 
documents the functional role of KLF4 in the metastasis of breast cancer cells. We address the 
effects of KLF4 expression on the growth of orthotopic mammary tumors, circulating tumor 
cells, and the spontaneous development of lung and liver metastases. We also examine the 
relationship of KLF4 and DDR1, a collagen-binding RTK that may influence the antimetastatic 
activity of KLF4. 
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Figure 1. Hedgehog signaling controls mouse development through Shh, Ihh, and Dhh. From 
Varjosalo, M and Taipale, J Genes Dev 2008 (2). Used under license (CC-BY-NC 4.0).The 
timeline of embryonic stages is indicated by days post coitum (dp) and Theiler stage (TS). 
Expression of Ptch, a Hh target gene, is shown as blue shading in the embryonic representations 
above the timeline. Bars below show when various developmental processes are controlled by 
Hh ligands, alone or in combinations according to the color scheme at lower left.  
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Figure 2. GLI proteins are effectors of Hedgehog signaling. From Hui, CC and Angers, S Annu 
Rev Cell Dev Biol 2011 (37). Permission allowed for dissertation use. Schematics indicate 
features of Drosophila melanogaster Cubitus interruptus protein, and Mus Musculus GLI1, 
GLI2, and GLI3 proteins. Note the absence of the Repressor and Processing determinant 
domains in GLI1. For comparison, human GLI1 contains 1107 amino acid residues.  
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Figure 3. A simplified schematic of Hedgehog signaling in vertebrates. Used with permission 
from Yang, L et al. Oncogene 2010 (94). (A) In the absence of Hh ligand, the receptor Patched 
(Ptch/Ptc) functions to inhibit the G protein-coupled receptor Smoothened (Smo). The GLI 
family of transcription factors are processed or degraded such that GLI acts as a transcriptional 
repressor (GLI
R
) of Hh target genes. (B) Hh ligands bind Patched, which alleviates Patched-
mediated inhibition of Smoothened. This alters the processing and degradation of GLI proteins, 
creating GLI forms that activate transcription (GLI
A
) of Hh target genes. In vertebrates, many 
events in Hh signaling occur at the primary cilia. The mechanisms controlling the processing and 
degradation of GLI proteins are not shown, but include phosphorylation by kinases including 
PKA, GSK3β, and CK1, and interaction with the ubiquitin-proteasome system through the E3 
ligase SCF
β-TrCP
. Effects on Smo localization, and interaction of key regulators such as Sufu, are 
also not shown. Examples of Hh target genes include PTCH1 and GLI1, which create negative 
and positive feedback, respectively.  
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Figure 4. Smoothened-independence of Hedgehog signaling in Kras-driven pancreatic ductal 
adenocarcioma. Adapted from Nolan-Stevaux, O et al. Genes Dev 2009 (34). Used under license 
(CC-BY-NC 4.0). Upper panels (A-D): Deletion of Smo in the pancreatic epithelium does not 
inhibit development of pancreatic intraepithelial neoplasia (A,B) or PDA (C,D) in Ptf1a-
Cre;LSL-Kras
G12D
;Trp53
flox/wt
 mice. In fact, Smo
F/F
 mice on average had slightly worse survival 
in comparison to Smo
F/+
 mice in this model of PDA (not shown). In a prior study, phenotypic 
defects were not observed in mice heterozygous for a Smo null allele (23). Lower panel: 
Expression of Hh target genes Gli1 and Ptch1 is maintained in Kras-driven PDA, regardless of 
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Smo depletion. PDA lesions were microdissected from two mice each of Smo
+/+
 (W), Smo
F/+
 
(H), and Smo
F/F
 (F) groups. Transcription of Hh target genes GLI1 and PTCH1 is a well-
characterized indicator of GLI protein transcriptional activity (39,85). The maintenance of Gli1 
and Ptch1 mRNA levels in the absence of functional Smo is therefore indicative of non-
canonical Hh signaling, independent of upstream factors such as hedgehog ligands, Ptch, and 
Smo. The expression of Shh by PDA cells is thought to exert paracrine signaling effects on 
stromal cells such as cancer-associated fibroblasts.  
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Figure 5. Role of GLI transcriptional activity in Kras-induced pancreatic ductal adenocarcinoma. 
From Rajurkar, M et al. Proc Natl Acad Sci U S A 2012 (130). Permission allowed for 
noncommercial use. Upper panel: Effect of suppressing GLI activity in a Kras-driven mouse 
model of PDA. The development of PDA in Ptf1a-Cre;LSL-Kras
G12D
;Trp53
flox/wt 
mice is delayed 
through expression of Gli3T (R26-Gli3T), which suppresses GLI transcriptional activation. 
Lower panel: GLI1 expression accelerates development of Kras-driven PDA. Ectopic GLI1 
expression alone (Ptf1a-Cre;R26-Gli1) did not affect pancreatic development (not shown) or 
initiate tumors. The slow development and progression of PanIN and PDA from activated Kras 
(Ptf1a-Cre;Kras
G12D
) is greatly accelerated by ectopic GLI1 (Ptf1a-Cre;Kras
G12D
;R26-Gli1). 
Note that Trp53 is not manipulated in this model, in contrast to the experiment presented in the 
upper panel.  
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Figure 6. Hedgehog signaling in pancreatic ductal adenocarcinoma. Used with permission from 
Morris, JP et al. Nat Rev Cancer 2010 (132). In the stroma, Hh ligands expressed from 
carcinoma cells signal to cell types such as cancer-associated fibroblasts. This paracrine, ligand-
dependent mechanism can alter the tumor microenvironment through effects on the extracellular 
matrix, angiogenesis, immune response, growth factor signaling, and other pathways. In contrast, 
Hh signaling is activated in tumor cells through non-canonical mechanisms, including through 
KRAS and TGFβ signaling. ANGPT1, angiopoietin 1; IGF, insulin-like growth factor; MMP9, 
matrix metalloproteinase 9; VEGFA, vascular endothelial growth factor A.   
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Figure 7. Therapeutic benefit of the Hedgehog pathway inhibitor vismodegib in a randomized, 
double-blind, placebo-controlled trial in patients with nevoid basal cell carcinoma syndrome. 
From Tang, JY et al. N Engl J Med 2012 (191). Permission allowed for dissertation use: 
Reproduced with permission from (191) Copyright Massachusetts Medical Society. (A,B) 
Number of new surgically eligible basal cell carcinomas (SEBs) in patients receiving vismodegib 
(A) or placebo (B). (C,D) Change in existing SEB size in patients receiving vismodegib (C) or 
placebo (D), as shown by the percent change from baseline in the sums of the longest diameters 
of SEBs.  
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Figure 8. The ubiquitin system. Used with permission from Deshaies, RJ and Joazeiro, CA Annu 
Rev Biochem 2009 (244). (A) E1 ubiquitin-activating enzyme activates ubiquitin and ubiquitin-
like proteins, so they may be transferred to an E2 ubiquitin-conjugating enzyme. (B) Ubiquitin is 
conjugated to a cysteine residue of an E2 enzyme through a thioester link. (C) An E3 ubiquitin 
ligase catalyzes the transfer of ubiquitin from the E2 ubiquitin conjugating enzyme to the protein 
substrate. (D) Monoubiquitylated proteins can dissociate from the ubiquitin ligase complex. The 
monoubiquitin then alters protein function through effects on protein interactions or other 
mechanisms. (E) Monoubiquitylated substrates can also receive additional ubiquitylations, which 
can occur through multiple attachment of single units (not shown) or as chain of ubiquitin. (F) 
Polyubiquitylation forms such as K63 chains can also act to alter protein function. (G) Chains 
through other ubiquitin residues, including K48 and K29, direct the substrate to the proteasome 
for degradation or processing. Ubiquitin receptor proteins (UbRs) can determine the effects of 
ubiquitylation, and are important in some cases to help deliver polyubiquitylated substrates to the 
proteasome.  
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Figure 9. Structure of F-box containing E3 ubiquitin ligases. Used with permission from Wu, G 
et al. Mol Cell 2003 (282). Two related E3 ubiquitin ligase structures are shown: SCF
SKP2
 
(topmost complex), and SCF
β-TrCP
 (lower complex). Rbx1 is included in both structures. The 
position of the E2 conjugating enzyme UbcH7, which interacts with Rbx1, and the active 
cysteine residue, which conjugates ubiquitin, are indicated. A substrate peptide fragment of β-
catenin is shown in association with the WD repeat motif of β-TrCP. The torus-like WD repeat 
structure is viewed from the side. The E3 ligase catalyzes transfer of ubiquitin from the E2 
enzyme to the substrate.   
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Figure 10. Overview of KLF structure. Used with permission from Pearson, R et al. Int J 
Biochem Cell Biol 2008 (328). KLFs contain three C2H2 zinc fingers. The linking region between 
the KLF zinc fingers is also highly conserved. Other elements of KLFs are poorly conserved, but 
usually contain at least one domain that functions in transcriptional activation or repression.  
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Figure 11. Human KLF4 locus, mRNA, and protein structure. Used with permission from Wei D 
et al. Carcinogenesis 2006 (599). (A) KLF4 spans a 6.3 kb region of chromosone 9q31. (B) The 
KLF4 gene contains five exons. (C) The KLF4 RNA transcript. Amongst the five exons, the open 
reading frame is found in exons 2-4, indicated by solid red. (D) KLF4 protein contains 470 
amino acid residues. Also shown are zinc fingers, a transcriptional activation domain (AD), 
inhibitory domain (ID), nuclear localization signal (NLS), and PEST sequences. Point mutations 
reported in tumor cells are indicated in blue.  
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Figure 12. KLF4 is required for the skin barrier function. Used with permission from Segre, JA 
et al. Nat Genet 1999 (388). In normal development of the mouse embryo (upper series), the skin 
develops a barrier function over the last three days of gestation, which prevents absorption of 
external dyes. In contrast, Klf4
-/-
 mice do not form an effective skin barrier. In this method, X-gal 
that successfully penetrates the skin is cleaved by endogenous β-galactosidase activity, resulting 
in blue precipitates.  
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Figure 13. Goblet cell deficiency in Klf4
-/-
 mice. Used with permission from Katz, JP et al. 
Development  2002 (391). In the colonic epithelium of wild-type mice (panels A and C), mature 
goblet cells represented 20% of all epithelial cells as determined by Alcian Blue staining and 
morphology (panel C arrows). In colon specimens of Klf4
-/-
 mice (panels B and D), only 2% of 
epithelial cells were mature goblet cells. Cells with Alcian Blue staining in the Klf4
-/-
 mouse 
colon did not have normal goblet cell morphology (panel D arrows).  
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Figure 14. KLF4 expression in the normal human colonic mucosa. Adapted from Zhang, W et al. 
Mol Cell Biol 2006 (371). Permission allowed for dissertation use. Immunohistochemical 
detection of KLF4 in human colon specimens reveals a distinct pattern of expression. The base 
of the crypt, containing stem cells that maintain the colonic epithelium, is characterized by low 
expression of KLF4 protein. In contrast, expression of KLF4 protein is high in the differentiated, 
growth-arrested epithelial cells at the crypt apex. KLF4 expression is therefore associated with 
epithelial differentiation and growth arrest in the colon. 
  
104 
 
 
 
Figure 15. Association of KLF4 expression with disease-free survival in colon cancer. From 
Patel NV et al. Cancer Epidemiol Biomarkers Prev 2010 (458). Adapted by permission from the 
American Association for Cancer Research:  Patel NV et al, Expression of the tumor suppressor 
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Krüppel-like factor 4 as a prognostic predictor for colon cancer, Cancer Epidemiology, 
Biomarkers & Prevention, 2010 October, vol 19. issue 10, 2631-8, doi: 10.1158/1055-9965.EPI-
10-0677. Upper panels: Expression of KLF4 protein detected by immunohistochemistry in 
normal human colon (A). Tumors specimens with ≥10% staining were scored as KLF4 positive 
(B), whereas tumors with less than 10% staining were considered KLF4 negative (C). Lower 
panels: Disease-free survival time is significantly enhanced in patients with KLF4-expressing 
tumors (P=0.0001). This retrospective study was performed using a tissue microarray of 367 
colon cancer cores. 
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Figure 16. Tissue-specific loss of KLF4 results in precancerous changes of the gastric 
epithelium. Used with permission from Katz, JP et al. Gastroenterology 2005 (401). Upper 
panels: Compared to controls, mice with Klf4 ablation in the glandular stomach (Foxa3-
Cre/Klf4
loxP/loxP
) showed epithelial hypertrophy of the epithelium and distorted gastric pit glands. 
There were increased mucus cells and decreased parietal cells. Middle panels: At 12 months, 
Klf4 loss resulted in further epithelial hypertrophy and gland distortion. Polyps were also found 
in Klf4 mutant mice, but gastric malignancies were not found in either group. Lower panels: 
Immunohistochemistry to detect bromodeoxyuridine reveals proliferating cells (arrows) in the 
gastric glandular epithelium. Compared to controls, there were increased numbers of 
proliferating cells in the Klf4 mutant epithelium, and the location of the proliferating cells was 
shifted towards the lumen. 
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Figure 17. KLF4 promotes malignant properties in the absence of p21. Used with permission 
from Rowland, BD et al. Nat Cell Biol 2005 (440). KLF4 promotes p21 and suppresses p53, and 
in the absence of p21, KLF4 may exert oncogenic effects. Upper panels: In wild-type MEFs, 
overexpression of KLF4 lacks transforming effects. In contrast, KLF4 overexpression in p21 
knockout MEFs results in proliferating colonies lacking contact inhibition. Lower panels: 
Overexpression of KLF4 in p21 knockout MEFs allows colony formation in soft agar, in a 
quantity comparable to that of p53
-/-
 MEFs transfected with activated RAS. 
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Figure 18. Survival in metastatic breast cancer. Used with permission from Thientosapol, ES et 
al. Intern Med J 2013 (522). The median overall survival from start of first-line chemotherapy 
for 273 women diagnosed with metastatic breast cancer was 20.4 months. Patients had a median 
age of 56 years. Tumors were hormone receptor positive in 69% of patients, HER2 positive in 
27%, and triple negative in 13%. 
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Figure 19. Steps and obstacles in metastasis. Used with permission from Vanharanta, S and 
Massagué, J Cancer Cell 2013(545). A sequence of steps involved in the metastasis of breast 
cancer, involving the events of primary tumor cells, dissemination, establishment of 
micrometastasis, and progression to macrometastasis. The dissemination of cells to distant sites 
can occur early in disease, whereas in most patients the development of macrometastasis occurs 
after initial treatment. Very few disseminated cells result in micrometastases, and most 
micrometastases do not progress to macrometastases. Critical bottlenecks in metastasis are 
considered to be later steps in the progression, such as the long-term survival and reactivation of 
cells at metastatic sites. 
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Figure 20. Circulating tumor cells in the metastatic cascade. Used with permission from 
Valastyan, S and Weinberg, RA Cell 2011 (543). An alternate view of metastasis highlights the 
role of tumor cells in circulation as an intermediate step in the metastatic process. It also possible 
for cancer cells to disseminate through the lymphatic system or via body cavities such as the 
peritoneum. Lymphatic vessels eventually drain into the bloodstream. The most common sites of 
distant metastasis in breast cancer are lungs, bone, liver, and brain. Of the tumor cells released 
into the bloodstream, the overwhelming majority are unable to form macrometastasis.   
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Figure 21. Spontaneous metastasis of MDA-MB-231 cells. Adapted from Iorns, E et al. PLoS 
One 2012 (537). Used under license (CC-BY). The MDA-MB-231 breast cancer cell line will 
spontaneously metastasize from primary orthotopic tumors in NSG mice. Panels illustrate 
spontaneous metastasis to axillary lymph nodes, lungs, skeletal muscle, and liver. Shown are 
gross specimens (left column), H&E sections (center column), and cytokeratin 18 (CK18) by 
immunohistochemistry (right column). In contrast to surrounding tissue, tumor cells strongly 
express CK18.    
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Figure 22. Expression of miR-7 and KLF4 in brain metastases of human breast cancer. From 
Okuda, H et al. Cancer Res 2013 (483). Adapted by permission from the American Association 
for Cancer Research: Okuda H et al, miR-7 suppresses brain metastasis of breast cancer stem-
like cells by modulating KLF4, Cancer Research, 2013 February 15, vol 73. issue 4, 1434-44, 
doi: 10.1158/0008-5472.CAN-12-2037. Upper panels: Expression of miR-7 is decreased in brain 
metastases of breast cancer, whereas expression of KLF4 mRNA is increased. miR-7 is plotted 
relative to RNU48, and KLF4 is plotted relative to ACTB. Lower panels: Increased nuclear 
expression of KLF4 (immunohistochemistry) in brain metastases as compared to primary breast 
tumors. 
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Abstract 
The High Mobility Group box protein SOX9 and the GLI1 transcription factor play 
protumorigenic roles in pancreatic ductal adenocarcinoma (PDA). In Kras transgenic mice each 
of these factors are critical for development of PDA precursor lesions. SOX9 transcription is 
directly regulated by GLI1, but how SOX9 functions downstream of GLI1 is unclear. We 
observed positive feedback, such that SOX9-deficient PDA cells have severely repressed levels 
of endogenous GLI1, attributed to loss of GLI1 protein stability. Sox9 associated with the F-box 
domain of the SKP1/CUL1/F-box (SCF) E3 ubiquitin ligase component, β-TrCP, and suppressed 
its association with SKP1 and GLI1, a substrate of SCF-β-TrCP. SOX9 also tethered β-TrCP 
within the nucleus and promoted its degradation. SOX9 bound to β-TrCP through its C-terminal 
PQA/S domain that mediates transcriptional activation. Suppression of β-TrCP in SOX9-
deficient PDA cells restored GLI1 levels and promoted SOX9-dependent cancer stem cell 
properties. These studies identify SOX9-GLI1 positive feedback as a major determinant of GLI1 
protein stability and implicate β-TrCP as a latent, SOX9-bound tumor suppressor with the 
potential to degrade oncogenic proteins in tumor cells. 
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Introduction 
The evolution of metazoans required new strategies for proper regulation of cell fate 
including intercellular signaling, signal reception, and signal transduction, processes in which 
transcription factors play critical roles (1,2). Central to cancer etiology is the dysregulation of 
cell fate, often through genetic changes that impinge on transcription factor signaling (3,4). 
GLI1, a member of the GLI family of zinc finger transcription factors, is a central regulator of 
cell fate that is deregulated in diverse tumor types (5-9). Increased levels of GLI1 mRNA and 
protein can result from genetic inactivation of tumor suppressors such as the Hedgehog pathway 
receptor Patched1 (PTCH1), or mutational activation of factors such as Smoothened (SMO). 
GLI1 signaling impacts multiple cancer-relevant cellular processes, promoting dedifferentiation, 
the generation of cancer stem cells (CSCs), tumor progression and metastasis. In addition, GLI1 
can directly induce the transcription of its own mRNA through a well-characterized, 
autoregulatory feedback, and therefore GLI1 mRNA levels often reflect the overall GLI 
transactivation capacity (10,11). 
Pancreatic ductal adenocarcinoma (PDA) is an aggressively metastatic tumor type that is 
often diagnosed at a later clinical stage (12,13). Although GLI1 is expressed in both epithelial 
PDA cells and stromal cells, a cell autonomous role within carcinoma cells appears central to the 
pathogenesis of this disease (14-17). Indeed, suppression of GLI1 in human PDA cells leads to 
loss of malignant properties (14,16,18). In a Kras-dependent mouse model of PDA, either Cre-
mediated excision of Gli1 or expression of a dominant negative GLI factor suppresses 
tumorigenesis, including the outgrowth of precursor lesions termed pancreatic intraepithelial 
neoplasia (PanIN) (19,20). Conversely, enforced expression of an active GLI factor in pancreatic 
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epithelial cells promotes tumorigenesis in mice (21). In the canonical Hedgehog/GLI pathway, 
GLI activity is dependent upon signaling by Hedgehog through PTCH and SMO, whereas in 
PDA cells GLI1 is instead maintained by activated KRAS (15-18,21,22).  
The protein stability of GLI1 is regulated by two E3 ubiquitin ligases, the Skp/Cul/F-box 
complex SCF
β-TrCP
 and NUMB/ITCH (23,24). Similar to slimb regulation of the Drosophila GLI 
homologue cubitus interruptus, the mammalian SCF
β-TrCP
 is a major regulator of the protein 
stability and/or proteolytic cleavage of mammalian GLI1 and its paralogues GLI2 and GLI3 
(25,26). SCF
β-TrCP
 is comprised of the bridging protein SKP1, the scaffolding protein CUL1, the 
substrate-recognizing F box protein β-TrCP, and the RING finger protein RBX1. This complex 
catalyzes the transfer of ubiquitin from E2 ligase to the substrate, leading to degradation by the 
ubiquitin proteasome system (UPS) (27). In cultured human keratinocytes, GLI1 stability is 
dependent upon epidermal growth factor (EGF) signaling through the MEK/ERK pathway (28). 
Similarly, in cultured human PDA cells, activated KRAS can stabilize the GLI1 protein through 
ERK1/2 signaling (18). These results suggest a broader role of RAS/MEK/ERK in stabilization 
of GLI1. 
GLI1 directly induces the transcription of SOX9, an Sry-like High Mobility Group 
(HMG) box transcription factor that plays key roles in sex determination, chondrogenesis and 
cell differentiation (29-31). Sox9 responds to Hedgehog/Gli signaling in multiple contexts 
including chondrocytes, retinal progenitor cells, and developing hair follicles (32-35). Consistent 
with these results the SOX9 promoter and upstream flanking region contains consensus GLI 
binding sites that, when linked to a transcriptional reporter, can be regulated by GLI1 in cultured 
cells (34,36). 
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In the developing pancreas, Sox9 is expressed in stem- or progenitor-like cells and is 
required for normal organogenesis (37,38). In the adult pancreas Sox9 is expressed in ductal and 
centroacinar cells, but is normally low or absent in acinar cells. Two types of studies have 
documented a protumorigenic role for SOX9 in PDA. First, xenograft experiments utilizing 
human PDA cells such as Panc-1 indicate that SOX9 promotes the maintenance of tumor-
initiating cells (34,39). Secondly, the induction of PanIN lesions in the conditional Kras
G12D
 
mouse model of PDA involves the early induction of Sox9 in acinar cells, followed by acinar-
ductal metaplasia and tumor progression (40). Conditional gene knockout or enforced expression 
revealed that Sox9 is critical for the occurrence of PanIN lesions. Similarly SOX9 is 
protumorigenic in other contexts including colorectal cancer and mammary cancer, promoting 
the induction of CSC factors such as BMI1 and/or cooperating with mesenchyme-inducing 
factors such as Snail or Slug (41,42). 
In the current study we found that Sox9 is important for efficient in vitro transformation 
by GLI1, attributed to its stabilization of GLI1. Like other SCF
β-TrCP
 substrates, GLI1 interacted 
with the C-terminal WD domain of β-TrCP. SOX9 instead interacted with the N-terminal F-box 
domain, and yet inhibited the association of GLI1 and β-TrCP. Consistent with a critical role of 
the SOX9-β-TrCP interaction for stabilization of GLI1, suppression of β-TrCP in SOX9-
deficient PDA cells led to restoration of GLI1 and promoted malignant properties. Because 
SCF
β-TrCP
 can promote the ubiquitination of functionally diverse proteins, its ultimate role as pro- 
vs. anti-tumorigenic may be context-dependent (27,43-45). Our data suggest that β-TrCP-
associated proteins such as SOX9 could be a critical aspect of this context, capable of 
suppressing SCF activity against multiple pro-tumorigenic substrates such as GLI1, β-catenin 
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and the anti-apoptotic factor MCL1. These results identify reactivation of latent β-TrCP as a 
strategy for the disruption of KRAS-mediated protumorigenic signaling. 
Results 
A role for Sox9 in GLI1-mediated epithelial transformation in vitro.  RK3E cells, 
derived from rat kidney cells by immortalization with adenovirus E1A, undergo malignant 
transformation in response to GLI1 and provide an epithelial context for functional studies 
(46,47). Utilizing this model, we identified increased Sox9 mRNA and protein as early responses 
to exogenous, human GLI1 (HsGli1, Fig. 1A and supplementary material Fig. S1A). In RK3E 
cells engineered to induce GLI1 when exposed to tetracycline (RK3E-TO GLI1 cells), the Sox9 
mRNA was induced between 1 and 3 hours after drug treatment. Kinetics were similar as for 
other well-established, GLI1-regulated genes including Ptch1 and Bcl2. Consistent with a direct 
interaction, ChIP analyses and luciferase reporter studies identified a candidate enhancer element 
containing a GLI1 consensus site, located downstream of the rat Sox9 coding region and 
approximately 1.0 kb downstream of exon 3 (supplementary material Fig. S1B, C, and D). 
To analyze Sox9 we generated shRNA expression vectors (shSox9-1 and -2) that stably 
suppressed the Sox9 mRNA in RK3E cells (Fig. 1B, upper panel). As compared to a non-
targeting control (Ctrl), plasmid cotransfection of GLI1 vector with either shRNA construct 
efficiently inhibited the outgrowth of transformed foci (Fig. 1B, lower panel). In contrast, Sox9 
appeared largely dispensable when transformed foci were instead generated using an ERBB2 
vector (supplementary material Fig. S1E). 
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Following siRNA-mediated suppression of Sox9 in GLI1-transformed RK3E cells, we 
found that GLI1 protein levels were reduced, suggesting a role for Sox9 in maintenance of GLI1 
(Fig. 1C, lanes 2 and 4). Treatment with proteasome inhibitor CLβL rapidly restored GLI1 
protein levels (Fig. 1D). These results identified Sox9 as a transcription factor with a potential 
role in GLI1 protein stability. 
Endogenous SOX9 stabilizes GLI1 in pancreatic cancer cells through regulation of 
β-TrCP-mediated degradation. Analysis of conditionally-deficient mice has shown that SOX9 
and GLI1 play critical roles in PDA development. We analyzed nine PDA tumor cell lines and 
found that, relative to non-malignant HPDE cells, SOX9 levels were markedly upregulated 
(range, 10.0- to 240-fold), and most lines likewise expressed increased levels of GLI1 (Fig. 1E). 
To examine a role for endogenous SOX9, we utilized transient or inducible siRNAs that 
target two distinct sequences (supplementary material Fig. S2A). To detect endogenous GLI1, a 
low abundance factor, we utilized IP and immunoblot analysis. Using this assay, either of two 
different GLI1 antibodies identified a protein of 150 kDa (supplementary material Fig. S2B and 
data not shown). Repression of SOX9 in PDA cells resulted in the reduction of endogenous GLI1 
protein levels (Fig. 1F), and mRNA analysis revealed synchronous loss of both SOX9 and GLI1 
signals after siRNA transfection (Fig. 1G). 
To analyze how SOX9 regulates GLI1, we engineered PDA cells that independently 
regulate the GLI1 mRNA and protein, through introduction of a GLI1 transgene under control of 
a retroviral promoter (Panc-1-GLI1). In these cells the exogenous GLI1 protein was reduced 
following SOX9 knockdown (Fig. 1H, lanes 3-4). Three independent experiments indicated loss 
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of 82% of the GLI1 (Fig. 1H, bar graph). In contrast, the GLI1 transgene-derived mRNA levels 
were not dependent upon SOX9 (Fig. 1H, right panel). In vector control cells the suppression of 
SOX9 repressed the endogenous GLI1 mRNA. These results indicate that loss of GLI1 mRNA 
following SOX9 suppression is due to destabilization of the GLI1 protein and its autoregulation 
of GLI1 transcription. 
Interaction of endogenous GLI1 and β-TrCP proteins was readily detected in human PDA 
cells (Fig. 1I, left panel). In the absence or presence of proteasome inhibitor the suppression of 
endogenous SOX9 increased the ratio of β-TrCP/GLI1 in IPs (Fig. 1I, right panel). Similarly to 
treatment with proteasome inhibitor, GLI1 expression was rescued by suppression of β-TrCP 
(Fig. 1J, lanes 5-6). Similar results were obtained using transient SOX9 siRNA or else the TO 
conditional approach in either Panc-1 or AsPC-1 cells (supplementary material Fig. S2C).  
Sox9 disrupts the interaction of GLI1 with β-TrCP. Sox9 was previously shown by 
co-IP and colocalization studies to associate with β-TrCP, likely through the SOX9 C-terminus, 
as deletion of this region abrogated binding (48). To investigate whether the association of Sox9 
with β-TrCP can modulate the targeting of GLI1 for ubiquitination, we utilized HEK293 cells 
that contain very low levels of endogenous SOX9. When expressed by transient transfection, 
GLI1 was found to associate with both endogenous and exogenous β-TrCP (Fig. 2A). Similarly 
as reported (48), the Sox9/β-TrCP interaction was readily detected (Fig. 2B). However, in 
multiple experiments we were unable to observe any association of GLI1 and SOX9 (Fig. 2C). 
Negative results were obtained for co-IP of endogenous proteins in Panc-1 cells as well as 
overexpressed proteins in HEK293, using both forward and reverse co-IP strategies. These 
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results suggested that Sox9 may not regulate GLI1 through a direct interaction but rather could 
regulate its association with the E3 ligase component, β-TrCP. 
Consistent with the established role of β-TrCP in GLI1 regulation, GLI1 levels were 
suppressed by transient delivery of exogenous β-TrCP, and restored by addition of proteasome 
inhibitor (Fig. 2D). In contrast to GLI1 there was no suppression of Sox9 levels in response to β-
TrCP (supplementary material Fig. S2D). These results suggested that exogenous Sox9 may 
prevent the binding of GLI1 to its E3 ligase and the subsequent ubiquitination (23). Indeed, assay 
of GLI1 stability using the protein synthesis inhibitor cycloheximide (CHX) showed that SOX9 
could extend the half-life (Fig. 2E). 
Sox9 contains three conserved domains: HMG, PQA and PQS (Fig. 2F). The HMG box 
mediates DNA binding while PQA and PQS promote transactivation. Deletion analysis indicated 
that the transactivation region (fragment PQA/S) is sufficient to interact with β-TrCP, and with 
comparable efficiency as WT Sox9 (Fig. 2F). As reported (48), deletions within the 
transactivation domain (ΔC or HMG) abrogated the interaction.  
The WD40 repeats of β-TrCP mediate substrate binding, and the first WD40 repeat plays 
a critical role in substrate recognition (27). In contrast, the F-box region mediates interaction 
with SKP1. Consistent with lack of a suppressive effect of β-TrCP on SOX9 (supplementary 
material Fig. S2D), and unlike SCF
β-TrCP
 substrates or pseudosubstrates (49), deletion analysis 
indicated that SOX9 associated with the F-box region of β-TrCP (Fig. 2G, left panel). As 
expected for a substrate, GLI1 interacted with the WD40 repeats of β-TrCP (fragment WD1-7), 
and deletion of the first WD40 repeat (fragment WD2-7) abrogated this interaction (Fig. 2G, 
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right panel). Although they interacted with distinct β-TrCP domains, co-IP of GLI1 and β-TrCP 
was nevertheless markedly suppressed in the presence of Sox9 (Fig. 2H, lane 2). In contrast the 
co-expression of Sox9ΔC, deficient for β-TrCP binding, had little effect (Fig. 2H, lane 3). Unlike 
for β-TrCP, using reciprocal co-IPs we observed no interaction of SOX9 with other F-box 
proteins including FBXW7 and SKP2 (supplementary material Fig. S2E and data not shown). 
SOX9 interferes with SKP1 binding and facilitates β-TrCP turnover in pancreatic 
cancer cells. As SOX9 interacted with F-box region of β-TrCP, we asked whether this 
association would interfere with β-TrCP/SKP1 binding. 293T cells contain much lower levels of 
endogenous SOX9 compared to Panc-1 cells (Fig. 3A). In 293T cells the binding of Myc-β-TrCP 
with endogenous SKP1 was suppressed by a mean of 67% in the presence of exogenous SOX9 
(Fig. 3B; three independent experiments). Conversely the binding of Myc-β-TrCP with 
endogenous SKP1 was increased by a mean of 76% following SOX9 knockdown in Panc-1 cells 
(Fig. 3C; three independent experiments). These results identify interference of the β-TrCP-
SKP1 association as a mechanism by which SOX9 can stabilize GLI1. 
In PDA cells SOX9 suppression resulted in consistent increases in β-TrCP protein levels 
relative to the mRNA (Fig. 3D; see also the lysate panels in Fig. 1I, right panel; Fig. 1J; and 
supplementary material Fig. S2C). Co-expression of SOX9 with β-TrCP in HEK293 or Panc-1 
cells promoted β-TrCP degradation (supplementary material Fig. S2D and data not shown). We 
therefore determined the half-life of SOX9 and β-TrCP proteins in control PDA cells and in cells 
deficient in SOX9 or β-TrCP. Knockdown of SOX9 increased the steady-state abundance of β-
TrCP and extended its half-life from 140 to 200 minutes (Fig. 3E). In contrast, β-TrCP 
suppression did not significantly alter the expression or stability of SOX9, which had a half-life 
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similar to 230 minutes (Fig. 3F). These results identify distinct inhibitory effects of SOX9 on 
SCF
β-TrCP
. 
SOX9 tethers β-TrCP within the nucleus and selectively protects nuclear GLI1 from 
degradation. Both SOX9 and β-TrCP are primarily localized to the cell nucleus (33,48-50). We 
analyzed the effect of endogenous SOX9 on the localization of transiently-expressed Myc-β-
TrCP in PDA cells. As previously shown for primary chondrocytes (48), SOX9 appeared to 
efficiently tether β-TrCP in this compartment (Fig. 4A). In SOX9-deficient PDA cells the β-
TrCP was instead dispersed throughout the cell such that the nuclear staining was reduced and 
cytoplasmic staining was increased. 
Exogenous GLI1 was detected in both in the nucleus and cytoplasm (Fig. 4B, upper row). 
In SOX9-deficient cells GLI1 was preferentially lost from the cell nucleus, but cytoplasmic 
staining was preserved (Fig. 4B, middle row). Consistent with a UPS role in suppression of 
nuclear GLI1, treatment of cells with CLβL restored nuclear staining (Fig. 4B, lower row). This 
immunostaining data appeared consistent with the partial suppression of exogenous GLI1 
observed by immunoblot analysis (Fig. 1H). The more complete suppression observed for 
endogenous GLI1 (Fig. 1F, I, J, and supplementary material Fig. S2C) remains unexplained, but 
could reflect its preferential nuclear localization relative to the overexpressed protein. These 
results support a role for SOX9 in tethering of β-TrCP within the nucleus of PDA cells. Selective 
loss of nuclear GLI1 upon suppression of SOX9 indicates that nuclear SCF
β-TrCP
 activity is 
increased despite the dispersal of β-TrCP throughout the cell. These results suggest that the 
apparent β-TrCP concentration can be discordant with its activity when SOX9 is present. 
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SOX9 promotes the malignant properties of PDA cells in a fashion dependent upon 
β-TrCP and GLI1. Both SOX9 and GLI1 appear critical for tumorigenesis in PDA (19,20,40). 
While SOX9-deficient Panc-1 cells fail to form tumors in a mouse xenograft assay, potential 
links to GLI1 function remain unexplored (34). For SOX9-deficient and control PDA cells we 
analyzed several in vitro correlates of the malignant phenotype, including proliferation, 
anchorage-independence, and survival. SOX9-deficient Panc-1 cells proliferated in 2D culture 
similarly to control cells (Fig. 5A), but were unable to efficiently form colonies in soft agar over 
a period of 2 weeks (Fig. 5B). Other PDA cell lines, AsPC-1 and MiaPaCa-2, responded 
similarly. When cells were suspended in low attachment plates for 24 or 48 hours (anoikis 
assay), deficiency in SOX9 resulted in a marked reduction in the overall viable cell number and 
the proportion of viable cells (Fig. 5C). These results confirm that SOX9 deficiency can abrogate 
the malignant properties of PDA cells. 
We used the anoikis assay to determine whether deficiency of SCF
β-TrCP
 substrates such 
as GLI1 may be responsible for the loss of malignant properties. We restored GLI1 expression in 
SOX9-deficient cells using β-TrCP siRNAs (Fig. 5D and supplementary material Fig. S3A). The 
cell death phenotype of SOX9-deficient PDA cells was attenuated by co-suppression of β-TrCP 
in both Panc-1 and AsPC-1. Consistent with a functional role for GLI1 as a mediator of the 
increased cell survival following β-TrCP suppression, co-suppression of GLI1 promoted cell 
death (Fig. 5E). 
SOX9 promotes the cancer stem cell-like properties of PDA cells in a β-TrCP-
dependent fashion. CSCs are an aggressively malignant subset of tumor cells (51). In PDA both 
SOX9 and GLI1 are important for maintenance of this subpopulation (34,39,52,53). To 
188 
 
determine whether there is phenotypic overlap following modulation of SOX9 or GLI1, we 
enriched for CSCs using spheroid formation or dye efflux assays (i.e., side population cells, SP) 
(54) (Fig. 6A). In addition to GLI or GLI-regulated factors (GLI1, GLI2, SOX9, SNAI1), these 
subpopulations had increased levels of pancreatic CSC markers (CD24, CD44, ESA, CD133, and 
CXCR4) as well as factors important for generation of induced pluripotent stem cells (OCT4 and 
KLF4) (55-57) (Fig. 6B). Consistent with a role for GLI1 in the phenotype of SOX9-deficient 
cells, suppression of either gene product in 2D cultures of PDA cells reduced the expression of 
CSC markers, resulting in very similar profiles (Fig. 6C). 
We next examined whether β-TrCP suppression could rescue the CSC phenotype in 
SOX9-deficient cells. Stable suppression of SOX9 reduced spheroid formation by 75% (Fig. 
6D). Consistent with this result, SOX9 suppression in 2D-cultured PDA cells also reduced the 
abundance of SP cells (Fig. 6E and supplementary material Fig. S3B). Absent SOX9 
suppression, transient suppression of β-TrCP had little effect on spheroid growth (Fig. 6F, left 
panel). However in SOX9-deficient cells siβ-TrCP partially rescued spheroid formation (Fig. 6F 
and supplementary material Fig. S3C). The remarkably similar expression profile in SOX9- and 
GLI1-deficient tumor cells, and restoration of spheroid formation by siβ-TrCP support a role for 
suppression of SCF
β-TrCP
 activity as a mechanism by which SOX9 can promote GLI1 expression 
and the CSC-like phenotype. 
SOX9 is increased while β-TrCP is decreased in primary human PDA.  The above 
data indicate that SOX9 functions in cultured PDA cells to antagonize β-TrCP expression and its 
activity toward GLI1. We utilized Oncomine microarray data (Compendia Bioscience) to 
analyze SOX9 and β-TrCP expression in primary human PDA specimens (58). Four studies each 
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detected increased levels of PDA signature genes, typified by SFN/14-3-3σ, in PDA tumor tissue 
relative to morphologically normal tissue (59-63) (supplementary material Table S1 and Fig. S4). 
In these studies SOX9 mRNA expression was upregulated (range, 1.00 to 1.87 fold) while 
transcripts encoding β-TrCP (BTRC) were consistently repressed (range, 1.12 to 1.25 fold). This 
increase of SOX9 and decrease of BTRC may contribute to the upregulation of GLI1 in PDA 
(14,16,64). 
SOX9 stabilizes other β-TrCP-regulated proteins. If SOX9 selectively stabilizes 
nuclear GLI1 by antagonizing β-TrCP activity in this compartment, then other substrates may be 
similarly affected, potentially with more subtle effects for cytoplasmic substrates. Consistent 
with their known regulation by SCF
β-TrCP, β-catenin, Snail and MCL1 protein levels were each 
reduced by similar to 50% following SOX9 knockdown in PDA cells, and CLβL treatment 
restored the levels (Fig. 7A) (65-67). For β-catenin, consistent results were obtained by 
transcriptional reporter assay (Fig. 7B) and immunofluorescence analysis (Fig. 7C). Cells 
transfected with SOX9 siRNA had similar to 50% reduced expression of both nuclear and 
cytoplasmic β-catenin (Fig. 7C and supplementary material Fig. S3D). These data are consistent 
with a predominant role of SOX9 in the nuclear tethering and suppression of SCF
β-TrCP
 activity 
through protein-protein interaction, with more subtle effects in the cytoplasm attributed to 
alteration of β-TrCP concentration (Fig. 4A). Fig. 7D presents a model summarizing the 
observed effects of SOX9 on β-TrCP and nuclear GLI1. 
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Discussion 
 SOX9 is critical for diverse developmental processes including sex determination, 
chondrogenesis and pancreatogenesis (29-31). For cancers of the prostate, colorectum, pancreas 
and breast SOX9 plays important roles in carcinoma cell malignant properties (33,34,39,39-
42,68). In chondrocytes SOX9 induces the transcription of genes such as COL2A1, COL11A2 
and Aggrecan (29,69,70). Although Sox9-responsive genes were analyzed in several contexts, 
the mechanisms by which SOX9 promotes malignant properties remain poorly understood, and 
the relative importance of transcriptional signaling vs. other biochemical activities is unclear 
(38,42,71). 
In rat RK3E epithelial cells we identified Sox9 as an early transcriptional response to 
GLI1, and linked this regulation to a downstream Sox9 enhancer element using ChIP and 
transcriptional reporter studies. These data are consistent with previous reports indicating 
regulation of mouse or human SOX9 by Hedgehog and/or GLI1 (32-35). In analyzing GLI1-
transformed cells we were surprised to observe a pronounced loss of GLI1 protein stability upon 
suppression of SOX9, attributed to UPS-mediated degradation. This effect was conserved in 
human PDA cells and indicated a consistent role for SOX9 in stabilization of GLI1. 
In a previous study focused upon chondrocytes, Sox9 was found to associate with β-TrCP 
and to promote β-TrCP nuclear localization and the degredation of nuclear β-catenin (48). In the 
current study focused upon PDA, we found that SOX9 likewise functions as a nuclear tether for 
β-TrCP, but few other aspects of the chondrocyte study appeared to extend to the PDA context. 
We instead obtained extensive data supporting a potent inhibitory role for SOX9 on β-TrCP 
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activity in the nucleus. Suppression of β-TrCP in SOX9-deficient cells restored GLI1 levels and 
promoted phenotypes attributed to SOX9 or GLI1. Supporting the identification of GLI1 as a 
major factor in the altered phenotype of SOX9-deficient cells, the CSC marker profile of SOX9- 
or GLI1-deficient PDA cells was remarkably similar. 
Consistent with an inhibitory effect on SCF
β-TrCP
, SOX9 interacted through its PQA/S 
region with the F-box domain of β-TrCP, and suppressed the association of β-TrCP with either 
endogenous or exogenous SKP1. Typical of other substrates, GLI1 associated with the WD 
domain. Co-immunoprecipitation assays indicated that GLI1 and SOX9 are mutually 
incompatible for β-TrCP association. Indeed, in SOX9-deficient PDA cells the association of 
GLI1 with β-TrCP was increased by several fold. It is unclear why SOX9 association with the F-
box region would prevent GLI1 from binding to the WD domain. Possibilities include steric 
hindrance, a conformational shift, or that SOX9 could facilitate the binding of other nuclear 
proteins such as hnRNP-U, a WD domain-binding pseudosubstrate, and thereby prevent the 
association of β-TrCP with GLI1 (49). 
An additional effect that strongly supported the inhibition of SCF
β-TrCP
 by SOX9 was the 
destabilization of β-TrCP. Whether this instability results from the reduced association with 
SKP1, from tethering within the nuclear compartment, and/or from some other effect of SOX9 or 
yet another associated factor is currently unclear. 
In SOX9-deficient PDA cells β-TrCP was more widely distributed throughout the cell, 
with reduced nuclear staining and similar to a two-fold increase in cytoplasmic staining 
compared with control cells. This redistribution appeared to impact not only nuclear GLI1 but 
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also cytoplasmic proteins such as the SCF
β-TrCP
 substrate β-catenin. While nuclear GLI1 was 
markedly destabilized, the cytoplasmic substrate β-catenin was suppressed by approximately 
50%. Similar effects were observed for two other well-established substrates of SCF
β-TrCP
, Snail 
and MCL1. These results indicate a broad role for SOX9 in the regulation of protein stability. 
In SOX9-deficient PDA cells the effects of untethered β-TrCP were quite distinct for 
nuclear and cytoplasmic GLI1. These results appear to indicate that nuclear GLI1 is selectively 
targeted by β-TrCP, although the mechanism(s) responsible for this selectivity is unclear. The 
results are overall consistent with identification of the Drosophila homologue as a short-lived 
nuclear transcriptional activator in response to Hedgehog signaling (72). We conclude that when 
SOX9 is present the β-TrCP nuclear staining intensity can be discordant with nuclear SCFβ-TrCP 
activity. 
Mouse model data have established clear roles for GLI1 and SOX9 in the malignant 
progression of PDA (14,16,18-21,34,40). Interestingly, both SOX9 transcript levels and GLI1 
protein stability appear critically dependent upon upstream signaling by RAS/MEK/ERK, but it 
remains unclear how either factor is regulated by this signaling (18,28,34,73). Whereas a Sox9 
transgene directed to the pancreatic acinar cells is sufficient on its own to initiate early PanIn 
lesions in mice, a GLI transgene does not induce these lesions, suggesting that GLI is the more 
dependent factor (21,40). These considerations suggest that KRAS may stabilize GLI1 by 
signaling through SOX9. Alternatively, it is possible that activated KRAS could more directly 
regulate GLI1 or both transcription factors in parallel. Blockade of this KRAS signaling in tumor 
cells, a current focus of research, has the potential to suppress SOX9 and to activate β-TrCP-
mediated degradation of multiple oncoproteins. 
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Materials and methods 
Expression vectors and plasmid transfection. pcDNA4/TO-HA-GLI1 was described 
(47). Retroviral vectors were made by inserting the HAGLI1 cassette of pcDNA4/TO-HA-GLI1 
into pB-puro and pLUT7. pLUT7 was provided by Alexey Ivanov (West Virginia University 
[WVU]). All cloned PCR products were verified by sequencing. 
Mouse β-TrCP1 vector containing a 3xMyc epitope tag at N-terminus (74) was used to 
generate truncated constructs by PCR. A human ubiquitin vector, Myc-Ub, was provided by 
Alexey Ivanov. pcDNA3-β-catenin (Addgene 16828) was a gift from Eric Fearon (75). pCMV-
Myc CDC4 WT* was a gift from Bert Vogelstein (FBXW7, Addgene plasmid # 16652). 
pcDNA3-myc-Skp2 was a gift from Yue Xiong (Addgene plasmid # 19947). 
pTRIPZ-TOshSOX9 lentivector was generated by transfer of the shRNAmir cassette 
from pGIPZ (V3LHS_396212, Thermo Scientific). Non-targeting TRIPZ lentiviral shRNAmir 
RHS4743 served as a control. shRNA vectors targeting rat Sox9 (RnSox9) were constructed in 
pSilencer 2.1-U6 neo as described  (47). shRNA target sequences are listed in supplementary 
material Table S2. 
Retroviral transduction was performed as described (46). Transient transfections were 
performed as described (76) using Lipofectamine 2000 Transfection Reagent (Life 
Technologies) for Panc-1 cells and TransIT-LT1 Reagent (Mirus) for other cells. 
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Isolation of rat Sox9 cDNA and generation of Sox9 expression vectors. PCR was used 
to synthesize cDNA fragments containing the RnSox9 5’ UTR and protein coding regions. The 
sequence has been deposited to the NCBI (accession pending). pBpuro-RnSox9 was used for 
stable expression studies. RnSox9 vectors tagged with hemagglutinin (HA), including HA-Sox9 
WT and truncations, were generated by PCR followed by insertion into pcDNA3.1. 
Cell culture and small molecules. The immortalized human pancreatic ductal epithelial 
cell line HPDE (H6c7), provided by Ming-Sound Tsao (University of Toronto, Canada), was 
cultured in keratinocyte serum-free (KSF) medium supplemented with bovine pituitary extract 
and epidermal growth factor (Life Technologies). S2-013 PDA cells were a gift of Martin 
Johnson (University of Alabama at Birmingham). S2-013, HEK293, 293T and RK3E cells were 
cultured in high-glucose DMEM supplemented with L-glutamine, penicillin, streptomycin, and 
10% (v/v) fetal bovine serum. Other PDA cell lines were from American Type Culture 
Collection (ATCC) and were cultured as recommended by ATCC. Doxycycline (Dox, 0.5 
µg/ml), tetracycline (tet, 1.0 µg/ml), cycloheximide (CHX, 50 µg/ml), clasto-Lactacystin β-
lactone (CLβL, 10 µM), and MG132 (20 µM) were from Sigma-Aldrich.  
siRNA transfection, RNA isolation and real-time quantitative PCR (qRT-PCR). 
siRNA target sequences are listed in supplementary material Table S2. siRNA transfection was 
performed using Lipofectamine RNAiMax (Life Technologies) as reported (76). For some 
experiments the Panc-1 cells were re-transfected after 24 hours. Cell extracts were prepared 48 
hours after the start of the initial transfection. Co-transfection of plasmids with siRNAs was as 
reported (76). 
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Total RNA was purified using the RNeasy Plus Mini kit (Qiagen). Reverse transcription 
was performed using SuperScript II (Life Technologies). qRT-PCR reactions utilized Brilliant II 
SyBr green QPCR master mix, GAPDH served as the internal control, and reactions were 
analyzed on an Mx3005P system (Agilent). Oligonucleotides are shown in supplementary 
material Table S3. qRT-PCR results represent three or more independent experiments (bars, 
s.d.). 
Luciferase reporter assay. Topflash (WT TCF4-binding sites) or Fopflash (mutated 
sites) reporter constructs were gifts of Bert Vogelstein. The Renilla luciferase vector pRL-TK 
served as an internal control. For siRNA co-transfection, siRNA Ctrl2 served as the control 
(supplementary material Table S2). Reporter assays were performed on 12-well plates at 48 
hours post-transfection using Dual-Luciferase Reporter Assays (Promega) as described (76). 
Data represent three or more independent experiments (bars, s.d.). 
Protein expression studies. For immunoblotting, mouse anti-GLI1 and rabbit anti-β-
TrCP, anti-SKP1 and anti-SNAI1/Snail were from Cell Signaling Technology. Rabbit anti-SOX9 
was from EMD Millipore. Mouse anti-Myc (9E10) and anti-β-catenin were from BD 
Biosciences. Rat anti-HA (3F10) was from Roche Applied Science. Anti-MCL1 was from Santa 
Cruz (S-19). 
Whole cell lysates for immunoblotting were obtained by extraction in ice-cold RIPA 
buffer without SDS as described (76). For IP and co-IP, cells were resuspended in NE-A buffer 
and then lysed by addition of NaCl and glycerol as described (77). GLI1 protein was precipitated 
with rabbit anti-GLI1 (47), while rabbit anti-SOX9 (H-90, Santa Cruz Biotechnology) or a 
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monoclonal anti-HA (12CA5, Roche) was used for SOX9. Normal rabbit or mouse IgG (Sigma-
Aldrich) was used as control. Protein complexes were recovered using Protein A-Sepharose 
(Sigma-Aldrich). 
For immunoblotting, proteins were transferred to nitrocellulose membrane and detected 
using chemiluminescence (Pierce ECL, Thermo-Scientific). Quantitative analysis of 
autoradiographic images was performed using Image J v1.42 (National Institutes of Health), and 
the normalized results were transferred to GraphPad Prism. 
In vitro transformation assay. RK3E transformation assays were performed as 
described (47). Cells were fixed and stained using Modified Wright Stain (Sigma-Aldrich) at 2–3 
weeks post-transfection, and foci with a diameter greater than 1.0 mm were counted. 
Soft Agar Assay. Anchorage-independent cell growth assays were performed on 6-well 
plates. A 2.0 ml underlay composed of 0.63% (w/v) agar in complete DMEM was placed in each 
well. 1.0 ml of cells (3.0 x 10
3
) in DMEM containing 0.33% agar was plated on top.  Cells were 
fed with 1.0 ml of 0.63% agar in DMEM each week. For induction of shRNA expression 
0.5µg/ml of doxycycline was included. Cells were fixed after 2-3 weeks in 10% methanol/10% 
acetic acid and stained with 0.1% crystal violet (Sigma-Aldrich) in 50% methanol. Colonies 
larger than 50µ in diameter were counted under phase contrast microscopy.   
Anoikis assay. Matrix deprivation assays were performed as described (78). 24 hours 
post siRNA-transfection, 2.0 x 10
4
 cells were resuspended in 1.0 ml of complete DMEM 
containing 1% methylcellulose (Sigma-Aldrich) and plated in 6-well low-attachment plates. 
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Assays were performed in triplicate (bars, s.d.). 24 and 48 hours later, cells were collected, 
resuspended in Accumax (Innovative Cell Technologies) to generate single cell suspensions, and 
mixed with 0.4% trypan blue (Cellgro). Trypan blue staining was scored using a hemacytometer. 
Spheroid formation Assay. PDA cells were trypsinized, counted, and suspended in 6-
well, low-attachment plates using 1:1 DMEM/F-12 supplemented with 1×B27, 4.0 μg/ml 
heparin, 20 ng/ml EGF, 20 ng/ml FGF and 1% methylcellulose. 2,000-5,000 cells of each sample 
were plated in triplicate in 2.0 ml final volume. The spheroids in each well were quantitated by 
phase contrast microscopy. For RNA isolation spheroids were harvested after 7-10 days by 
centrifugation at 200 X g for one minute. 
Flow cytometry. For side population analysis cells were trypsinized, washed with PBS, 
and resuspended in staining buffer (DMEM, 2% [v/v] FBS, 1.0 mM HEPES-KOH, pH 7.0). 
Samples were incubated for 30 min at 37°C with or without 50 μg/ml of verapamil (Sigma-
Aldrich), mixed with Hoechst 33342 (Sigma-Aldrich) to a final concentration of 5.0 μg/ml and 
incubated for 90 min at 37°C with intermittent mixing. The cells were washed twice with PBS, 
resuspended in sorting buffer (1XPBS, 5.0mM EDTA, 1% [w/v] BSA, 25mM HEPES-KOH, pH 
7.0), and maintained at 4°C in the dark. Analysis was performed using a FACSAria III cell sorter 
(BD Biosciences) and both Hoechst Red and Hoechst Blue were measured. 
Immunofluorescent staining and quantitation. Cells were treated with CLβL or 
DMSO for 3 hours before fixation. Cells were fixed and stained as described (79) at 48 hours 
post-transfection using rabbit anti-SOX9 (1:1,000, EMD Millipore), mouse anti-GLI1 (1:100, 
Cell Signaling), anti-Myc (9E10, 2.5 µg/ml, BD Biosciences), and/or anti-β-catenin (0.17 µg/ml, 
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BD Biosciences). Secondary antibodies were cross-absorbed Alexa Fluor 647 goat anti-rabbit 
IgG and Alexa Fluor 555 goat anti-mouse IgG (Life Technologies). Nuclei were counterstained 
in DAPI prior to mounting of coverslips using ProLong Antifade (Life Technologies).  
Digital images were captured and pseudocolored using a Zeiss LSM 510 laser scanning 
confocal on an upright Zeiss AxioImager and Zeiss LSM software (Carl Zeiss). Images were 
exported as tiff files and Corel software was used to make minor, identical adjustments to the 
experimental and control panels in parallel. β-catenin was quantitated using Image J. 
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FIG. 1. SOX9 stabilizes GLI1 in the rat RK3E epithelial model and in human PDA cells. 
(A) Rapid induction of SOX9 by GLI1. RK3E-derived, tet-on (TO) GLI1 cells were induced 
with tet or with vehicle control, and gene expression was analyzed by qRT-PCR (N=4; column, 
mean; bars, s.d.). (B) Role of Sox9 for GLI1-mediated in vitro transformation. Upper panel: 
Sox9 shRNA constructs were transfected into RK3E cells. Sox9 mRNA was analyzed by qRT-
PCR following drug selection. Lower panel: GLI1-mediated in vitro transformation was assayed 
in RK3E cells by counting morphologically-transformed foci. Dishes are representative of three 
independent experiments. Background was determined using empty vector and was <1 focus per 
dish (not shown). (C) Dependence of GLI1 protein expression on Sox9. GLI1-transformed RK3E 
cells were transfected with the indicated siRNA. Protein expression was analyzed at 48h post-
transfection (asterisk, nonspecific). (D) Proteasome inhibition restores GLI1 in SOX9-deficient 
cells. GLI1-transformed RK3E cells were transfected with Sox9 siRNA. Cells were treated with 
vehicle (DMSO, 1h) or with proteasome inhibitor (CLβL) for the indicated interval. Cell extracts 
for protein analysis were prepared at 48h post-transfection. (E) SOX9 and GLI1 were analyzed in 
human PDA cell lines. mRNA levels were normalized to immortalized pancreatic ductal 
epithelial cells (HPDE). (F) Dependence of GLI1 protein expression on SOX9. Panc-1 cells were 
treated with control or SOX9 siRNA, and endogenous GLI1 protein levels were determined by 
IP-immunoblot analysis. (G) Dependence of GLI1 mRNA expression on SOX9. Panc-1 cells 
were treated with siRNA and SOX9 and GLI1 mRNA levels were assessed at the indicated post-
transfection interval. (H) SOX9 can regulate GLI1 protein levels independently of the mRNA. 
To circumvent the GLI1 autoregulation of its own transcription, a GLI1 retroviral vector was 
transduced into Panc-1 cells such that the preponderance of GLI1 mRNA was transcribed under 
control of the LTR promoter (Panc-1-GLI1) vs. the endogenous GLI1 promoter (Panc-1-pBabe). 
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The impact of SOX9 deficiency on GLI1 protein level in Panc-1-GLI1 cells was then analyzed 
by immunoblot (left panel). Following normalization to β-actin, the GLI1 protein level in control 
and SOX9-deficient cells was quantitated for three independent assays (middle panel). Similarly, 
mRNA levels were analyzed by qRT-PCR (right panel). (I) SOX9 regulates the association of 
GLI1 and β-TrCP. Left panel, endogenous GLI1/β-TrCP interaction in Panc-1 cells was 
determined by Co-IP-immunoblot analysis. Right panel, Panc-1 cells were treated with control 
siRNA, SOX9 siRNA, and/or CLβL as indicated; endogenous GLI1/β-TrCP interaction was 
evaluated by Co-IP-immunoblot analysis. (J) Role of β-TrCP and the proteasome in the 
regulation of GLI1 by SOX9. Panc-1 cells were treated as indicated and endogenous protein 
levels were determined by IP-immunoblot analysis. *, P0.05; **, P0.01; ***, P0.001; ns, not 
significant. 
FIG. 2. Sox9 and GLI1 interact with distinct regions of β-TrCP in a mutually incompatible 
fashion. Enforced expression studies were performed in HEK293 cells (A-H). (A) Co-IP 
analysis of GLI1and β-TrCP. Immunoprecipitated proteins were analyzed by immunoblot 
analysis. Lysate lanes represent 5% of the input extract. (B) Co-IP analysis of Sox9 and β-TrCP. 
(C) Co-IP analysis of GLI1 and SOX9. (D) Role of the proteasome in the regulation of GLI1 by 
β-TrCP. Cells were transfected with indicated vectors and treated with proteasome inhibitor 
(MG132) or vehicle (DMSO) for 6 hours prior to preparation of cell extracts for immunoblot 
analysis. (E) Stabilization of GLI1 by SOX9. Cells transfected with indicated vectors were 
treated with cycloheximide (CHX) prior to preparation of cell extracts for immunoblot analysis. 
(F) Co-IP analysis of Myc-β-TrCP with wild-type or truncated HA-Sox9 constructs. Precipitated 
proteins were detected by immunoblot. (G) SOX9 and GLI1 interact with distinct regions of β-
TrCP. Co-IP analysis of GLI1 or SOX9 with wild-type or truncated Myc-β-TrCP constructs. 
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Precipitated proteins were detected by immunoblot analysis (asterisk, nonspecific species). (H) 
The Sox9 C-terminal region is required for disruption of the GLI1 interaction with β-TrCP. Cells 
stably transduced with a GLI1 retroviral vector were transfected with the indicated expression 
vectors. Myc-β-TrCP plasmid amount were doubled when co-transfected with wild type Sox9 
(middle lane) to achieve similar Myc-β-TrCP protein levels. Cells were treated with MG132 for 
3 hours before they were harvested for Co-IP analysis. Similar results were obtained in an 
independent experiment. 
FIG. 3. SOX9 disrupts the β-TrCP/SKP1 association and destabilizes β-TrCP in PDA cells. 
(A) Relative levels of SOX9, β-TrCP, and SKP1 protein levels in HEK293T and Panc-1 cells. 
(B) Effect of exogenous SOX9 on the association of SKP1 and β-TrCP. 293T cells were 
transfected with the indicated expression vectors. Myc-β-TrCP plasmid amounts were doubled 
when co-transfected with wild type SOX9 to achieve similar Myc-β-TrCP protein expression. 
Cells were treated with MG132 for 3 hours before they were harvested for Co-IP analysis. The 
results of three independent experiments are indicated (bars, s.d.). (C) Effect of endogenous 
SOX9 on the association of SKP1 and β-TrCP. Panc-1 cells were transfected with the indicated 
expression vectors and siRNAs. Cells were treated with MG132 for 3 hours before harvested for 
Co-IP analysis. The results of three independent experiments are indicated. (D) Effect of SOX9 
on expression of β-TrCP. Panc-1 cells were treated with the indicated siRNA and then analyzed 
by immunoblot analysis (left panel) or by qRT-PCR (right panel). (E-F) Analyses of protein 
stability. Panc-1 cells were transfected with the indicated siRNA and then treated with 
cycloheximide (CHX) for the indicated interval prior to preparation of extracts for immunoblot 
analysis at 48h post-transfection. The scanned images were quantitated using NIH Image J and 
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normalized to β-actin. Rate constants and protein half-lives were determined using the first order 
rate law. 
FIG. 4. SOX9 tethers β-TrCP within the nuclei of PDA cells and protects nuclear GLI1 
from degradation. (A) Panc-1 cells were transfected with exogenous, Myc epitope-tagged, β-
TrCP together with indicated siRNA. (B) Panc-1 cells were infected with lentiviral GLI1 vector 
and then with the indicated siRNA. Cells were treated with CLβL or vehicle (DMSO) for the 
final 3 hours prior to fixation. Cells were fixed and processed for indirect immunofluorescence 
analysis at 48 hours posttransfection. Scale bar, 10µ. 
FIG. 5. In a GLI1-dependent fashion, β-TrCP suppression rescues malignant properties in 
SOX9-deficient PDA cells. (A) Panc-1 cell growth in 2D culture was analyzed following 
transfection of SOX9 or control siRNAs (upper panel). Alternatively, Panc-1-TO shRNA cells 
were treated with Dox (lower panel). (B) Analysis of anchorage-independent growth regulation 
by SOX9. Soft agar assay was performed using PDA cells (N=3; bars, s.d.). Scalebar, 400µ. (C) 
Analysis of anoikis regulation by SOX9. Anoikis assay was performed using Panc-1 cells. The 
number of surviving cells (left Y-axis) and the percentages of viable cells (right Y-axis) are 
indicated for each timepoint (N=3; bars, s.d.). (D-E) Role of β-TrCP in the phenotype of SOX9-
deficient cells. Following siRNA transfection, anoikis assays were performed in Panc-1 cells. 
FIG. 6. β-TrCP suppression rescues CSC properties in SOX9-deficient PDA cells. (A) Panc-
1 cells form spheroids when suspended in stem cell growth medium (left panel; scale bar, 200µ). 
Side population (SP) Panc-1 cells were identified by verapamil-sensitive dye efflux (right panel). 
(B) Expression profiling of spheroid cells and SP cells. (C) Roles of SOX9 and GLI1 in the 
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regulation of CSC markers. The expression of putative CSC markers was determined in Panc-1 
cells treated with the indicated siRNA. (D) Spheroid formation assay of Panc-1-TO shRNA cells 
(N=3; bars, s.d.). (E) SP analysis of PDA cells. Cells were treated with Dox or vehicle for five 
days and then stained with Hoechst 33342. The results of three independent experiments are 
presented (right panel). (F) Role of β-TrCP in the growth of tumor spheroids. siβ-TrCP had little 
effect on its own in parental Panc-1 cells (left panel). The effect of siβ-TrCP was then analyzed 
in the context of SOX9-deficient PDA cells (middle and right panels). 
FIG. 7. SOX9 stabilizes β-catenin in Panc-1 cells. (A) Regulation of diverse SCFβ-TrCP 
substrates by SOX9. Panc-1 cells were treated with the indicated siRNA and protein expression 
was analyzed by immunoblot. (B) Regulation of β-catenin activity by SOX9 and β-TrCP. Panc-1 
cells were transfected with the indicated siRNA and TCF4-dependent transcriptional activity was 
determined by luciferase reporter assay. (C) Regulation of β-catenin protein expression by 
SOX9. Panc-1 cells were treated with the indicated siRNA and then analyzed by indirect 
immunofluorescence analysis. Scale bar, 10µ. Quantitation of β-catenin is shown in Fig. S3D in 
the supplemental material. (D) A model depicting the effects of SOX9 on β-TrCP in PDA cells, 
including nuclear tethering (1), disruption of its association with Gli1 (2), promotion of UPS-
mediated turnover (3) and disruption of its association with SKP1 (4).  
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Figure 1. SOX9 stabilizes GLI1 in the rat RK3E epithelial model and in human PDA cells.  
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Figure 2. Sox9 and GLI1 interact with distinct regions of β-TrCP in a mutually incompatible 
fashion. 
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Figure 3. SOX9 disrupts the β-TrCP/SKP1 association and destabilizes β-TrCP in PDA cells. 
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Figure 4. SOX9 tethers β-TrCP within the nuclei of PDA cells and protects nuclear GLI1 from 
degradation. 
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Figure 5. In a GLI1-dependent fashion, β-TrCP suppression rescues malignant properties in 
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SOX9-deficient PDA cells. 
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Figure 6. β-TrCP suppression rescues CSC properties in SOX9-deficient PDA cells. 
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Figure 7. SOX9 stabilizes β-catenin in Panc-1 cells. 
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Table S1: Microarray expression analyses of Sox9 and β-TRCP in primary pancreatic cancer.  
Data Source Sox9 (Cancer vs Normal) β-TrCP (Cancer vs Normal) Stratifin (Cancer vs Normal) 
(Reference) Probe P value Fold Probe P value Fold Probe P value Fold 
Badea et al., 2008 202936_s_at 0.0020 1.87 204901_at 6.5E-07 -1.22 33323_r_at 1.8E-11 6.66 
    222374_at 1.2E-05 -1.21    
Iacobuzio-Donahue 
et al., 2003 
IMAGE:75318
4 
0.19 1.35 IMAGE:4616
28 
0.061 -1.25 IMAGE:2027
515 
1.1E-06 20.2 
Pei et al., 2009 202936_s_at 0.014 1.79 222374_at 0.034 -1.12 33323_r_at 2.3E-08 19.0 
Segara et al., 2005 202936_s_at 0.50 1.00 204901_at 0.026 -1.23 33323_r_at 3.3E-06 9.74 
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Table S2: Oligonucleotide sequences for siRNA and shRNA 
  siRNA/shRNA Target sequence (5’-3’) Source 
Ctrl Firefly luciferase  
siGENOME Non-Targeting siRNA #2, Thermo 
Scientific (Dharmacon), D-001210-02 
Ctrl2 GATGGGGAGTTTCCAGGTTCA Thermo Scientific (Dharmacon), custom 
BTRC #1 GCGACATAGTTTACAGAGA 
siGENOME siRNA, Thermo Scientific (Dharmacon),  
D-044048-04 
BTRC #2 Smart Pool 
siGENOME SMARTpool siRNA, Thermo Scientific 
(Dharmacon), M-003463-01 
GLI1 Smart Pool 
ON-TARGETplus SMARTpool siRNA, Thermo 
Scientific (Dharmacon), L-003896-00 
SOX9 GAACGCACATCAAGACGGA 
siGENOME siRNA, Thermo Scientific (Dharmacon),  
D-059108-01 
TO shCtrl Scrambled sequence 
Non-silencing TRIPZ lentiviral inducible shRNAmir 
control (Open Biosystems, RHS4743) 
TO shSOX9 ACCCGCTCACAGTACGACT 
The hairpin sequence from pGIPZ-shRNAmir (Open 
Biosystems, V3LHS_396212) was inserted into pTRIPZ.  
Rat Sox9 #1 AGAACAAGCCACACGTCAA Thermo Scientific (Dharmacon), custom 
Rat Sox9 #2 CTGCTGAACGAGAGCGAGA Thermo Scientific (Dharmacon), custom 
Rat shCtrl Scrambled sequence 
Hairpin sequence was inserted into the pSilencer 2.1-U6 
neo vector (Life Technologies, AM5764). 
Rat Sox9 sh1 GAGAGCGAGGAAGATAAAT 
Hairpin sequence was inserted into the pSilencer 2.1-U6 
neo vector (Life Technologies, AM5764).  
Rat Sox9 sh2 GGAAGATAAATTCCCAGTGTG 
Hairpin sequence was inserted into the pSilencer 2.1-U6 
neo vector (Life Technologies, AM5764). 
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Table S3: Oligonucleotides for real-time quantitative PCR analysis 
 
Gene Sense (5’-3’) Antisense (5’-3’) 
BTRC CTGCAGGGACACTCTGTCTAC GAAGTCCCAGATGAGGATTGTG 
CTNNB1 CCCACTGGCCTCTGATAAAGG ACGCAAAGGTGCATGATTTG 
c-Myc CGACGAGACCTTCATCAAAA TGCTGTCGTTGAGAGGGTAG 
CD24 AAACAACAACTGGAACTTCAAGTAACT GGTGGTGGCATTAGTTGGATTT 
CD44 TGCCGCTTTGCAGGTGTAT GGCCTCCGTCCGAGAGA 
CD133 TGGATGCAGAACTTGACAACGT ATACCTGCTACGACAGTCGTGGT 
CXCR4 GCCTTATCCTGCCTGGTATTGTC GCGAAGAAAGCCAGGATGAGGAT 
ESA GCAGCTCAGGAAGAATGTG CAGCCAGCTTTGAGCAAATGAC 
GAPDH TCACCACCATGGAGAAGGC GCTAAGCAGTTGGTGGTGCA 
GLI1 ACAGAAGGACTGTCTGGCCCGC GGTGAGATGGACAGTGCCCGC 
GLI2 GCCCTTCCTGAAAAGAAGAC CATTGGAGAAACAGGATTGG 
KLF4 AGAGTTCCCATCTCAAGGCA GTCAGTTCATCTGAGCGGG 
OCT4 GAAGCAGAAGAGGATCACCTTG TTCTTAAGGCTGAGCTGCAAG 
SNAI1 TCTGAGTGGGTCTGGAGGTG CTCTAGGCCCTGGCTGCTAC 
SOX2 AACCCCAAGATGCACAACTC GCTTAGCCTCGTCGATGAAC 
SOX9 CCCTTCGTGGAGGAGGCGGA CCGGAGGAGGAGTGTGGCGA 
Rat Bcl2 CGGAGGCTGGGATGCCTTTGT TGTGGCCCAGGTATGCACCCA 
Rat Gapdh TCACCACCATGGAGAAGGC GCTAAGCAGTTGGTGGTGCA 
Rat Ptch1 CCAGGCTGCTGTGGTGGTGG CCGGCTGACACAGGGGCTTG 
Rat Sox9 GCGAGGAAGATAAATTCCCAGTG GTGGTCTTTCTTGTGCTGCACGC 
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Figure S1. Sox9 is activated by GLI1 in the rat RK3E epithelial model and is required for GLI1-
mediated malignant transformation. (A) RK3E-derived, tet-on (TO) GLI1 cells were induced 
with tet and cell extracts were analyzed by immunoblot. (B) Schematic of the RnSox9 locus. 
Potential GLI-binding sites (arrows) each contain one mismatch to the consensus 
GACCACCCA. ChIP-analyzed fragments (A1-A10) and fragments inserted into a luciferase 
reporter  (pGL3-D, pGL3-E) are indicated below. Primer sequences are listed in Table S3 in the 
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supplemental material. (C) ChIP analysis of Sox9 gene in RK3E cells. Chromatin was prepared 
from RK3E cells stably-transduced with HA-GLI1 retrovirus (GLI1) or empty vector (Vector).  
Ptch1 served as a positive control. (D) Regulation of luciferase reporter activity by GLI1 relative 
to empty vector in HEK293 cells. (E) In vitro transformation by GLI1 or ERBB2 was assessed in 
RK3E cells. ***, P<0.001; ns, not significant. 
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Figure S2. SOX9 interrupts β-TrCP-mediated GLI1 degradation. (A) SOX9 suppression 
mediated by transient siRNA or stable, conditional vector (TO-shSOX9) in Panc-1 cells. These 
two strategies target distinct sequences within SOX9. (B) Analysis of GLI1 protein in Panc-1 
cells by immunoblot or  IP-immunoblot analysis. Left panel: RK3E cells expressing exogenous 
GLI1 served as a control. By immunoblot a background species (asterisk) is detected in Panc-1 
cells. In contrast, IP-immunoblot detects endogenous GLI1 (right panel). (C) SOX9 stabilizes the 
GLI1 protein in PDA cells. Left panel: Cells were treated with dox or vehicle control for 5 days 
and then analyzed by IP-immunoblot analysis.  Right panel: Cells were treated as indicated and 
then analyzed by IP-immunoblot analysis. (D) Despite interacting with b-TrCP, SOX9 
expression is not suppressed by the exogenous F-box protein. Instead, SOX9 suppresses b-TrCP 
expression in a proteasome-dependent fashion. Cells were transfected with the indicated vectors 
and treated with proteasome inhibitor (MG132) or vehicle (DMSO) prior to immunoblot 
analysis. The Myc-β-TrCP plasmid quantity in the transfection mixture was three-fold higher in 
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the indicated lanes (+++). (E) SOX9 selectively interacts with b-TrCP as compared to another F-
box protein, FBXW7. Co-IP analysis of HA-SOX9 with Myc-tagged F box proteins in HEK293 
cells after transient expression. Lysate lanes represent 5% of the input extract. 
  
229 
 
Figure S3. SOX9 is critical for cancer cell malignant properties, cancer stem cell properties and 
expression of β-catenin in PDA cells. (A) Anoikis assays were performed in AsPC-1 using two 
β-TrCP siRNAs. (B) PDA cells were treated with dox or vehicle for 5 days and then analyzed for 
Side population (SP) cells. (C) Roles of SOX9 and b-TrCP in tumor spheroid growth. (D) 
Regulation of b-catenin by SOX9. Panc-1 cells were treated with the indicated siRNA and the 
expression of β-cateninin was quantitated in the nucleus and cytoplasm. For each sample, 
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confocal images were captured for ten randomly selected fields and immunofluorescence was 
quantitated using Image J. 
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Figure S4. Gene expression profile analysis of human PDA. Human pancreatic carcinoma 
samples and normal pancreatic tissue were analyzed for expression of SOX9 and BTRC. 
Published studies that showed upregulation of established PDA markers such as SFN (14-3-3s) 
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were selected for analysis of SOX9 and BTRC. Box plots indicate median and inter-quartile 
range (box), 10th and 90th percentiles (whiskers), and minimum and maximum values (asterisk). 
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Abstract  
 In breast cancer cells, Krüppel-like factor 4 (KLF4) is recognized to suppresses apoptosis 
and is upregulated in the cancer stem cell population. Still, the role of KLF4 in human breast 
cancer remains unclear in many respects. We found endogenous KLF4 to potently suppress 
spontaneous metastasis of breast cancer cells in a mouse model system. The antimetastatic effect 
of KLF4 in our studies was not explained by a difference in primary tumor growth, yet we 
observed increased circulating tumor cells in mice with KLF4 knockdown tumors, suggesting 
KLF4 acts to inhibit metastasis at an early stage. Suppression of KLF4 was associated with 
increased expression of discoidin domain receptor 1 (DDR1), a receptor tyrosine kinase that 
binds collagen and is implicated in cancer progression. In agreement with increased DDR1 
function, KLF4 knockdown cells exhibited greater adherence to collagen. The function of KLF4 
to suppress metastasis of breast cancer cells may then relate to DDR1 expression.   
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Introduction 
 Metastatic breast cancer remains an incurable disease for most patients, although survival 
is improving (1,2). Research into the molecular events that regulate breast cancer metastasis may 
help inform the development of new therapies or prognostic models (3). To form clinically 
relevant metastases, tumor cells must successfully progress through a cascade of events to escape 
the primary tumor, navigate the circulatory system, and then achieve survival and proliferation at 
a distant site (4). Failure at any point in the process may be sufficient to inhibit metastasis (5,6). 
Malignant cells that are successful in the early stages of metastasis, gaining access to the 
vasculature, can be detected as circulating tumor cells (CTCs), and are of prognostic significance 
in both early and late stage breast cancer (7). Meanwhile, the later steps of survival and 
proliferation in ectopic sites are increasingly viewed as limiting factors in cancer metastasis 
(4,5,8,9).  
 Kruppel-like factor 4 (KLF4) is a zinc finger transcription factor with numerous 
biological functions, regulating proliferation, differentiation, and apoptosis (10,11). KLF4 is also 
a crucial mediator of pluripotency (12-14). In cancer, KLF4 has context-dependent functions that 
may promote or suppress malignancy (15). Downregulation of KLF4 is associated with 
carcinomas of the colon (16-20), stomach (21-23), esophagus (24), liver (25), and pancreas (26). 
In contrast, increased expression of KLF4 has been associated with breast cancer (27), although 
this result was not reproduced by large scale RNA-sequencing of breast tumors (28).   
 KLF4 is reported to contribute to malignant properties in breast cancer cells through 
several mechanisms. Through miR-21 and miR-26, which suppress expression of RASA1 and 
236 
 
SPRED1, KLF4 enhances RAS/ERK signaling in MDA-MB-231 cells, thereby promoting 
resistance to anoikis (29). KLF4 also acts to maintain the population of cancer stem cells (CSCs) 
in breast cancer cell lines, and is upregulated in CSCs isolated from primary tumor cells of the 
murine MMTC-Neu and C3(1)TAg mouse models, as well as in patient-derived xenografts 
(30,31). Consistent with established anti-apoptotic roles, KLF4 also promotes resistance to 
HER2-targeted therapy through upregulation of anti-apoptotic factors MCL1 and BCL-XL (32). 
 Discoidin domain receptors (DDRs) 1 and 2 are receptor tyrosine kinases (RTKs) that 
interact through extracellular domains with collagen (33). Specimens of many human tumor 
types show dysregulated DDR expression (34), including breast cancer (35,36). DDRs have been 
shown to influence cancer-relevant processes including EMT, adhesion, motility, and invasion, 
and may also promote metastasis (34). DDRs are poorly understood in comparison to many other 
RTKs, and the mechanisms underlying the apparent dysregulation of DDRs in malignancy 
remain largely uncharacterized.  
 In the present study, we report that KLF4 suppresses spontaneous metastasis of breast 
cancer cells in a mouse model. This effect was consistent using both gain- and loss-of-function 
approaches, and was independent of primary tumor volume. Loss of KLF4 significantly 
enhanced the dissemination of cells from the primary tumor, as demonstrated by increased levels 
of CTCs. KLF4 knockdown cells were characterized by increased expression of DDR1, and had 
superior adhesion to collagen I. KLF4 may then possibly exert antimetastatic effects through 
suppression of DDR1. 
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Results 
 Suppression of KLF4 enhances spontaneous metastasis of breast cancer cells. The 
effects of KLF4 in models of breast cancer are variable. Overexpression of KLF4 can readily 
suppress cell proliferation of murine 4T1 cells, and similarly inhibits orthotopic tumor growth in 
BALB/c mice (37). In contrast, KLF4 gain-of-function using the KLF4-estrogen receptor (ER) 
fusion protein (38) enhances growth of Py2T tumors in mice receiving tamoxifen (39). We 
previously reported that depletion of KLF4 could impair tumor initiation of MDA-MB-231 cells 
in athymic nude mice, yet did not affect the growth kinetics of tumors that did successfully 
initiate (31).   
 In NOD/SCID/γ (NSG) mice, MDA-MB-231 cells are highly metastatic to the lungs and 
liver (40), and we asked whether suppression of KLF4 would affect spontaneous metastasis in 
this context. We found that stable suppression of KLF4 in MDA-MB-231 cells (Fig. 1A) did not 
affect orthotopic tumor initiation, as all mice developed primary tumors. Similarly, we did not 
observe a statistically significant difference in tumor growth between groups (Fig. 1B). To 
enumerate lung metastasis, we euthanized mice 32 days after injection, and counted the 
metastases present on fixed specimens. Suppression of KLF4 resulted in greatly increased 
spontaneous lung metastasis (Fig. 1C and D). In an independent experiment, we also addressed 
the function of KLF4 in metastasis to the liver. As expected, expression of KLF4 had little effect 
on primary tumor growth (Fig. 1E), yet we observed significantly greater liver metastases 
resultant from KLF4 knockdown.  
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 We additionally examined the role of KLF4 in spontaneous metastasis using M6 cells, a 
line derived from mouse mammary tumors of the C3(1)TAg transgenic model (41). The shRNA-
mediated suppression of KLF4 in M6 cells was incomplete (Fig. 2A). Still, the partial loss of 
KLF4 still favored enhanced metastasis to the lungs, without any significant effects on primary 
tumor volume (Fig. 2B-D). These data indicate endogenous KLF4 can function to suppress the 
spontaneous metastasis of breast cancer cells. 
 Overexpression of KLF4 suppresses spontaneous metastasis of breast cancer cells. 
To date, several reports have suggested that KLF4 overexpression can suppress spontaneous 
metastasis, including results in breast cancer cells (37,39), and in cell lines representing 
gastrointestinal malignancies (42-44). Metastasis suppressor proteins, in which metastasis is 
inhibited without meaningful effects on primary tumor growth, are also largely characterized 
based on the effects of ectopic expression (45). Although we have previously observed 
retroviral-mediated overexpression of KLF4 to suppress cell proliferation in culture (46), we 
wondered whether ectopic KLF4 would exert a similar effect in breast cancer cells in vivo. In 
NSG mice, the stable overexpression of KLF4 using a retroviral vector did not significantly alter 
tumor growth of MDA-MB-231 cells (Fig. 3A) or MDA-MB-435 cells (Fig. 3C). In agreement 
with role of endogenous KLF4 (Fig. 1 and 2), overexpression of KLF4 resulted in decreased 
liver metastasis of MDA-MB-231 cell (Fig. 3B), and decreased lung metastasis of MDA-MB-
435 cells (Fig. 3D).          
 KLF4 suppresses affects metastasis at an early stage. Our data suggest KLF4 is a 
suppressor of metastasis in breast cancer cells. While this effect was clearly independent of 
primary tumor growth, the specific metastatic process or processes affected by KLF4 remained 
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unclear. To help clarify the effect of KLF4 expression on the metastatic cascade, we sought to 
determine the effect of KLF4 on circulating tumor cells (CTCs). As in prior experiments, we 
observed no significant effect of endogenous KLF4 expression on orthotopic tumor growth (Fig. 
4A). 
 While CTCs are often distinguished from leukocytes based on expression of markers 
such as epithelial cell adhesion molecule (EpCAM) and other factors (47), we instead indentified 
CTCs based on fluorescence. This technique was facilitated by the high constitutive GFP 
expression of the MDA-MB-231 cells as conferred by the shRNA vector. At the time mice were 
euthanized, we detected approximately three-fold more CTCs as a result of KLF4 suppression 
(Fig. 4B). There were no overt metastases at this stage. 
 This assessment of CTCs indicated KLF4 acts at an early stage of metastasis to inhibit 
the dissemination of cells from the primary tumor. Previous reports have indicated endogenous 
KLF4 can promote motility and invasion of MDA-MB-231 cells (30,46). We attempted to verify 
this result using two distinct shRNAs, and as expected, KLF4 knockdown cells exhibited 
decreased migration and invasion (Figs. 4C and D).  
 KLF4 suppresses DDR1 expression and collagen interaction. In earlier work, we have 
identified a role of KLF4 (in submission) in the reprogramming of kinase expression as a 
response to MEK inhibition (48). These efforts had suggested KLF4 can negatively regulate 
expression of DDR1. In MDA-MB-231 cells, we found increased expression of DDR1 protein 
and mRNA resultant from suppression of endogenous KLF4 (Fig. 5A and B). Additionally, Ddr1 
expression was 7-fold higher increased in mammary tumors of C3(1)/TAg Klf4
+/-
 mice as 
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compared to Klf4 homozygous controls (Fig. 5C). We then performed chromatin 
immunoprecipitation (ChIP) to test whether KLF4 could interact with DDR1 regulatory 
elements. Analysis of putative KLF4 response elements upstream of the DDR1 coding sequence 
indicated enrichment of KLF4 at one of two sites tested (Fig. 5D). Enrichment at this site was 
abolished by suppression of KLF4 (Fig. 5E). DDR1 binds and is activated by possibly all 
collagen types, including collagen I (49). The altered DDR1 expression found in KLF4 
knockdown cells suggested that KLF4 might regulate collagen binding, which we determined 
through adhesion assays. Suppression of KLF4 resulted in significantly increased adhesion of 
MDA-MB-231 cells to collagen I (Fig. 5F). In contrast, KLF4 did not increase adhesion to a 
fibronectin substrate.  
Discussion  
 We have shown that KLF4 suppresses spontaneous metastasis of breast cancer cells in a 
mouse model, through mechanisms independent of primary tumor growth. Regulation of 
metastasis may occur at multiple levels in the metastatic cascade, and metastasis suppressor 
proteins have been shown to function at different steps of metastasis (50). To help distinguish the 
effects of KLF4 between early and later events in metastatic process, we assessed CTCs in mice 
with primary tumors of comparable size.  In some cases a change in CTCs can be discordant with 
the finding of metastatic cells; for example, overexpression of miR-200c/miR-141 in breast 
cancer cells results in enhanced lung colonization even though CTCs are decreased (51). In 
contrast, our data show agreement between CTC levels (Fig. 4) and spontaneous metastasis (Fig. 
1 and 2), associating experimental suppression of KLF4 with increased CTCs and greater 
metastasis to the lung and liver. While these results do not preclude an effect of KLF4 on later 
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events in metastasis, it seems likely that KLF4 in some manner restricts access of primary tumor 
cells to the vasculature.  
 Overexpression of KLF4 in breast cancer cells was previously reported to suppress 
orthotopic tumor growth (37), a result consistent with the well-documented antiproliferative 
function of KLF4 (52,53). In contrast, we did not observe inhibition of tumor growth in 
association with exogenous KLF4 (Fig. 3). This may reflect differences amongst cell lines, 
microenvironment effects of the host mouse strain, or may relate to the expression level of KLF4 
protein. It is possible that high expression of KLF4 in breast cancer cells may restrict the growth 
of primary mammary tumors, whereas a lesser amount of KLF4 could suppress metastasis 
without noticeably affecting orthotopic growth.         
 DDR expression is upregulated in many carcinomas, although it is not always clear 
whether this corresponds to increased receptor activation (34). In non-small cell lung cancer, 
high DDR1 activation was identified through phosphoproteomic methods (54), supported by 
reports of DDR1 upregulation (55), association with poor prognosis (56), and possible 
contribution to metastasis (57). In breast cancer, DDR1 expression may be increased (35), or in 
some cases decreased in association with DDR2 upregulation (36).  
 The mechanisms that may explain the role of DDRs in breast cancer and other 
malignancies remain poorly understood. Experimentally, both soluble and immobilized collagens 
are capable of activating DDRs (58), resulting in DDR autophosphorylation of tyrosine residues 
to create docking sites for proteins with SH2, SH3 and PTB domains (34). DDR signaling can 
result in activation of downstream pathways such as RAS/MAPK and NF-κB (59,60). We have 
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previously reported KLF4 suppression in MDA-MB-231 cells to result in decreased RAS/ERK 
activation (29), suggesting that the increased DDR1 levels in KLF4 knockdown cells (Fig. 5) 
may promote metastasis through alternative mechanisms.  
 In a mouse model of metastasis to bone, suppression of DDR1 inhibited the homing and 
colonization of lung cancer cells (57). Similarly, suppression of DDR2 resulted in decreased 
metastasis of melanoma cells to the liver (61). Endogenous DDR2 is also reported to promote 
spontaneous metastasis of breast cancer cells (62). In agreement, our data associate increased 
expression of DDR1 with spontaneous metastasis of breast cancer cells. It seems likely that the 
increase in CTCs observed as a result of KLF4 suppression (Fig. 4B), in association with 
upregulated DDR1 (Fig. 5), is related to an effect on invasion in vivo that is not recapitulated by 
transwell assay (Fig. 4D). We intend to characterize the functions of KLF4 in breast cancer cells 
within a 3D collagen matrix. In comparison to 2D assessments of motility and invasion, a 3D 
matrix may offer a better recapitulation of the physiologic role of DDR1.   
Materials and methods 
Cell lines and cell culture. MDA-MB-231 cells, obtained from Katri S. Selander, and M6 cells, 
provided by Jeffrey E. Green (National Cancer Institute), were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) by volume. MDA-MB-435 
cells were provided by Danny R. Welch (University of Kansas) and cultured in media containing 
equal parts DMEM and Ham’s F12, with 5% FBS and 1% non-essential amino acids solution.  
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Viral transduction. Stable suppression of KLF4 was achieved using the following pGIPZ 
shRNA vectors (GE Dharmacon): In MDA-MB-231 cells, V2LHS_28277 as shKLF4(1) and 
V3LHS_410934 as shKLF4(2); in M6 cells, V3LMM_459916 as shKLF4(1) and 
V3LMM_524009 as shKLF4(2). The pBabePuro KLF4 expression vector was previously 
described (46). Transductions were performed as previously described (46). MDA-MB-231 and 
M6 lines were selected and maintained using 1 μg/mL puromycin. MDA-MB-435 lines were 
selected using 3 μg/mL puromycin and maintained in 1 μg/mL puromycin. 
C3(1)TAg mammary tumors. C3(1)/TAg Klf4
+/+
 and C3(1)/TAg Klf4
+/-
 mice, and the 
harvesting of mammary tumors for analysis by qRT-PCR, were previously described (31). 
Immunoblot and PCR, and ChIP. Protein detection by immunoblot was performed as 
previously described (46). Primary antibodies were used against KLF4 (H180, Santa Cruz), 
DDR1 (D1G6, Cell Signaling), and β-actin (C4, Santa Cruz). RNA isolation, reverse 
transcription, and quantitative real-time PCR using SYBR Green (Life Technologies) were 
performed as previously described (46). Primers used were human DDR1, 5’-
CACCAAGAGCAGCAGCAGTA-3’ and 5’-GGACTTGAAGGAATGCCAAG-3’; human 
B2M, 5’-TGCTCGCGCTACTCTCTCTTT-3’ and 5’-TCTGCTGGATGACGTGAGTAAAC-3’; 
mouse Klf4, 5’-GGAAAAGAACAGCCACCCAC-3’ and 5’-GTGGTAAGGTTTCTCGCCTGT-
3’; mouse Ddr1, 5’-TGGATCCCTCTGGTCTATGG-3’ and 5’-TCAGACCTGGATCCCCAA-
3’; mouse Rplp0, 5’-GGACCCGAGAAGACCTCCTT-3’ and 5’- 
GCACATCACTCAGAATTTCAATGG-3’. ChIP to assess KLF4 binding sites was performed 
as previously described (29). Putative KLF4 binding sites to DDR1 and primers used were ChIP 
site 1 (-169/+75) (functional): 5’-CTCCTAGATTCTCCCCCTCT-3’ and 5’-
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AATGTGACCATGGCAACCAAGT-3’; DDR1 ChIP site 2 (-959/-810) (non-functional): 5’-
AACTCTCCCTCTCAGACGCA-3’ and 5’-ATGATCCCAAAGCCAAAGGT-3’. 
Transwell migration and invasion. Migration and invasion assays were performed using a 
transwell kit as described previously (29). Initial seeding was 1x10
4
 cells per well. 
Statistics. Tumor growth rates were compared using repeated measures ANOVA with Dunnett’s 
Multiple Comparison test. Other data was compared using ANOVA, with Dunnett posttest to 
compare against the control condition. Statistical calculations were performed using GraphPad 
Prism version 5.01. Statistical significance is noted as *, p<0.05;**, p<0.01; ***, p<0.001; NS, 
non-significant.  
Animal models and metastasis. All animal procedures and studies were performed under 
approval of the West Virginia University Animal Care and Use Committee. NOD.Cg-Prkdc
scid
 
IL2rg
tm1wjl
/SzJ (NSG) mice were purchased (JAX) or locally bred. Females were used for 
experiments at 6-10 weeks of age, and experimental groups were age-matched.  For injection, 
cells were cultured to >80% confluence and dissociated by trypsin. Each injection consisted of 2 
x 10
6
 cells suspended in 100μL serum-free DMEM. Injections were performed into the left 
fourth mammary fat pad. Tumor volume was assessed at least twice per week by calipers, using 
the formula π/6 * length * width2. Mice were euthanized by CO2 asphyxiation. To quantify 
metastasis, lung and liver specimens were immersed in Bouin’s fixative for at least 24 hours, 
dissected into component lobes, and examined under a dissecting microscope (63).   
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CTC analysis. Blood for CTC analysis was drawn by cardiac puncture, using a 25 gauge needle 
and 3mL syringe prewashed with 500mM EDTA, performed immediately following euthanasia. 
The blood was then added to an EDTA venous collection tube (BD). RBC lysis by ammonium 
chloride, and resuspension of the remaining cellular fraction, were performed as previously 
described (31). Specimens were analyzed using a BD LSRFortessa, with CTC/mL calculated as 
the number of GFP+ cells divided by the blood specimen volume. The efficacy of this method 
was first verified using blood drawn from tumor-free mice and inoculated with known quantities 
of GFP-expressing tumor cells.     
Adhesion assays. In a 96 well low-attachment plate, wells were coated with 5μg/mL collagen I 
(BD) or 10μg/mL fibronectin-like polymer (Sigma), then blocked with 1% culture-suitable BSA 
in Hank’s balanced salt solution. Non-enzymatic Cell Dissociation Solution (Life Technologies) 
was used to harvest cultured cells, which were added in the amount of 5x10
4
 cells per well in 
100μL complete DMEM. Cells were allowed to adhere 30 minutes at 37 degrees Celsius. To 
remove non-adherent cells, wells were washed 4x with phosphate-buffered saline (PBS). 
Remaining cells were quantified by adding 100μL complete DMEM and using the ATPlite kit 
(PerkinElmer) according to manufacturer protocol. To determine the fraction of adherent cells, 
this result was divided by the signal obtained from 5x10
4
 cells per well adherent in a standard 
96-well cell culture plate. 
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FIG. 1.  Suppression of KLF4 enhances spontaneous metastasis of MDA-MB-231 cells to 
the lungs and liver. (A) Immunoblot of KLF4 levels in MDA-MB-231 cells stably expressing 
shRNA targeting KLF4 or scrambled control. (B-D) Effect of KLF4 expression on spontaneous 
lung metastasis. (B) Volume of orthotopic tumors in NSG mice (error bars represent SEM). (C) 
Intact lung specimens, after fixation in Bouin’s solution (upper panels), with magnified view of 
metastatic foci (lower panels). (D) Quantification of lung surface metastases. Each point 
represents the total lung surface metastases from an individual mouse, obtained from the sum of 
metastases present on each component lobe of the lungs (bars, SEM). (E-G) Effect of KLF4 
expression on spontaneous liver metastasis. (E) Volume of orthotopic MDA-MB-231 tumors in 
NSG mice (error bars, SEM). (F) Intact liver specimens, after fixation in Bouin’s solution. (G) 
Quantification of liver surface metastases. Each point represents the total liver surface metastases 
from an individual mouse, obtained from the sum of metastases present on each component lobe 
of the liver (bars, SEM). 
FIG. 2. Suppression of KLF4 enhances spontaneous metastasis of M6 cells to the lungs. (A) 
Immunoblot of KLF4 levels in M6 cells stably expressing shRNA targeting KLF4 or scrambled 
control. (B-D) Effect of KLF4 expression on spontaneous lung metastasis. (B) Volume of 
orthotopic tumors in NSG mice (bars represent SEM). (C) Intact lung specimens, after fixation in 
Bouin’s solution. (D) Quantification of lung surface metastases (bars, SEM). 
FIG. 3. Overexpression of KLF4 suppresses spontaneous metastasis of MDA-MB-231 and 
MDA-MB-435 cells. (A) Immunoblot of KLF4 protein in MDA-MB-231 cells stably expressing 
exogenous KLF4 or vector control. (B) Volume of orthotopic tumors in NSG mice (bars, SEM). 
(C) Quantification of liver surface metastases (bars, SEM). (D) Immunoblot of KLF4 levels in 
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MDA-MB-435 cells with stably expressing exogenous KLF4 or vector control. (E) Volume of 
orthotopic tumors in NSG mice (bars, SEM). (F) Quantification of lung surface metastases (error 
bars, SEM). 
FIG. 4. Effect of KLF4 expression on CTC levels, migration, and invasion of MDA-MB-231 
cells. Cell lines are from Fig. 1A. (A) Volume of orthotopic tumors in NSG mice (bars, SEM). 
(B) Concentration of circulating tumor cells expressed as CTCs per mL of blood (bars, SEM). 
(C-D) Cell migration (C) and invasion (D) as determined by a Boyden chamber transwell assay 
(bars, SD).  
FIG. 5. KLF4 suppresses DDR1 expression. (A) Immunoblot of indicated proteins in MDA-
MB-231 cells stably expressing shRNA targeting KLF4 or scrambled control. ERK2 is used as a 
loading control. (B) Expression of DDR1 mRNA in MDA-MB-231 cells by qRT-PCR (bars, 
SEM). Reactions were normalized to B2M. (C) Expression of Ddr1 and Klf4 mRNA by qRT-
PCR in mammary tumors from C3(1)/TAg Klf4
+/+
 and C3(1)/TAg Klf4
+/-
 mice (bars, SEM). 
Reactions were normalized to Rplp0. (D,E) ChIP analysis of a putative KLF4 binding site in 
MDA-MB-231 cells (bars, SEM). (F) Adhesion to low-attachment plates coated with indicated 
substrate (bars, SEM). 
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Figure 1.  Suppression of KLF4 enhances spontaneous metastasis of MDA-MB-231 cells to the 
lungs and liver.   
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Figure 2. Suppression of KLF4 enhances spontaneous metastasis of M6 cells to the lungs.  
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Figure 3. Overexpression of KLF4 suppresses spontaneous metastasis of MDA-MB-231 and 
MDA-MB-435 cells.   
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Figure 4. Effect of KLF4 expression on CTC levels, migration, and invasion of MDA-MB-231 
cells. 
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Figure 5. KLF4 suppresses DDR1 expression.  
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CHAPTER 4 
Summary Discussion 
 This dissertation addresses the function of the zinc finger transcription factors GLI1 and 
KLF4 in cancer. GLI1 is a potent transcriptional activator and effector protein of the Hedgehog 
signaling pathway, while KLF4 has similarly widespread functions in normal cells and in 
disease. GLI1 is regulated by degradation through the ubiquitin-proteasome system, and we 
provide evidence of a feedback mechanism determining GLI1 protein stability. While KLF4 can 
promote malignant properties in some contexts, we determined that KLF4 effectively suppresses 
metastasis of breast cancer cells.  
SOX9 inhibits β-TrCP-mediated degradation of GLI1 
 The transcription factors SOX9 and GLI1 are implicated in the development of pancreatic 
ductal adenocarcinoma (PDA), and this dissertation describes a mechanistic function of SOX9 
downstream of GLI1 in PDA cells. GLI1 directly promotes transcription of SOX9, and in a 
positive feedback relationship, SOX9 protein maintains the stability of GLI1. SOX9 interacted 
with the F-box domain of β-TrCP, disrupting the association of β-TrCP with SKP1 and inhibiting 
the function of the SCF
β-TrCP
 E3 ubiquitin ligase. Additionally, SOX9 promoted nuclear 
localization and destabilization of β-TrCP. In PDA cells, the loss of GLI1 protein and malignant 
properties in SOX9-deficient cells could be restored through suppression of β-TrCP. SOX9 was 
similarly important for cancer stem cell properties and the PDA cell side population. In addition 
to GLI1, other SCF
β-TrCP
 substrates such as β-catenin exhibit regulation by SOX9. This work 
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demonstrates the role of GLI1-SOX9 feedback in stabilizing GLI1 protein, and shows that SOX9 
can antagonize β-TrCP-mediated protein degradation.   
SOX9 
 Our results implicate SOX9 expression as critical for GLI1 protein stability in pancreatic 
cancer cells. SOX9 is a transcription factor with important roles in developmental processes 
including sex determination and chondrogenesis, as well as cell differentiation in both embryonic 
and adult contexts (1-4). Expression of SOX9 contributes to development of numerous organs, 
involving all vertebrate germ layers (5).   
 The first of the SOX genes to be studied was sex-determining region Y (SRY), also 
known as testis determining factor (TDF) (6,7). The SRY gene is found on the Y chromosome, 
and the gene product, commonly known as testis determining factor (TDF), is responsible for 
determining the male sex in almost all extant mammalian species. SRY contains a high mobility 
group (HMG) box domain. The HMG-box domain is found in some transcription factors, 
including SRY, where it functions to bind DNA. HMG-box domains are also found in other 
types of proteins, and the HMG-box domain may have functions such as protein-protein 
interaction (8). There are different types of HMG-box domain, and proteins containing an HMG-
box domain with sufficient homology to SRY are called SRY box (SOX) proteins (9). A crucial 
function of SRY in determining the male sex is to promote expression of SOX9, which signals to 
induce Sertoli cell differentiation and the formation of testes (2). In conjunction with 
steroidogenic factor 1 (SF1) and other factors, SOX9 promotes expression of anti-Müllerian 
hormone (AMH) in Sertoli cells, blocking development of a female reproductive system (10).  
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 Mutations of SOX9 in humans are associated with campomelic dysplasia, characterized 
by skeletal abnormalities associated with the function of SOX9 in chondrocyte differentiation 
(11-13). Campomelic dysplasia is also associated with disorders of sexual development in 
affected males, which can result in normal female phenotypic development in an individual with 
the 46, XY karyotype. Consistent with the mechanisms of SOX9 in sexual determination, 
individuals with campomelic dysplasia and having a 46, XX karyotype are not affected by sex 
reversal (14).  
Hedgehog-SOX9 signaling 
 In several contexts, SOX9 is already implicated as a downstream mediator of Hh 
signaling. Along with BMP signaling, Shh pathway activation helps establish SOX9 expression 
to regulate chondrocyte differentiation (15). In another study, Shh was overexpressed in mouse 
chondrocytes under control of the collagen II promoter/enhancer regulatory elements (16). This 
led to aberrant upregulation of SOX9, and skeletal abnormalities linked to defects in chondrocyte 
differentiation. Targeted inactivation of SOX9 in the skin prevents development of a hair stem 
cell niche and leads to alopecia (17). This study also demonstrated induction of SOX9 by Shh 
signaling, and suggested that the constitutive Hh pathway activation seen in basal cell carcinoma, 
a malignancy derived from hair follicular cells, leads to upregulation of SOX9. A genomics 
approach identifying conserved GLI binding sites identified the SOXE group, consisting of 
SOX8, SOX9, and SOX10, as regulated by Hh-Gli signaling, with a role in the development of 
Müller glial cells in the retina (18). Upregulation of SOX9 by Hh signaling has also been shown 
in basal cell carcinoma and pancreatic adenocarcinoma cells (19). 
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 Previous reports (19,20), and data presented in our results, indicate GLI protein 
transcriptionally promotes SOX9 expression by interacting with an upstream response element. 
Our results therefore establish an additional means of positive feedback in Hh-GLI signaling, 
whereby SOX9 protein interacts with SCF
β-TrCP
 to stabilize GLI1 protein. Another feedback 
mechanism is that GLI1 strongly promotes expression of itself at the transcriptional level. We 
observed this GLI1-SOX9 feedback in pancreatic cancer cells, where GLI may be activated by 
noncanonical mechanisms such as RAS, but both mechanisms seem likely to occur in diverse 
biological contexts of Hh pathway activation. Such examples would include normal and disease 
processes in which Hh-GLI is activated through Hh ligands, and malignancies such as basal cell 
carcinoma where the Hh pathway is activated through mutation of classical Hh pathway 
components.  
Hedgehog-SOX9 feedback in cancer 
 It could be easily examined whether the GLI1-SOX9 feedback mechanism in pancreatic 
cancer cells extends to other contexts. To test this hypothesis, one would determine whether the 
suppression of SOX9, as can be accomplished through RNA interference, has a negative effect 
on GLI1 protein. As an initial screen, GLI transcriptional activity could be assessed through 
effects on GLI1 and PTCH mRNA, or through a GLI-binding site transcriptional reporter. The 
effect on GLI1 stability, and the dependence upon SCF
β-TrCP
, could then be verified using the 
methods previously used in pancreatic cancer cells. We showed that the DNA binding domain of 
SOX9 is not required for GLI1 stability, and instead that the transactivation domain of SOX9 
interacts with β-TrCP. By expressing a SOX9 construct lacking the DNA binding domain (HMG 
box), it should be possible to test whether a particular phenotype of SOX9 is dependent upon 
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SOX9-mediated transcriptional regulation, or instead involves mechanisms such as stabilization 
of GLI protein.   
 Melanoma may represent the context most analogous to GLI signaling in pancreatic 
cancer. As in pancreatic cancer, GLI can be activated in melanoma by oncogenic RAS signaling 
(21). SOX9 is frequently expressed in human melanoma specimens (22,23), and while 
overexpression of SOX9 can inhibit the growth of melanoma cells (24,25), the contribution of 
endogenous SOX9 to malignant properties in this setting is unclear. We expect that GLI 
signaling in melanoma cells, partially mediated by RAS activation, will exhibit dependence on 
SOX9 expression, such that oncogenic GLI signaling may be blocked by SOX9 knockdown. 
 Oncogenic Hh-GLI signaling is activated in basal cell carcinoma by mutations in the Hh 
pathway, most often by inactivation of the tumor suppressor PTCH (26,27), and occasionally 
through mutational activation of Smo (28). Interestingly, SOX9 is also highly expressed in basal 
cell carcinoma specimens and in a transgenic mouse basal cell carcinoma model (17,29). SOX9 
is also expressed in trichoepithelioma and trichilemmoma, tumors likewise thought to originate 
from follicles, as well as some other adnexal tumors, but not in Bowen’s disease or in Merkel 
tumors. Notably, GLI1 overexpression in the skin leads not only to basal cell carcinoma, but also 
to development of trichoepithelioma , cylindroma, and trichoblastoma; all are follicular-derived 
tumors (30). The co-expression of SOX9 and GLI in normal follicles, and in follicle-related 
malignancies, has led to a hypothesis that SOX9 is a general effector of Hh signaling (29). By 
stabilizing GLI1, our data provide a means whereby this Hh-SOX9 signaling can promote 
tumorigenesis. A role for SOX9 in the regulation of hair follicles by Hh signaling (31) also 
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seems quite plausible. SOX9 is not required for hair follicle formation, but is critical for a CD34
+
 
population of follicle stem cells (17). 
Hedgehog-SOX9 feedback in development 
 Considering the vital developmental roles of both Hh signaling and SOX9, mutations of 
each pathway should result in some degree of phenotypic overlap if GLI-SOX9 feedback is 
relevant in normal physiological contexts of Hh signaling. This question is more complex, as the 
Hh pathway in mammalian development signals through the balance and interplay of GLI 
transcriptional activation (GLI
A
) and repression (GLI
R
) functions, distributed amongst the GLI 
family members (32). Moreover, GLI1 is seemingly not required for normal development (33). 
This result suggests the transactivation function of GLI2 can compensate for the loss of GLI1. In 
contrast, GLI2 loss results in embryonic lethality (34-36). Therefore, future studies into the 
involvement of SOX9 in Hh-GLI mediated developmental processes should take into account 
whether GLI2 is dependent upon SOX9.  
 The developmental defects associated with Hh mutations, including holoprosencephaly, 
appear at first glance to be distinct from SOX9-associated campomelic dysplasia. In fact, SOX9 
has important roles in craniofacial development (37), and mutations of both SOX9 and of 
components of the Hh-GLI signal pathway have been associated with cleft lip and cleft palate 
(38). Whether craniofacial defects associated with SOX9 mutations result to some degree from 
destabilization of GLI protein is unclear. 
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Effect of SOX9 on β-TrCP substrates 
 One of the more puzzling aspects of our results concerns the relative effects of SOX9 on 
GLI1 protein as compared to other substrates of SCF
β-TrCP
. Using both knockdown and 
overexpression of SOX9, we showed that SOX9 protein regulates SCF
β-TrCP
 complex formation, 
specifically observing that the association of β-TrCP and SKP1 is inhibited by SOX9. This 
mechanism suggests many substrates of SCF
β-TrCP
 in addition to GLI1 should be stabilized by the 
presence of SOX9 (Chapter 2, Fig. 7A-C).  
 We found some evidence in support of the broader stabilization of β-TrCP substrates. 
MCL1 protein was noticeably decreased upon suppression of SOX9. This effect was 
proteasome-dependent, consistent with a stabilizing effect of SOX9. Additionally, β-catenin 
seemed to be stabilized by SOX9 as observed by immunoflourescence, and a TCF4 
transcriptional reporter was markedly decreased following SOX9 knockdown. In contrast, the 
effect on β-catenin protein by immunoblot was less pronounced, and the levels of some β-TrCP 
substrates were unaffected by SOX9 knockdown (not shown). In fact, none of the other SCF
β-TrCP
 
substrates we examined were as dependent as GLI1 upon SOX9 expression. Others have 
reported that overexpression of GLI1 in cancer cells results in elevated nuclear expression of β-
catenin (39). It would be interesting to examine whether this effect could be partly attributed to 
the stabilization of β-catenin by GLI-promoted SOX9. 
 A complicating factor in the analysis of the stability of SCF
β-TrCP
 substrates, or indeed the 
substrates of any E3 ubiquitin ligase, is that proteins may be targeted by multiple E3 ligases. For 
example, GLI1 can also be ubiquitylated by Numb-Itch (40,41), and β-catenin is also targeted for 
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ubiquitylation by Jade-1 (42) and c-Cbl (43). At present, the overall effects of alternative E3 
ligases upon SCF β-TrCP substrates are difficult to predict. There are hundreds of E3 ubiquitin 
ligases, including many without known substrates. Furthermore, it seems likely there are still 
unknown substrates of even well-characterized E3 ubiquitin ligases such as SCF
β-TrCP
 and 
SCF
CDC4
. 
β-TrCP in cancer: Substrates and context-dependence 
 While there are as yet no clinical therapies that specifically target the ubiquitin cascade, 
this approach could offer greater specificity in modulating the protein levels of specific E3 
ubiquitin ligase substrates. Proteasome inhibitors, in contrast, are likely to affect all proteins with 
26S proteasome-dependent stability. By limiting stabilizing effects to a more narrow range of 
substrates, a therapy targeting the function of an E3 ligase could also offer decreased toxicities. 
Adverse events represent a serious drawback of current clinically approved proteasome 
inhibitors, and can include neurologic and hematologic effects (44-46). In contrast, therapeutic 
strategies to enhance the activity of the E3 ligase SCF
β-TrCP
, as could be accomplished by 
antagonizing SOX9, could potentially have anticancer activity by destabilizing GLI1. An 
obstacle to the rational therapeutic inhibition of E3 ubiquitin ligases, is that the substrates and 
function in cancer of many E3 ligases is poorly understood. 
 This knowledge gap includes β-TrCP, as while SCFβ-TrCP is seemingly one of the best-
studied E3 ligases, the role of β-TrCP in human cancer is still unclear. In contrast, the F-
box/WD-repeat protein FBXW7/CDC4 is a well-documented tumor suppressor (47-50) with 
mutations in breast cancer (51,52), ALL (53), gastric cancer (54), and other malignancies (55). 
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As discussed in the Introduction (Chapter 1), overexpression of β-TrCP has been reported in 
some cancers (56-59), with evidence of increased tumors in β-TrCP-overexpressing GEM 
models (60). β-TrCP could promote malignancy through the degradation of substrates with 
tumor-suppressive properties, such as IκB proteins or PDCD4, and overexpression of β-TrCP 
leads to unrestrained activation of NF-κB signaling (61). 
 There is also evidence that β-TrCP might have tumor-suppressor functions. β-TrCP could 
act as a tumor suppressor by promoting the degradation of oncoproteins such as GLI1 or β-
catenin. β-TrCP mutations seem rare in cancer, but have been observed. The Okajima gastric 
cancer cell line harbors a BTRC2 mutation leading to an F462S substitution of β-TrCP2 protein 
(62). This mutation is located within the WD-repeat region, and could therefore potentially alter 
or block substrate recognition. It would be informative to evaluate whether this mutation leads to 
the stabilization of GLI protein. Additionally, deletions of the β-TrCP WD region that could 
result in substrate stabilization are reported in prostate cancer (63).  
 The association of SCF
β-TrCP
 with substrates classically involves substrate 
phosphorylation, followed by binding through a phosphodegron motif to β-TrCP, although 
proteomics methods also suggest propensity for non-classical binding (64). The stability of 
classical β-TrCP substrates is thus regulated by the activity of kinases, in addition to myriad 
other mechanisms. The interaction of β-TrCP with substrates is therefore likely to be highly 
context-dependent, and regulated by many factors aside from β-TrCP protein expression. For 
example, our results indicate that SOX9 protein inhibits the interaction of GLI1 and β-TrCP. 
Methods to identify context-sensitive interaction between E3 ubiquitin ligases and their 
substrates will be of increasing relevance. A proteomics approach, using immunoprecipitation 
270 
 
and mass spectrometry, could be used to identify and compare substrates of SCF
β-TrCP
 (64,65) 
and other E3 ubiquitin ligases under varying experimental conditions. Previous efforts to screen 
for E3 ligase substrates have also used genetic methods such as global protein stability (GPS) 
profiling (66,67). Such efforts could significantly improve understanding of the ubiquitin-
proteasome system in cancer.  
KLF4 suppresses metastasis of breast cancer cells 
 In breast cancer, the transcription factor KLF4 promotes malignant properties and 
supports the cancer stem cell population, yet the overall role of KLF4 on tumor progression and 
metastasis in this context remains unclear. In this dissertation, we examine the effect of KLF4 
expression on the spontaneous metastasis of breast cancer cells. We performed orthotopic 
injection of breast cancer cells in immunocompromised mice, finding that the stable suppression 
of KLF4 resulted in greater metastasis to the lungs and liver. Similarly, we found overexpression 
of KLF4 to inhibit metastasis. Suppression of KLF4 resulted in increased numbers of circulating 
tumor cells, yet the metastatic phenotype was unrelated to changes in primary tumor growth, and 
did not correlate with invasion and motility in 2D experiments. The expression of DDR1, a 
collagen receptor implicated in metastasis, was suppressed by KLF4, such that KLF4 knockdown 
led to increased DDR1 and adhesion to collagen. We propose that KLF4 suppresses metastasis 
through downregulation of DDR1. 
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KLF4 and DDR1 signaling 
 We have shown that suppression of KLF4 leads to increased spontaneous metastasis of 
breast cancer cells in association with increased expression of DDR1. Significantly, KLF4 
knockdown resulted in higher levels of CTCs, suggesting that KLF4 regulates the metastatic 
cascade at a stage before tumor cells arrive at distant sites. While endogenous DDR1 (68), as 
well as DDR2 (69,70), were previously implicated as promoting metastasis, we have not yet 
examined the functional relationship of KLF4-DDR1 signaling in the metastasis of breast cancer 
cells. We hypothesize that silencing of DDR1 in KLF4 knockdown cells will lead to suppression 
of metastasis. Such a result would suggest that breast cancer metastasis is inhibited by the KLF4-
mediated suppression of DDR1. 
 If a KLF4-DDR1 signaling pathway is indeed relevant in the metastasis of breast cancer 
cells, the mechanisms downstream of DDR1 would be of interest. DDR1 is unusual amongst 
RTKs in that the activating ligand of DDR1 is collagen, a structural component of the 
extracellular matrix. It therefore seems that DDR1 could potentially affect metastasis through 
distinct processes. DDR1 autophosphorylation could stimulate pathways associated with DDR1 
activation, including RAS, MAPK, and NF-κB (71,72). Additionally, DDR1 expression might 
affect the interaction of cancer cells with the extracellular matrix, impacting processes such as 
matrix contraction and remodeling, invasion, motility, and intravasation.  
 It is unclear whether pathways downstream of DDR1 could suppress metastasis. The NF-
κB pathway is known to protect cancer cells from apoptosis (73) and promote EMT (74). 
Additionally, NF-κB signaling is highly linked to tumor initiation and progression (75-77), and 
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may promote metastasis through CXCR4 (78). RAS and MAPK signaling likewise represent 
classic pathway associated with malignancy (79-82). While we have previously reported that 
KLF4 can promote malignant properties through RAS/MAPK signaling (83), this may not be 
true in every instance. JUNB and JUND, which may act as tumor suppressors (84), seem to be 
downregulated in metastasis with some consistency (85). In preliminary experiments we have 
observed decreased AP-1 reporter activity as a result of KLF4 suppression (not shown), although 
we have not directly examined the effect of KLF4 and DDR1 on FOS/JUN expression, and 
MAPKs are known to regulate AP-1 activity through several mechanisms (86). 
 Expression of DDR1 might affect metastasis through mechanisms independent from the 
direct effect DDR1 activation on cell signaling pathways. One such process is the interaction of 
cells with the ECM. Current, ongoing research in our lab suggest that suppression of KLF4 in 
MDA-MB -231 cells results in enhanced rigidity and contraction of a 3D collagen matrix, 
although it is not yet known whether this effect is a result of DDR1 upregulation. In addition to 
DDRs, the interaction of cells with collagen occurs through other receptors, including integrins 
(87-89). While several studies have indicated a causal relationship between breast cancer 
progression and stiffening of the ECM, the signal transduction from the collagen matrix was 
reported to occur through integrins receptors (90,91). We plan to use a shRNA approach to 
address the specific contribution of DDR1 expression in breast cancer cells towards the rigidity 
and contraction of a 3D collagen matrix. It may also prove useful to evaluate the effects of KLF4 
on the expression of alternate collagen receptors, including integrins such as α1β1. Our results 
indicate suppression of KLF4 leads to increased adhesion to collagen, and it will be of interest 
whether this effect is attributable to DDR1 upregulation. DDRs are known to regulate the 
behavior of cells in collagen matrices in vitro (92,93), and evidence suggests the effects of 
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DDR1 on cell spreading and migration over collagens are mediated through interaction with 
myosin IIA (94). It may then be of interest to examine whether KLF4 expression can regulate the 
co-immunoprecipitation of DDR1 and myosin IIA. 
KLF4 and the origins of metastasis 
 Evidence from our lab and others indicate endogenous KLF4 can promote malignant 
properties of breast cancer cells in vitro and in vivo (83,95-98). For this reason, we were 
surprised to discover KLF4 to be a highly effective metastasis suppressor of breast cancer cells 
in the NSG mouse model. One mechanism to explain these effects is that KLF4 expression could 
support the development of primary tumors, while subsequent downregulation of KLF4 
facilitates metastasis. This could be assessed in the NSG model by comparing the expression of 
KLF4 in primary tumors and metastases. While a microarray study in MDA-MB-231 cells did 
not find KLF4 mRNA expression to be consistently altered in spontaneous metastasis (99), the 
PCR-based quantification of KLF4 in this context may prove more accurate.   
 While the severe immunodeficiency of the NSG mouse clearly enhances results in 
increased metastasis of breast cancer cell lines (99), this model system accordingly fails to 
account for the important roles of the immune system in the metastatic process (100). Still, the 
metastatic capability of cells in NSG mice has been shown to have clinical relevance. For 
example, the capability of primary melanoma cells to form spontaneous metastases in NSG mice 
corresponded with patient clinical outcome (101). 
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 Reports comparing gene expression in human patients of matched primary tumors and 
metastases are somewhat rare. In unsupervised hierarchical clustering of microarray-derived 
expression profiles, breast cancer metastases tend to cluster with the corresponding tumor of the 
same patient, as opposed to primary tumors or metastatic lesions of other patients (102). This 
was interpreted to signify that gene expression does not differ between primary tumors and 
metastasis. Similarly, it has been hypothesized that metastasis is largely preordained by the 
events in which normal cells are transformed into cancer cells (103,104). Current perspectives on 
metastasis take into account that development of an invasive carcinoma occurs over a much 
longer time interval as compared to what is required for the subsequent development of 
metastasis (105,106). The lack of well-defined genetic changes specific to metastasis must also 
be reconciled with compelling evidence that metastases occur from only a subset of the primary 
tumor cell population (107-109). 
 There is some evidence of differential gene regulation between primary tumors and 
metastasis. A meta-analysis of 28 total studies evaluated microarray data of primary tumors and 
distant metastasis (85). These included samples in which the authors concluded there was no 
difference between primary and metastatic gene expression (102). A metastatic signature of 79 
genes was identified, and all except one were downregulated in metastasis. Examples of 
downregulated genes included some known metastasis suppressors as gelsolin (110) and 
connexin-43 (111). Additionally, a consistent set of differentially regulated genes has also been 
identified in lymph node metastasis of breast cancer (112). By restricting the metastatic 
specimens to lymph nodes, the variability imposed by the microenvironment in different sites 
such as lung and liver is reduced. 
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 While KLF4 could be downregulated in metastasis, there are other possibilities that could 
account for the seemingly discordant effects of KLF4 on different stages of carcinogenesis. 
Other changes in gene expression could compensate for the effects of KLF4. In accordance with 
the “seed and soil” hypothesis, it is also reasonable that KLF4 may exert distinct functions in the 
later steps of metastasis, in which breast cancer cells interact with a foreign microenvironment 
(113). It is still unexplained as to why KLF4 knockdown results in more CTCs in mice with 
comparably-sized primary tumors. Plausibly, suppression of KLF4 could lead to increased 
numbers of CTCs escaping the primary tumor into the vasculature, or the survival of tumor cells 
in circulation could be affected. Although suppression of KLF4 results in reduced motility and 
invasiveness of MBA-MD-231 cells in 2D culture, such effects of KLF4 in a 3D context are 
unknown. Given the effect of KLF4 on DDR1 expression and collagen adhesion, we plan to 
assess the effect of KLF4 on breast cancer cell invasion in a 3D collagen matrix, which might 
offer a better model of the in vivo phenotype. 
Circulating tumor cell detection and relationship to metastasis 
 While the definition of a CTC is conceptually simple, the experimental determination of 
CTCs is complicated by their rarity in comparison to the normal cellular component of blood. 
Frequently, the presence of cytokeratins and the absence of the white blood cell (WBC) marker 
CD45 are considered indicative of CTCs (114). This immunologic approach is the basis of the 
only CTC assay that is currently approved for clinical use, having prognostic significance in 
several patient studies (115). In this method, any nonmalignant epithelial cells found in 
circulation would also be considered CTCs, although such CTCs are rare in patients without 
malignancy (116).  
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 Another concern with immunologic detection of CTCs is that cancer cells may undergo 
EMT, perhaps to promote invasion and survival in the bloodstream; CTCs with EMT 
characteristics could exhibit downregulation of epithelial markers used to define CTCs and 
thereby escape detection (117-119). Future advancements in the clinical detection of CTCs may 
benefit from analysis of EMT-related markers (115). Single-cell analyses of CTCs have revealed 
expression of EMT-related genes cancers of the breast (120) and prostate (121). 
 The detection of CTCs may also be accomplished using quantitative PCR methods. For 
example, evaluation of blood samples for expression of a transgene may indicate the presence of 
CTCs in a xenograft model (122). PCR-based CTC detection has also been applied with 
prognostic significance in a number of clinical studies (115). While we considered using PCR to 
detect CTCs in our experiments, the high GFP expression of MDA-MB-231 pGIPZ cell lines 
proved amenable to detection by flow cytometry. Whether this method of CTC detection can be 
used in other contexts will likely depend on the magnitude of fluorescence of the cells.  
 In M6 cells, lentiviral transduction of the same vector resulted in less expression of GFP 
as compared to MDA-MB-231 cells (not shown), and despite antibiotic selection, there remained 
a population of M6 cells without meaningful fluorescence above background. Although we 
attempted to evaluate CTCs from M6 primary tumors, the presence of cells lacking green 
fluorescence resulted in less reliable determination of CTCs, as these cells might be confused 
with mouse leukocytes. In contrast, by inoculating blood specimens from tumor-free mice with 
the MDA-MB-231 pGIPZ cell lines, we established to our satisfaction that we would not 
overlook an appreciable number of cells. It remains possible that some tumor cells could lose 
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expression of GFP during in vivo proliferation, although most methods of CTC analysis rely on 
continued expression of some type of marker.  
 Overall, the gene expression of CTCs is somewhat labile in comparison to primary 
tumors and metastases. This effect may perhaps result from comparing the expression profile of 
single CTCs to that of bulk samples from solid tumor masses. In a study involving 62 patients 
with metastatic breast cancer, CTC profiling of a 35-gene set found discordant expression in 
48% of patients as compared with the primary tumor (123). The CTC expression profile did not 
have prognostic significance. In breast cancer, CTCs are not necessarily predicted by the 
characteristics of primary tumors or axillary lymph node status (124).  
 One area of continuing uncertainty is the source of CTCs, as metastases could 
conceivably account for CTCs in circulation. A similar question is whether metastases can 
themselves give rise to other distant metastases (125), a proposition that has seen arguments on 
both sides (126,127). Mathematical modeling of tumor growth and metastasis has predicted that 
metastases of metastases are not likely to comprise a significant portion of overall tumor burden 
in human patients (128). In our model system, we detected CTCs in mice lacking discernible 
lung metastases, suggesting that at this stage, the overall burden of cancer cells in the mice was 
primarily determined by the orthotopic tumor.  
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